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ABSTRACT 
Heidi M. Roskens Dalzell 
A STUDY OF THE BETA-2 TOXIN GENE AND THE BETA-2 TOXIN IN 
CLOSTRIDIUM PERFRINGENS STRAINS ISOLATED FROM                   
HUMAN SOURCES 
Clostridium perfringens is an important human pathogen known to cause a 
range of diseases including diarrhea, necrotizing bowel disease and gas 
gangrene.  Though potentially pathogenic, this microorganism is commonly 
identified in the fecal microbiota of healthy individuals.  The major clinical findings 
associated with C. perfringens diseases are linked to production of potent toxins.  
In 1997, Gibert et al. identified a new toxin, the beta2 toxin, from a C. perfringens 
strain from a piglet with necrotic enteritis.  Subsequently, this new beta2 toxin 
gene (cpb2) has been identified in C. perfringens from dogs, horses, and other 
animals.  The principal objective of this investigation was to study cpb2 and the 
beta2 toxin in C. perfringens isolates from human sources.  The C. perfringens 
isolates were grouped into three different populations: 1) fecal samples from 
patients suspected of having C. perfringens gastrointestinal illnesses (e.g. 
antibiotic-associated diarrhea or colitis), 2) extraintestinal specimen sources (e.g. 
wounds, abscesses, blood cultures), 3) a control group of isolates from healthy 
volunteers.  Results of studies using different PCR methods and nucleotide 
sequencing revealed that cpb2 was present in the genome of isolates from all 
populations, and that the genetic variation between cpb2 from the different C. 
perfringens isolates was greater then expected.  Using western immunoblotting 
 vii 
techniques, it was found that the beta2 protein was not expressed by all cpb2 
positive C. perfringens isolates.  Finally, different variants of cpb2 were cloned 
into E. coli, and the recombinant beta2 protein used in cell cytotoxicity assays.  
Results from these assays demonstrated that recombinant beta2 proteins caused 
a range of cellular damage at different levels of protein concentration and 
different lengths of time.  Our results from these experiments provided new 
information regarding cpb2 in C. perfringens isolates from human sources; as 
well as on the range of variation of cpb2 genes, differences in beta2 toxin 
expression, and differences in the effects of recombinant beta2 toxin on 
enterocytes.  This information could help to explain differences in virulence 
between C. perfringens isolates, differences in diseases and disease severity.   
 
Stephen D. Allen, M.D., Chair 
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  1 
INTRODUCTION 
 
 
Clostridium perfringens: Classification, Morphology, and Biochemical Features 
 
Clostridium perfringens (referred to as C. welchii especially in Great 
Britain) is an anaerobic, gram-positive rod capable of forming environmentally 
resistant spores.  It is a ubiquitous microorganism found in a variety of habitats, 
including soil, water, lower mammals, and humans.  The first recognizable 
description of this bacterium was by Welch and Nuttall in their 1892 paper 
describing an organism they called Bacillus aerogenes capsulatum (Lucey and 
Hutchins, 2004; Welch and Nuttall, 1892; and reviewed by Hatheway, 1990).  
Veillon and Zuber also provided a recognizable description of C. perfringens in 
brief form in 1897, and again in 1898 in a more descriptive paper which 
described numerous anaerobes isolated from patients with pulmonary gangrene 
or appendicitis (referred to by Finegold, 1994; Veillon and Zuber, 1897; Veillon 
and Zuber, 1898).  In the “classical” classification scheme, C. perfringens 
belonged to the kingdom Monera, phylum Bacteria, class Schizomycetes, order 
Eubacteriales, family Clostridiaceae, genus Clostridium, and species perfringens 
(Euzeby, 1997; Sneath et al., 1986).  According to Bergey’s Manual of 
Systematic Bacteriology, classification of bacteria in the higher taxonomic 
groupings is described as irregular and unreliable (Sneath et al., 1986).  By the 
1990s the genus Clostridium had become one of the largest and most diverse of 
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all bacterial genera and was in need of taxonomic revision (Collins et al., 1994).  
Therefore, recent phylogenetic studies have focused on using ribosomal RNA 
analysis for the formation of new molecular data-based taxonomy for 
classification of microorganisms (Schmidt and Relman, 1994).  Interest in the use 
of ribosomal RNA analysis in the phylogeny and taxonomy of microorganisms in 
recent years has lead to the development of the Ribosomal Database Project 
(RDP-II), an online resource for ribosomal RNA sequence analysis (Cole et al., 
2005).  Studies by Collins and associates using 16S ribosomal RNA (rRNA) gene 
sequencing have revealed extreme heterogeneity in the genus Clostridium, and 
suggest that extensive reclassification of the clostridia is necessary (Collins et al., 
1994).  Based on rRNA analysis, the new phylogeny of the clostridia would place 
C. perfringens into Cluster I (equivalent to the rRNA group I proposed by 
Johnson and Francis (1975)).  This division contains almost half of the known 
Clostridium species but is phylogenetically distinct from the other 18 clusters 
described (Collins et al., 1994).  Beyond the species level, C. perfringens is 
further divided into five subtypes: A, B, C, D, or E, based on the production of the 
four commonly named major lethal toxins.  
In clinical microbiology laboratories today, the identification of C. 
perfringens is based on demonstrating a number of phenotypic characteristics.  
In Gram’s stained preparations, the organism typically is a large, boxcar-shaped, 
gram-positive rod (figure 1a); sub-terminal spores are produced but are rarely 
observed in the laboratory.  When grown on Centers for Disease Control and 
Prevention (CDC) formulated anaerobe blood agar plates under anaerobic 
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conditions at 35º C, creamy yellow to gray colonies are formed within 24 hours.  
The colony margins can be smooth, giving the appearance of a round, slightly 
raised colony, or rough, in which case the colonies are relatively flat.  A 
characteristic feature of C. perfringens is a double-zone of hemolysis (figure 1b).  
The inner zone is an area of complete lysis of the red blood cells caused by 
production of the theta toxin (figure 1b, arrow).  The outer, wider zone of 
incomplete hemolysis is due to the alpha toxin (figure 1b, arrowhead).  A positive 
test for lecithinase activity also aids in identifying C. perfringens and is based on 
the presence of the alpha toxin.  Lecithinase activity is visible as a cloudy 
precipitate in the agar surrounding colonies grown on egg yolk agar (figure 1c).   
A number of biochemical tests are performed to confirm a bacterial isolate 
as C. perfringens in the laboratory.  These tests include the determination of the 
carbohydrate fermentation profile, hydrolysis of esculin, production of indole, 
reduction of nitrate, hydrolysis of gelatin, and “stormy” fermentation reaction in 
the milk proteolysis test (figure 1d).  Expected results for the traditional 
biochemical tests for C. perfringens and other clostridia that give results similar to 
C. perfringens are shown in table 1.  Short-chain fatty acid analysis using gas-
liquid chromatography also aids in identification.  Typically, C. perfringens 
displays peaks that indicate production of acetic acid, propionic acid, and butyric 
acid on the volatile fatty-acid chromatograph (Koneman et al., 1997), and may 
show peaks that indicate production of succinic acid and lactic acid (table 1) 
(Reig et al., 1981).  Chromatographic profiles of volatile and non-volatile short-
chain fatty acids characteristically produced by C. perfringens are in figure 2.    
  4 
Clinically Important Diseases Associated with C. perfringens  
 
Clostridial Myonecrosis 
 
As previously mentioned, C. perfringens is commonly present in the fecal 
microbiota of healthy humans and animals, but it is also a clinically significant 
pathogen that causes a range of human and animal diseases.  The symptoms 
and signs of C. perfringens diseases are due to the production of numerous 
toxins that exhibit cytotoxic, hemolytic, hemorrhagic, necrotic, or other damaging 
effects on cells (Petit et al., 1999).  The best-known major human disease 
caused by C. perfringens is clostridial myonecrosis or gas gangrene.  The toxins 
of C. perfringens that are attributed with causing the clinical features of clostridial 
myonecrosis include the alpha toxin and the theta toxin (Bryant et al., 2000); the 
genes for both of these toxins are present in all subtypes of C. perfringens.  This 
disease typically occurs when C. perfringens (exogenous or endogenous) is 
introduced into a soft tissue wound caused by trauma or surgery, although cases 
in healthy humans have been reported without antecedent trauma (Zelic et al., 
2004).  Clostridial myonecrosis is a life-threatening disease characterized by a 
rapid progression with severe muscle necrosis, extensive gas production, shock, 
and renal failure.  Diagnosis is usually based on the clinical presentation because 
prompt treatment is associated with better patient outcomes and because the 
presence of bacteria that have the typical Gram reaction and cellular morphology 
of C. perfringens may simply indicate normal microbiota in the patient specimen 
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(Halpin and Molinari, 2002).  Patients with clostridial myonecrosis have a poor 
prognosis even with aggressive therapies such as surgical débridement, high-
dose antibiotics, or amputation (Bangsberg et al., 2002).   
 
 
Gastrointestinal Diseases 
 
Although clostridial myonecrosis is the disease caused by C. perfringens 
that may be most familiar, the gastrointestinal diseases produced by this 
microorganism are more common.  Clostridium perfringens type A is the third 
most common cause of food-borne illness in the United States (Sparks et al., 
2001) and the second most common cause in the United Kingdom (Adak et al., 
2002).  Like other food-borne zoonoses, such as those caused by 
Campylobacter spp., Salmonella spp. and Escherichia coli (O'Brien, 2005), C. 
perfringens food-borne disease is also attributed to animal food sources (Labbe, 
1989; Lin and Labbe, 2003).   
Many other types of bacteria also cause food-borne illness by various 
pathogenic mechanisms.  For example, Staphylococcus aureus and C. botulinum 
grow and produce toxins within improperly handled foods.  The clinical 
manifestations observed with disease due to these organisms are due to 
ingestion of the pre-formed toxin that is in the food (Rasooly et al., 1997; Sharma 
and Whiting, 2005).  In contrast, viable C. perfringens is ingested, grows, and 
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produces toxins directly within the upper small bowel.  Clostridium perfringens 
toxins having multiple effects on the intestinal lumen (Popoff, 1998).  The clinical 
symptoms of C. perfringens type A food-borne disease are typically mild and 
follow an 8 to 24 hour incubation period. There is often abdominal pain, nausea, 
and diarrhea lasting 12 to 18 hours.  Fatal complications in the young and elderly 
are rare and usually due to dehydration (Brynestad and Granum, 2002).   
Another gastrointestinal disease that may be associated with C. 
perfringens type A is antibiotic-associated diarrhea (AAD), and it is second in 
incidence only to Clostridium difficile AAD (Modi and Wilcox, 2001; Sparks et al., 
2001).  It has not been determined whether AAD associated with C. perfringens 
is due to proliferation of resident C. perfringens or acquisition of C. perfringens 
after exposure to antibiotics (Vaishnavi et al., 2005).  The evidence supports C. 
perfringens as a potential cause of AAD rather than simply a harmless member 
of the patient’s microbiota isolated by chance (Borriello et al., 1984).  The 
incidence of AAD associated with C. perfringens has varied from less then one 
percent to greater then six percent (Heimesaat et al., 2005).  The higher rate of 
greater then six percent approaches the incidence of C. difficile associated AAD 
(Abrahao et al., 2001).  In a study by Asha and others (2006), risk factors found 
in patients with C. perfringens AAD were female gender and the use of antacids.  
No specific antibiotic classes that increased the risk of AAD due to C. perfringens 
were identified.  Metronidazole has been associated with successful treatment of 
AAD due to C. perfringens and is also an effective treatment for AAD due to C. 
difficile (Borriello and Williams, 1985).  Thus, treatment of patients with AAD with 
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metronidazole could succeed without regard to determining if the agent is C. 
difficile or C. perfringens.  
In addition to food-borne disease and AAD, C. perfringens is associated 
with other gastrointestinal illnesses in humans, including sporadic diarrhea and 
enteritis necroticans.  Sporadic diarrhea caused by C. perfringens type A is 
usually a non life-threatening illness with spontaneous resolution occurring after 
2 to 7 (Brett et al., 1992).  Unlike sporadic diarrhea, enteritis necroticans is a 
rare, often fatal severe intestinal disease of humans caused by C. perfringens 
type C, a type not found in the normal fecal microbiota of humans; however it can 
be found in the intestinal microbiota of sheep and can cause an enteritis 
necroticans-like disease in pigs (Lawrence and Cooke, 1980).  Also known as 
Darmbrand, enteritis necroticans due to C. perfringens type C was prevalent in 
post-World War I Europe (Gui et al., 2002).  In Papua New Guinea, “pigbel” is 
synonymous with Darmbrand and enteritis necroticans in terms of etiology and 
clinical findings.  Pigbel is associated with ceremonial village feasts of large 
quantities of sweet potatoes and pork contaminated with C. perfringens type C 
spores (Davis, 1984).  A few cases of enteritis necroticans due to C. perfringens 
type C have recently been reported in the United States, primarily in diabetic 
patients who ingested contaminated pork products (Gui et al., 2002; Petrillo et 
al., 2000; Severin et al., 1984).  Although most cases of enteritis necroticans 
have been associated with C. perfringens type C, a recent report identified C. 
perfringens type A as the cause of enteritis necroticans in an outbreak consisting 
of seven patients in which two died (Brynestad and Granum, 2002).  Patients 
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with enteritis necroticans typically present with symptoms of abdominal pain and 
severe, bloody diarrhea.  Examination of the bowel following removal of the 
necrotic portion or at autopsy often reveals intestinal distention with increased 
fluid, mucosal necrosis, pseudomembranes (Gui et al., 2002), and evidence of 
gas-formation in the mucosa and sub-mucosa (Severin et al., 1984).  Current 
treatment of enteritis necroticans includes administration of fluids or resection of 
the affected bowel when symptoms are severe (Severin et al., 1984), along with 
antimicrobial agents (e.g., penicillin and metronidazole) administered 
intravenously (Watson et al., 1991).  Immunization with a vaccine composed of a 
beta toxoid (a toxin modified to be non-harmful) developed from the beta toxin 
effectively prevented disease in the endemic area of Papua, New Guinea 
(Lawrence et al., 1990).  Unfortunately, the vaccine is difficult to obtain since few 
companies presently produce the beta toxoid.  In addition, neither anti-gas-
gangrene antitoxin nor specific beta antitoxin are effective as treatment options 
for necrotic enteritis (Watson et al., 1991).  
Economically important animal species are also susceptible to C. 
perfringens diseases.  Clostridium perfringens gastrointestinal diseases in 
animals include diarrhea in piglets and foals, necrotic enteritis in calves, piglets, 
lambs and foals, and enterotoxaemia in sheep and horses (Rood, 1998).  These 
diseases can be mild and self-limiting or highly virulent and lethal.  The severity 
and range of the diseases caused by C. perfringens in humans and animals 
make C. perfringens a clinically, socially, and economically important 
microorganism to study.  
  9 
Genomics of C. perfringens 
 
The genome of C. perfringens is a circular chromosome of approximately 
3.6 mega-base pair in size (due to strain variation the range is 3.07 to 3.65 
mega-base pair), with a low guanine + cytosine (G + C) content of about 25% 
(Canard et al., 1992; Casjens, 1998).  The genome of C. perfringens also 
includes extrachromosomal genetic elements (e.g. plasmids and phage encoded 
mobile genes) that can vary in size and composition (Bruggemann, 2005; 
Rooney et al., 2006).  A role for phages in the transfer of genes between strains 
of C. perfringens has not been identified (Zimmer et al., 2002).  Many of the 
virulence genes that are important in the pathogenesis of illnesses due to C. 
perfringens are located on plasmids, including the beta, epsilon, and iota toxin 
genes (Katayama et al., 1996).  The enterotoxin gene associated with C. 
perfringens gastrointestinal diseases can be located either on the chromosome 
or a plasmid (Brynestad et al., 1997; Cornillot et al., 1995).  Both the epsilon toxin 
and the beta toxin genes are located on plasmids.  These plasmids can be lost 
during maintenance of C. perfringens stock cultures in the laboratory (Katayama 
et al., 1996).  This has implications with respect to investigations of genes 
encoded on a plasmid.  However, loss of a plasmid encoded gene has not been 
described for other genes in C. perfringens, and stability of some plasmids in 
stock cultures has been demonstrated (Mahony et al., 1987).  Conjugative 
transfer of plasmids between C. perfringens strains has been demonstrated 
(Brefort et al., 1977), including transfer of plasmids encoding resistance genes 
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for tetracycline and chloramphenicol (Abraham and Rood, 1985; Abraham et al., 
1985).  However, few plasmids have been shown to change the defined 
phenotype of a strain of C. perfringens (Rood and Cole, 1991).  The potential for 
transfer of other plasmids that contain toxin or other virulence genes has obvious 
potential for affecting the pathogenecity of C. perfringens strains; therefore 
further studies are needed in this area. 
 
 
The Toxins of C. perfringens 
 
The pathogenesis of C. perfringens diseases is directly linked to the many 
toxins and enzymes this organism produces.  The major lethal toxins are termed 
alpha, beta, epsilon, and iota.  These four toxins are used to assign C. 
perfringens to one of five toxin types (table 2).  Determination of the toxin type of 
an isolated strain of C. perfringens was classically accomplished using cultured 
organisms and type-specific anti-sera to neutralize the effects of the strain in 
experimental animals, such as mice and guinea pigs (Sterne and Warrack, 1964; 
Yamagishi et al., 1997).   
Since the development of modern molecular biology and the identification 
of the C. perfringens toxin genes, techniques such as Polymerase Chain 
Reaction (PCR) are now more commonly used to determine the toxin type of an 
isolated strain of C. perfringens (Yoo et al., 1997).  Each C. perfringens toxin 
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type is generally associated with specific diseases and is found in certain types 
of animals.  In addition to the four major lethal toxins, there are at least 15 other 
C. perfringens-produced toxins (Rood and Lyristis, 1995; Rood, 1998) that may 
participate in the pathogenesis of disease (Hatheway, 1990).  Two of these 
toxins, the beta2 toxin and the C. perfringens enterotoxin (CPE), are of particular 
interest for their possible association with disease in humans and animals.   
 
 
Control and Regulation of Toxin Production 
 
There is increasing evidence that many C. perfringens virulence genes are 
regulated by elements of a two-component regulatory system similar to that 
described in other bacteria (Lyristis et al., 1994; Shimizu et al., 1994).  These 
two-component systems include a histidine kinase sensor and a response 
regulator component (Gross, 1993; Stock et al., 1989).  In C. perfringens the 
components involved in transcriptional control of some virulence genes are 
termed VirS and VirR (figure 3).  Aspects of the histidine kinase family of sensor 
proteins have been shown in VirS, in addition to a membrane spanning region 
and a region that can interact with the organism’s environment to receive 
external stimuli (Cheung et al., 2004; Lyristis et al., 1994).  The external stimuli 
have not yet been identified for C. perfringens, nor have the stimuli been shown 
to be environmental factors versus related to growth phase factors.  Further 
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evidence for VirS as a sensor protein for this system is the presence of a highly 
conserved histidine residue that is capable of undergoing autophosphorylation at 
histidine residue-255 (Cheung et al., 2004; Lyristis et al., 1994).  
VirR is the response regulator, the second element of this two-component 
system.  VirR is activated by phosphorylation at an aspartic acid residue (Asp-57) 
by the activated VirS; the phosphorylated VirR then functions as a DNA-binding 
protein to regulate transcription from specific promoters (Lyristis et al., 1994; 
Shimizu et al., 1994).  Direct regulation of transcription by phosphorylated VirR 
can be positive or negative, depending on the target promoter (Banu et al., 
2000).  Studies of the C. perfringens VirR protein have shown that a pocket of 
basic amino acids in the C-terminal region of the VirR protein, referred to as the 
SKHR motif, is essential for proper function of the protein (McGowan et al., 
2003).  Studies have also revealed that the VirR protein binds independently to 
two imperfect direct repeats (CCCAGTTNTNCAC) located upstream of the gene 
promoter (Cheung and Rood, 2000), and that the spatial organization of these 
repeats is important for transcription of the gene (Cheung et al., 2004).  
VirR can also play an indirect role in the regulation of many genes by 
affecting regulatory genes, including the VirR-RNA regulatory element (VR-RNA) 
(Ohtani et al., 2002; Shimizu et al., 2002b).  The VR-RNA has been shown to 
positively and negatively regulate gene transcription in C. perfringens.  Although 
the 3’-region is essential for function, VR-RNA does not regulate gene 
transcription by binding to complementary DNA or RNA of a promoter region.  
The actual mechanism of gene regulation has not been described (Shimizu et al., 
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2002b).  Fifteen proteins have been identified as regulated by the VirS/VirR 
system in studies that compare a wild type C. perfringens proteome profile to a 
VirR mutant (Shimizu et al., 2002a).  The affected genes can be located on the 
chromosome or on plasmids (Banu et al., 2000; Ohtani et al., 2003).  Clostridium 
perfringens genes regulated by the VirS/VirR system include positive regulation 
of the theta toxin (perfringolysin O), collagenase (kappa toxin) (Shimizu et al., 
1994), and phospholipase C (alpha toxin) genes (Ba-Thein et al., 1996) and 
negative regulation of the cystathionine gamma-synthase and cysteine synthase 
genes (Banu et al., 2000).  The beta2 toxin gene, cpb2, is of particular interest in 
this study.  It is indirectly regulated in a positive manner by the VR-RNA 
component of the VirS/VirR regulatory system (Ohtani et al., 2003).  In addition to 
the VirS/VirR system, phylogenetic analysis has identified other potential two-
component signal transduction systems; 23 sensor kinases and 17 response 
regulator genes are conserved in three strains of C. perfringens (Myers et al., 
2006).   
Quorum sensing via cell-cell communication allows for regulation of gene 
expression in many different pathogenic bacteria as a response to changes in 
population density (Waters and Bassler, 2005).  Ohtani and others (2002) 
identified a homologue of the luxS gene in C. perfringens, which appears to be 
regulated by the VirS/VirR system (Ohtani et al., 2000).  The luxS gene has been 
identified in a number of pathogenic bacteria, first in Vibrio harveyi and then in 
Escherichia coli and Salmonella typhimurium (Surette et al., 1999).  In C. 
perfringens the luxS gene is involved in stimulation of production of the theta, 
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alpha, and kappa toxins through a cell-cell signaling mechanism, at either the 
transcriptional or post-transcriptional level (Ohtani et al., 2002).  Additional data 
by Ohtani and others (2002) provides evidence that the VirS/VirR system is an 
essential component for luxS regulation of these toxins.   
The luxS gene is responsible for production of a molecule initially 
identified as autoinducer-2.  Autoinducer-2 appears to be involved in quorum 
sensing and cell-cell signaling in type III secretion systems for E. coli (Sperandio 
et al., 1999; Sperandio et al., 2003).  A role for autoinducer-2 activation of the 
VirS/VirR system has not been shown.  Furthermore, Walters and Sperandio 
(2006) found that the autoinducer signaling molecule dependent on the luxS 
gene was not autoinducer-2, but was a different signaling compound that was 
then named autoinducer-3.  Studies are needed to determine if autoinducer-3 is 
produced by C. perfringens and whether it plays a role in the luxS regulation of 
the alpha, kappa, theta toxins, or other toxin genes.  
 
 
The Alpha Toxin 
 
All strains of C. perfringens (types A to E) carry the alpha toxin gene (cpa, 
sometimes referred to as plc).  Of the four major toxins, type A C. perfringens 
produces only the alpha toxin (table 2).  Type A is the most common C. 
perfringens type in the environment and the most common type identified in 
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humans, either as part of the normal microbiota or in disease (Petit et al., 1999).  
Outbreaks of C. perfringens food-borne illness in the United States are due to 
primarily to type A strains (Koneman et al., 1997), as are most cases of C. 
perfringens myonecrosis in humans (Stevens and Bryant, 1999).  
Unlike many of the virulence genes of C. perfringens that are located on 
plasmids, the alpha toxin gene is located on the chromosome (Rood, 1998).  It is 
1197 base pair in length and encodes a protein that contains 398 amino acids, 
with a 28 amino acid signal sequence that is cleaved before the mature protein is 
secreted (Titball et al., 1989).  The molecular weight of the alpha toxin 
(determined using SDS-PAGE) is approximately 43,000 kDa, and the isoelectric 
point is pH 5.4 (Jolivet-Reynaud et al., 1988).  Although the alpha toxin gene is 
found in all types of C. perfringens, differences in the level of alpha toxin 
production between types have been observed (Mollby and Holme, 1976).  This 
may be due to differences in the transcription rate (Katayama et al., 1993).  How 
differences in transcription rates are controlled has not been described, although 
there is an A+T-rich region upstream of the -35 promoter that may be involved in 
negative regulation of expression of the alpha toxin gene (Toyonaga et al., 1992).  
There is also evidence that the alpha toxin gene is positively regulated by the 
VirS/VirR system through luxS mediated signaling (Ohtani et al., 2002).    
The alpha toxin is a zinc-metallophospholipase C sphingomyelinase that 
hydrolyzes phospholipids and sphingomyelin and causes disorganization of 
plasma membranes (Sakurai et al., 2004).  Other pathogenic bacteria, including 
Bacillus cereus (Gilmore et al., 1989) and Listeria monocytogenes (Camilli et al., 
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1991), as well as other clostridia such as C. bifermentans (Tso and Siebel, 1989) 
and C. novyi (Taguchi and Ikezawa, 1978) produce phospholipase C 
enzymes/toxins that are homologous to the alpha toxin.  There are two distinct 
domains of the alpha toxin.  The enzymatic phospholipase C activity is restricted 
to the N-terminal domain (Naylor et al., 1998).  The C-terminal domain is 
responsible for the binding and insertion of the alpha toxin into the lipid bilayer of 
a cell (Nagahama et al., 2002) and may contribute to the membrane damaging 
effects observed with the alpha toxin.  The non-enzymatic C-terminal domain is 
also essential for the alpha toxin’s hemolytic activity (Titball et al., 1991).   
The alpha toxin is hemolytic, dermonecrotic, and lethal to mice (Rood and 
Lyristis, 1995).  The alpha toxin is also capable of directly affecting myocardial 
contractility, which accounts for the decrease in cardiac index and mean arterial 
pressure when alpha toxin is administered to mice (Stevens et al., 1988).  
Recombinant alpha toxin produced in E. coli induces hemolysis of murine 
erythrocytes (Titball et al., 1989).  Unlike other toxins of C. perfringens, alpha 
toxin activity is only slightly decreased by treatment with chymotrypsin and is not 
affected by treatment with trypsin (Ginter et al., 1996).  Additional features of the 
alpha toxin include its ability to cause tissue necrosis, inhibit polymorphonuclear 
cell recruitment, and produce thrombosis (Awad et al., 2001).  All of these effects 
are observed in clostridial myonecrosis (Bryant et al., 2000; Zelic et al., 2004).  
The extensive array of cellular damage caused by the alpha toxin explains why 
investigators have concluded that it is the primary mediator of the tissue damage 
is associated with gas gangrene (Stevens and Bryant, 1997).   
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The Beta Toxin 
 
The beta toxin is produced by C. perfringens types B and C.  Type C 
strains are associated with enteritis necroticans (also known as “Darmbrand” and 
“pigbel”) in humans.  Newborn animals (in particular piglets) are especially 
susceptible to infection with C. perfringens type C (Tweten, 2001).  
Enterotoxemias associated with types B and C are of concern in the veterinary 
sciences, impacting neonatal and young horses, sheep, goats, cows and pigs 
(Sterne and Warrack, 1964).  Type B and C strains of C. perfringens have also 
been isolated from the intestines of a variety of healthy animals (Songer, 1996), 
apparently as part of the intestinal microbiota.  
 The beta toxin gene, cpb, has been located on different large plasmids 
that are carried by C. perfringens types B and C (Duncan et al., 1978) that have 
received little study to date.  The gene for the beta toxin is 1007 base pair long; it 
is translated into a protein of 336 amino acids.  Twenty-seven of these amino 
acids comprise a signal sequence that is cleaved prior to secretion (Hunter et al., 
1993).  The secreted toxin has similarities (based on 17% to 28% identity) to 
other toxins that are known to form pores in the plasma membranes of eukaryotic 
cells.  These include the S. aureus alpha toxin, components of the gamma toxin, 
components of leukocidin, and the cytotoxin K of Bacillus cereus (Smedley et al., 
2004).  Mechanisms for regulation of transcription or secretion of the beta toxin of 
C. perfringens have not been described to date.   
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The beta toxin is heat labile and is readily inactivated by denaturation, 
dilution, oxidizing agents (Sakurai and Fujii, 1987), or trypsin (Lawrence, 1997).  
When injected intravenously or intraperitoneally, the beta toxin is lethal to adult 
mice, whereas oral administration is lethal to neonatal mice (Sakurai and Fujii, 
1987).  The beta toxin has been demonstrated to cause toxemia in mice, cardiac 
failure in rats (Steinthorsdottir et al., 1998), and fluid accumulation with mucosal 
hemorrhage in rabbit ileal loops (Yamagishi et al., 1987).  Recent reports suggest 
disease manifestations result from the ability of the beta toxin to cause cation 
dependent pore formation in susceptible cell membranes (Nagahama et al., 
2003; Shatursky et al., 2000; Steinthorsdottir et al., 2000).  However, the 
question of what makes some cell membranes susceptible remains unanswered. 
 The importance of the beta toxin in human and animal diseases has been 
demonstrated by immunization studies with beta toxoid (a non-toxic version of 
the beta toxin protein).  The beta toxoid vaccine has resulted in decreases in the 
incidence of pigbel caused by C. perfringens type C in humans (Lawrence et al., 
1990) and similar diseases in animals (Kennedy et al., 1977).  
 
 
The Epsilon Toxin 
 
Epsilon toxin is produced by C. perfringens types B and D, which are 
causes of rapidly fatal enterotoxemias in animals.  Recently, C. perfringens 
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epsilon toxin was classified as a category B potential bioweapon.  This category 
includes agents of the second highest priority that are relatively easy to spread, 
have moderate to low mortality rates, and require diagnostic capabilities not 
available in the routine microbiology laboratory (http://www3.niaid.nih.gov/topics/ 
BiodefenseRelated/Biodefense/ research/CatA.htm, accessed March 12, 2008).  
However, no human cases of disease associated with epsilon toxin producing 
strains of C. perfringens or purified toxin have been reported (Marks, 2004).  The 
epsilon toxin gene is 986 base pair and codes for a 328 amino acid prototoxin 
(Hunter et al., 1992).  The inactive prototoxin is secreted extracellularly, and 
proteolytic activation (e.g., by trypsin or chymotrypsin) is necessary for it to be 
toxic (Miyata et al., 2001).  The epsilon toxin gene is located on a large plasmid 
(Katayama et al., 1996).  It has not been the focus of many studies, so little 
information is available.   
Regulation of production of the epsilon toxin has not been elucidated.  The 
activated epsilon toxin binds to vascular endothelial cells of lamb, guinea pig, 
mouse, rabbit and sheep, and causes vascular damage and edema in the brain, 
heart, lungs, kidneys, and other organs (Buxton, 1978; Gardner, 1973).  
Neurological illnesses due to the ability of the toxin to cross the blood-brain 
barrier include opisthotonos and convulsions (Miyamoto et al., 1998).  The 
epsilon toxin is particularly active against hippocampal cells and kidney cells 
(Tamai et al., 2003).  
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The Iota Toxin 
 
The iota toxin is produced by type E C. perfringens, and has been 
implicated in cases of sporadic diarrhea in lambs and calves (Barth et al., 2004). 
Unique among C. perfringens extracellular toxins, the iota toxin is a binary toxin 
that consists of two separate proteins, designated iota-a and iota-b.  The iota 
toxin genes are located on a plasmid, and both are located within the same 
stretch of DNA in the same reading frame (Perelle et al., 1993).  The iota-a gene 
is 1,163 base pair in length.  It codes for a peptide that is 387 amino acids in 
length that is cleaved to form the mature 346 amino acids peptide.  The iota-b 
gene is 2,627 base pair in length, coding for a peptide of 875 amino acids in 
length (Perelle et al., 1993).  Regulation of the iota toxin at the transcriptional or 
translational level has not been described.  However, there is evidence the iota 
toxin may be activated extracellularly by a VirR/VirS regulated trypsin-like 
enzyme secreted by type E C. perfringens strains (Gibert et al., 2000).  Both 
proteins, iota-a and iota-b, are necessary for the toxic activities associated with 
the iota toxin (Nagahama et al., 2004).  The binding component iota-b is 
activated by trypsin removal of a 20kDa N-terminal peptide.  After activation the 
iota-b component can bind to a cell surface receptor (Stiles et al., 2000).  The 
bound iota-b facilitates internalization of the enzymatic iota-a component via 
receptor-mediated endocytosis (Blocker et al., 2001).  The internalized iota-a 
acts directly on actin monomers by ADP-ribosylation, impairing cell division and 
migration (Aktories, 1994).  
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Other Toxins and Enzymes 
 
Clostridium perfringens strains area also capable of producing up to 15 
minor toxins and enzymes, in addition to the four major lethal toxins.  The actions 
of these additional toxins and enzymes can affect the severity and course of an 
infection caused by C. perfringens.   
The theta toxin (also known as perfringolysin O) many be present in all 
strains of C. perfringens.  Like the alpha toxin, it is chromosomally encoded and 
positively regulated via the luxS system by the VirR/VirS two component 
regulatory system (Ohtani et al., 2002).  By binding cholesterol and causing lysis 
of red blood cells, the theta toxin can cause edema and ischemia that leads to 
decreased oxygen delivery to affected tissue (Iwamoto et al., 1993; Stevens et 
al., 1997).  Through a cardiac pressor effect, the theta toxin injected 
intravenously is lethal for mice (Stevens et al., 1988).  These actions of the theta 
toxin contribute to the necrotic effects seen in C. perfringens diseases, including 
clostridial myonecrosis.  
Some minor toxins have been found only in specific types of C. 
perfringens.  The delta toxin is a hemolysin with affinity for sheep, goat, and pig 
erythrocytes but is less active against erythrocytes from other mammals.  It is 
associated with only types B and C C. perfringens (Alouf and Jolivet-Reynaud, 
1981).  The lambda toxin is a proteinase that digests gelatin, hemoglobin, and 
casein.  The gene for the lambda toxin is located on a large plasmid and is 
associated with C. perfringens types B, D, and E (Jin et al., 1996).  Other 
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extracellular toxins associated with all types of C. perfringens include the 
following: the kappa toxin, a collagenase; the mu toxin, a hyaluronidase; as well 
as a neuraminidase (Rood, 1998); a hemolysin; a nuclease; and an extracellular 
endonuclease (Rood and Cole, 1991).  Because many of the genes for these 
minor toxins are located on the variably sized plasmids of C. perfringens, it has 
been suggested that it is possible to gain or lose these virulence genes 
(Katayama et al., 1996; Petit et al., 1999).  
 
 
The Enterotoxin 
 
The C. perfringens enterotoxin (CPE) has been extensively studied.  CPE 
is known to play a key role in outbreaks of C. perfringens food-borne illness 
(McClane, 1992), some cases of AAD (Modi and Wilcox, 2001; Sarker et al., 
1999; Sparks et al., 2001), and cases of sporadic diarrhea (Collie et al., 1998).  
The C. perfringens enterotoxin gene (cpe) has been identified in approximately 
5% of all C. perfringens isolates (Sarker et al., 2000; Sparks et al., 2001) and can 
be located on either the chromosome or a plasmid (Collie et al., 1998; Collie and 
McClane, 1998; Cornillot et al., 1995).  There is a positive correlation between 
strains with a chromosomally located cpe and food poisoning (Sarker et al., 
1999; Sarker et al., 2000; Sparks et al., 2001), while C. perfringens strains 
associated with non-food-borne gastrointestinal diseases carry cpe on a plasmid 
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(Collie and McClane, 1998; Sarker et al., 2000; Sparks et al., 2001).  The 
enterotoxin gene is 957 base pair long, encoding a polypeptide that is 319 amino 
acids (Czeczulin et al., 1993).  It is highly conserved regardless of whether the 
gene is located on the chromosome or a plasmid (Cornillot et al., 1995).  The 
enterotoxin is primarily associated with C. perfringens type A, although it has also 
been identified in some type C and type D strains (McClane, 1998; Skjelkvale 
and Duncan, 1975).  There is evidence that most type E strains of C. perfringens 
carry cpe on a plasmid; however, CPE is not produced by these strains.  
Although cpe is still highly conserved in these type E strains, there are a number 
of minor mutations that result in nonsense or frameshift mutations, as well as an 
absence of promoters upstream of the gene (Billington et al., 1998).  
Unlike other toxins produced by C. perfringens, CPE is not secreted from 
the cell; it is produced while the organism undergoes sporulation and is released 
when C. perfringens is lysed to release the spore (Labbe, 1989; Smedley et al., 
2004).  Regulation of CPE production occurs at the transcriptional level and 
appears to rely on a sporulation-specific sigma factor or transcriptional activator 
(McClane, 1998; Melville et al., 1994).  In the intestinal lumen, CPE binds to 
protein receptors on enterocytes.  Enterocyte receptors include claudins, proteins 
that serve a role in the formation of tight junctions between cells (Katahira et al., 
1997).  CPE forms protein complexes after binding cells that express the 
appropriate receptor in the host cell plasma membrane, including a small 
complex that corresponds in size to receptor-bound CPE (Wieckowski et al., 
1994).  The small complex cannot induce cytotoxicity, but the formation of a large 
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complex with an unknown composition precedes plasma membrane permeability 
changes and initiation of cytotoxicity (Kokai-Kun et al., 1999; Wnek and McClane, 
1989).  CPE induces pore formation in intestinal cell membranes, which results in 
fluid and electrolyte loss leading to cell death (McClane, 2000; Popoff, 1998).  
The main effects of CPE are on intestinal epithelial cells, especially those 
at the tips of the villi.  The highest activity is in the ileum, with lower activity in the 
jejunum (McDonel, 1979; Meer et al., 1997).  High concentrations of CPE can 
result in inflammation in the intestine, which likely contributes to some of the 
clinical manifestations associated with C. perfringens gastrointestinal diseases 
(Chakrabarti et al., 2003).  Although the mode of action of CPE has been well 
described and its association with food-borne disease in the United States has 
been documented, laboratory testing for CPE is seldom performed except in 
public health or research laboratory settings.  This is due in part to a lack of 
reliable commercially available rapid tests for identification of CPE in human 
clinical specimens.  Rapid tests are needed because CPE degrades very quickly 
in stool.  Also, the techniques and materials involved in the induction of 
sporulation and subsequent CPE production in C. perfringens strains isolated 
from humans with disease are complex and difficult for routine clinical 
laboratories to perform.    
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The Beta2 Toxin 
 
The beta2 toxin was first differentiated from the beta toxin by Gibert et al. 
in a 1997 publication.  However, the beta2 toxin was actually first described in a 
1986 publication by Jolivet-Reynaud et al. (of the same laboratory as Gibert), 
although it was thought to be the beta toxin.  These investigators were attempting 
to purify and characterize the beta toxin from CWC245, a type C strain of C. 
perfringens isolated from a piglet with necrotizing enterocolitis.  The purified toxin 
was lethal to mice, induced a dermonecrotic effect in guinea pigs, and was 
inactivated when trypsin was present (Jolivet-Reynaud et al., 1986).  All of these 
findings correlated with activities previously reported for the beta toxin (Lawrence 
and Cooke, 1980).  Additionally, the unknown toxin isolated by Jolivet-Reynaud 
et al. (1986) was cytotoxic to Chinese Hamster Ovary (CHO) cells and caused 
hemorrhagic necrosis of intestinal mucosa when a guinea pig ligated intestinal 
loop assay was performed.  However, the molecular weight of this isolated toxin 
was 27,670 Da (Jolivet-Reynaud et al., 1986), which differed from the molecular 
weight of 34,861 Da reported for the beta toxin (Hunter et al., 1993).  This 
difference in molecular weight prompted further study and characterization of the 
unknown toxin.  The new toxin was termed the beta2 toxin because of the 
similarity in biological activity to the beta toxin (Gibert et al., 1997).  Confirmation 
of the beta2 toxin as a novel toxin was shown by a lack of nucleotide sequence 
or amino acid sequence similarity with the beta toxin (Hunter et al., 1993) or any 
other known protein or toxin (Gibert et al., 1997).  It was suggested that the beta2 
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toxin was associated with some veterinary diseases because C. perfringens 
strains isolated from piglets with necrotic enteritis and from horses with 
enterocolitis were positive for the beta2 toxin gene (Gibert et al., 1997).    
Since the first publication identified the beta2 toxin in 1997 (Gibert et al., 
1997), other investigators have identified the presence of the beta2 toxin gene 
(cpb2) in all types (A-E) of C. perfringens isolated from a variety of animals 
(Baums et al., 2004; Bueschel et al., 2003; Garmory et al., 2000).  Manteca et al. 
(2002) identified strains of C. perfringens positive for cpb2 using a cpb2 gene 
probe followed by intestinal ligated loop assays in a study of bovine 
enterotoxaemia.  They postulated a synergism between the beta2 toxin and the 
alpha toxin in these bovine diseases.  Other investigators have identified cpb2 
using PCR or gene probes in C. perfringens strains associated with veterinary 
diseases in studies involving the following: diarrheic dogs (Thiede et al., 2001), 
an African elephant with ulcerative enteritis (Bacciarini et al., 2001), lambs with 
dysentery (Gkiourtzidis et al., 2001), a goat with enterotoxemia (Dray, 2004), 
reindeer (Aschfalk et al., 2002), cod fish (Aschfalk and Muller, 2002), hooded 
seals (Aschfalk and Muller, 2001), and chickens (Engstrom et al., 2003).  
Because the beta2 toxin was first identified in a strain of C. perfringens isolated 
from a piglet with necrotic enteritis, some studies of the beta2 toxin focused on 
porcine strains of C. perfringens.  Several studies found cpb2 in C. perfringens 
strains from pigs with gastrointestinal diseases, often associated with cpb (the 
beta toxin gene, in types B and C) (Bueschel et al., 2003; Garmory et al., 2000; 
Klaasen et al., 1999).  These studies also confirmed production of the beta2 toxin 
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in C. perfringens strains positive for cpb2 (Waters et al., 2003).  Other studies 
have focused on the possible relationship between the beta2 toxin and C. 
perfringens related diseases in horses.  In horses cpb2 was identified in C. 
perfringens type A; this was in contrast to porcine studies in which cpb2 was 
primarily associated with types B and C (Herholz et al., 1999; Tillotson et al., 
2002).  Immunohistochemistry was used to localize beta2 toxin in the 
gastrointestinal tract of horses with C. perfringens related disease (Bacciarini et 
al., 2003).  Others reported that they did not identify the beta2 toxin in their cpb2 
positive strains from horses and suggested that the beta2 toxin was below the 
detection level of their Western blotting assay (Waters et al., 2005).  Variation in 
production of the beta2 toxin by cpb2 positive strains of C. perfringens of all 
types (A-E) has been reported (Bueschel et al., 2003; Jost et al., 2005; Vilei et 
al., 2005).   
Nucleotide sequencing of cpb2 revealed that there was variation between 
cpb2 from different isolates.  The “consensus” sequences described by Jost et al. 
(2005) were similar to the sequence of the first cpb2 described (Gibert et al., 
1997), and isolates with these sequences were usually found to express the 
beta2 toxin.  However, strains of C. perfringens with “atypical” cpb2 sequences 
often did not produce the beta2 toxin (Jost et al., 2005).  The extent of the 
variability of cpb2 and the role of the beta2 toxin in virulence in C. perfringens 
diseases remains unclear.  
At the commencement of this investigation, there was a lack of information 
regarding beta2 in C. perfringens isolates from human sources.  We were 
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intrigued by questions concerning the possibility of a role for beta2 in C. 
perfringens diseases.  For instance, was cpb2 present in C. perfringens isolates 
from humans?  If so, how frequently or infrequently was it present?  Another 
question was whether the beta2 toxin was expressed in cpb2 positive isolates.  
Also of interest was whether the beta2 toxin could be implicated as a virulence 
factor in C. perfringens related diseases in humans.  Veterinary studies provided 
support for the hypothesis that beta2 toxin produced by C. perfringens from 
humans could be involved in human gastrointestinal diseases.   
Additionally, there were cpb2 sequences in GenBank that were not 
described in any publication we could find.  These were identified by the 
submitters as pseudogenes of cpb2 (accession numbers AJ537533-AJ537551).  
This seemed to suggest that these investigators had identified cpb2 nucleotide 
sequences that were not expressed.  If these genetic variants contained 
information necessary for transcription, then it was possible they might contain 
mutations that would prevent translation, or would change the structure of the 
protein such that function was affected.  As such, they would be unlikely to play a 
role in any disease process; therefore, it would be relevant to determine the 
functionality of cpb2 and the product of this gene, the beta2 toxin.  Studies 
focusing on these questions would provide much needed information concerning 
the beta2 toxin and its possible link to disease in humans, and could also aid in 
the general understanding of how C. perfringens causes disease. 
As this investigation progressed, new reports were published which 
provided further information about cpb2 and the beta2 toxin.  Specifically, reports 
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were published that focused on cpb2 and the beta2 toxin in C. perfringens 
isolates from humans with gastrointestinal diseases.  The C. perfringens type A 
strains from humans with antibiotic-associated diarrhea (AAD) or sporadic 
diarrhea (SD) carried the cpe gene on a plasmid, while most isolates from 
humans with food-borne disease carried the cpe gene on the chromosome 
(Fisher et al., 2005).  The association of cpe with cpb2 varied remarkably 
depending on the location of cpe; greater than 75% of C. perfringens isolates 
were cpb2 positive if cpe was located on a plasmid, while less then 15% were 
positive for cpb2 if cpe was on the chromosome (Fisher et al., 2005).  Other 
studies have provided additional information regarding cpb2 positive C. 
perfringens strains from humans with AAD or SD, including evidence that cpb2 is 
regulated at the transcriptional level (Harrison et al., 2005).  The plasmids that 
carry cpb2 have been described (Miyamoto et al., 2006).  These reports help to 
support the results and conclusions from this investigation, namely that the beta2 
toxin may be a virulence factor in C. perfringens diseases in humans.  
 
 
Research Aims 
 
The principal objective of this study was to determine the prevalence of 
cpb2, the beta2 toxin gene, in C. perfringens isolates from a variety of human 
sources, including isolates from a population of healthy volunteers.  Reports in 
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the literature have described the identification of cpb2 and a possible role for the 
beta2 toxin in gastrointestinal diseases of animals.  At the commencement of this 
study, information was lacking regarding the question of the possibility of a role 
for cpb2 and the beta2 toxin in C. perfringens related diseases in strains isolated 
from humans.     
After determining whether cpb2 was present in the C. perfringens isolates 
from the different human populations, we formed two interconnected hypotheses 
concerning cpb2 and the beta2 toxin of C. perfringens and their possible role in 
diseases of humans.  First, we hypothesized that cpb2 was present in isolates 
from humans with C. perfringens related diseases at a higher frequency than 
isolates from healthy volunteers.  The second hypothesis was that cpb2 positive 
C. perfringens isolates from healthy volunteers either contained a gene that was 
expressed at low levels, expressed a non-functional variant of the toxin, or 
encoded a gene that was not expressed.   
To determine the validity of our hypotheses, we defined three additional 
research aims.  First, we sought to identify any genetic variations of cpb2, which 
could predict the sequences of the protein toxin or variants of the protein toxin.  
This knowledge could aid in our understanding of differences in disease 
presentation, disease severity, and virulence of C. perfringens isolates in 
humans.  In addition, we also investigated the expression of beta2 toxin in cpb2 
positive isolates.  Finally, the last aim of this study was to determine the activity 
of recombinant beta2 toxin from C. perfringens strains from human sources 
produced by transformed E. coli in caco-2 cultured cells.  
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MATERIALS AND METHODS 
 
 
Clostridial Strains 
 
Growth and Storage of Organisms 
 
All strains of C. perfringens used in this study, with the exception of the 
reference strains, were selected from the stock culture collection of the Anaerobe 
Laboratory, Division of Clinical Microbiology, Department of Pathology and 
Laboratory Medicine, Indiana University School of Medicine.  These strains had 
been isolated from clinical specimens from volunteers for previous research 
studies.  The types of clinical specimens included: feces, wound or abscess 
material, blood, peritoneal fluid, and other normally sterile body fluids.  
Organisms were identified as C. perfringens based on Gram reaction and 
microscopic features, aerotolerance testing, colony characteristics, short-chain 
fatty acid profile, and reactions in biochemical tests.  Stock cultures were 
maintained in cooked meat (CM) storage medium (Remel Inc., Lenexa, KS).  The 
following scheme was used to grow and verify the correct identities of the 
bacteria included in this study (figure 4): each clostridial isolate was first cultured 
from the cooked meat (CM) storage medium onto a CDC formulation anaerobe 
blood agar plate (CDC-AnBAP) (Remel).  If there was no initial growth on the 
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CDC-AnBAP, the organism was inoculated into pre-reduced anaerobically 
sterilized (PRAS) cooked meat carbohydrate broth (PRAS-CMC) (Remel), and 
incubated under anaerobic conditions (in an atmosphere of 10% H2, 5% CO2, 
and 85% N2) at 35º C overnight in an anaerobic chamber (Anaerobic Chamber 
model B, Coy Laboratory Products Inc., Grass Lake, MI).  Organisms grown on 
the CDC-AnBAP were subcultured a minimum of three times on CDC-AnBAP to 
ensure purity and viability of the organism.  After subculturing, traditional 
phenotypic methods were used to confirm the identity of each isolate, including 
colony morphology, appearance of the growth on the CDC-AnBAP, and Gram’s 
stain features.  Colonies from the CDC-AnBAP were also used to inoculate two 
PRAS-CMC broth tubes and incubated under anaerobic conditions at 35º C 
overnight.  One PRAS-CMC tube was used for short-chain fatty acid analysis 
(both volatile and non-volatile fatty acids) using gas-liquid chromatography 
(GLC), and the other tube used to inoculate the appropriate PRAS media to 
determine the biochemical characteristics of the organism (table 1 and figure 2).  
If the organism was confirmed as C. perfringens based on colony characteristics, 
Gram’s stain features, short-chain fatty acid profiles, and biochemical reactions, 
then genomic DNA was collected from the isolate.  Typical colonies of C. 
perfringens on a CDC-AnBAP and the microscopic appearance on Gram’s stain 
of a pure culture of C. perfringens are shown in figure 1.  Organisms that were 
not verified as C. perfringens were not maintained or used in this study.  
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Short-Chain Fatty Acid Analysis 
 
Short-chain fatty acid analysis of volatile and non-volatile fatty acids using 
GLC was performed as part of the identification process for each clostridial strain 
(figure 2) (Jousimies-Somer et al., 2002).  Isolated colonies were used to 
inoculate a PRAS-CMC broth culture tube.  Following overnight incubation under 
anaerobic conditions at 35º C, the broth in the PRAS-CMC culture tube was 
acidified with 400 µl of a 50% (w/v) H2SO4 solution (Fisher Scientific International 
Inc., Hampton, NH) and divided equally into two glass tubes (2.0 ml each).  For 
analysis of volatile fatty acids, one tube containing 2.0 ml of acidified broth 
culture was extracted once using an equal volume of ethyl ether (Fisher).  The 
organic layer was then removed and the volatile fatty acid profile determined 
using a Varian 3700 Gas Chromatograph (Varian Instrument Group, Walnut 
Creek, CA) fitted with an SP 1000 column (Supelco Inc., Bellefonte, PA) and 
flame ionization detector.  For analysis of the non-volatile fatty acids, the other 
tube containing 2.0 ml acidified culture was used.  Accordingly, 1.0 ml of 
methanol (Fisher) was added along with 100 µl of a 50% (w/v) solution of H2SO4.  
Then the tube was vortexed vigorously and heated to 60º C for 30 minutes.  After 
cooling to room temperature, 500 µl of chloroform (Fisher) was added and the 
tube was centrifuged in a bench top clinical centrifuge for 5 minutes to allow the 
chloroform and water layers to separate.  The water layer was removed by gentle 
vacuum suction, and the bottom chloroform layer collected for determination of 
the non-volatile fatty acid profile using GLC analysis with a Varian 3700 Gas 
  34 
Chromatograph (Varian Instrument Group, Walnut Creek, CA) fitted with an SP 
1000 column (Supelco Inc., Bellefonte, PA) and flame ionization detector.  
Typical profiles for both volatile fatty acids and non-volatile fatty acids are shown 
in figure 2.   
 
 
Biochemical Characterization 
 
The biochemical characteristics of each strain of C. perfringens were 
determined using the identification scheme of the Anaerobe Laboratory, which 
was originally based on data from Holdeman et al. (1977), but updated recently 
(Winn et al., 2006; Jousimies-Somer et al., 2002).  Broth from an overnight 
culture of PRAS-CMC (figure 4) was used to inoculate the PRAS biochemical 
media (Remel; by injection of three to five drops through the rubber stopper).  
The PRAS biochemical media was incubated at 35º C in ambient air.  The 
following day, the carbohydrate fermentations were determined by direct 
measurement of the pH of the cultures using a Zeromatic SS-3 pH meter 
(Beckman, Palo Alto, CA).  Other biochemical tests were either interpreted after 
addition of appropriate indicators (e.g., for nitrate reduction, indole production, 
and bile esculin) or directly interpreted (e.g., for milk digestion, and hydrolysis of 
gelatin). Typical findings for C. perfringens carbohydrate fermentations are 
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shown in table 1, and an image of a typical result for digestion of milk is shown in 
figure 1d.  
 
 
Reference Strains 
 
Reference strains of C. perfringens were obtained from two sources: the 
American Type Culture Collection (ATCC) (Manassas, VA) and the National 
Collection of Type Cultures (NCTC) (London, United Kingdom).  Strains ATCC 
13124 and ATCC 8009 were both type A; ATCC 12917 was type A and cpe 
positive; ATCC 27324 was type E and cpe positive.  NCTC 4964 was type B; 
NCTC 3227 and NCTC 10719 were both type C; NCTC 8503 was type D.  The 
lyophilized materials were reconstituted per the instructions provided by the 
supplier with the strains.  These bacteria were grown on CDC-AnBAP under 
anaerobic conditions at 35º C and checked for purity and rapidity of growth.  The 
reference strains were verified as C. perfringens by using the same procedure 
described above for the isolates obtained from the Anaerobe Laboratory culture 
collection at Indiana University.  Gram reaction, cellular features, aerotolerance 
testing, colony characteristics, short-chain fatty acid profile, and biochemical 
characteristics were all used to confirm the identity of the reference strains. 
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Genomic DNA Isolation from C. perfringens Isolates 
 
After confirming the identity of an isolate as C. perfringens, a single colony 
from the CDC-AnBAP was used to inoculate 10 ml of brain heart infusion broth 
(BHIB) and grown under anaerobic conditions at 35º C overnight.  Genomic DNA 
was then isolated from each overnight culture according to the following 
procedure.  First, the culture was centrifuged at 2500 x g at 4º C for 15 minutes in 
a Sorvall RC-3B using the H-4000 rotor to pellet the bacterial cells, and the cell 
supernatant was removed.  The cells were then washed in 10 ml of 10X TE 
(100mM Tris-HCl (pH 8.0) and 10mM EDTA), and centrifuged again at 2500 x g 
at 4º C for 15 minutes in a Sorvall RC-3B using the H-4000 rotor to pellet the 
bacterial cells, and the 10X TE buffer was aspirated.  The cells were 
resuspended in 2.0 ml of 10X TE buffer, to which 10 µl of lysozyme (100 mg/ml in 
0.25 M Tris-HCl, pH 8.0) was added, and incubated for 1 hour at 35º C with 
agitation.  Next, 200 µl of 10% (w/v) sodium dodecyl sulfate (SDS) was added, 
and the mixture incubated at 60º C for 10 minutes.  This was followed by addition 
of 20 µl of 0.5 M EDTA, and 6.0 µl of proteinase K (15.1 mg/ml) (Sigma), with 
incubation at 35º C for 2 hours.  Then 440 µl of 5 M NaClO4 (Sigma) was added, 
and the mixture was incubated at 65º C for 30 minutes.  Following this 
incubation, the cell lysate was extracted by addition of an equal volume of 
phenol:chloroform:isoamyl alcohol in a 25:24:1 ratio (PCI), and mixed well for 5 
minutes at room temperature.  The phases were then separated by centrifugation 
at 2,500 x g at 4º C for 5 minutes in a Sorvall RC-3B (Thermo Electron 
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Corporation, Ashville, NC) using the H-4000 rotor, and the upper (aqueous) 
phase was removed to a fresh tube.  The cell lysate was extracted again with an 
equal volume of chloroform:isoamyl alcohol in a 24:1 ratio for 30 minutes with 
agitation, and separated by centrifugation at 2,500 x g at 4º C for 15 minutes in a 
Sorvall RC-3B (Thermo Electron) using the H-4000 rotor.  Next, the upper 
(aqueous) phase was removed to a fresh tube, and the DNA was precipitated 
with an equal volume of 2-propanol at -20º C overnight.  The DNA was pelleted 
by centrifugation at 14,000 x g in a microcentrifuge for 10 minutes, and the 2-
propanol was removed.  The pellet of DNA was washed with 70% ethanol and 
centrifuged for 5 minutes at 14,000 x g in a microcentrifuge.  Finally, the 70% 
ethanol was removed, the pellet of DNA allowed to dry, and the DNA 
resuspended in 200 µl of H2O.  After collection of the total DNA, aliquots were 
made of each sample.  Some aliquots were stored at 4º C and the others stored 
at -20º C, for later use in multiple experiments. 
 
 
Quantitation and Qualification of DNA 
 
To determine the concentration of DNA isolated from each C. perfringens 
strain, ultraviolet absorbance spectrophotometry was performed using a 
Beckman DU 640 UV/Visible spectrophotometer (Fullerton, CA).  Samples were 
diluted 1:100 in distilled deionized water for total volume of 100 µl.  The 
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absorbance of the sample at 260 nm and 280 nm was read by the 
spectrophotometer.  At an absorbance of 260 nm, 1.0 correlates with 50 µg/ml of 
double stranded DNA.  The concentration of DNA (µg/ml) was calculated by 
multiplying the absorbance of the sample at 260 nm by 100 (the dilution factor) 
and then multiplying by 50 because the sample is double stranded DNA.  To 
estimate the purity of the genomic double stranded DNA isolated from each C. 
perfringens strain, the ratio of the absorbance of the sample at 260 nm to the 
absorbance of the sample at 280 nm was determined.  A ratio of 1.8 indicated a 
more pure, or better quality, sample of double stranded DNA.  A ratio above or 
below 1.8 signified a sample contaminated with either phenol or protein.  
 
 
Polymerase Chain Reaction (PCR) 
 
Oligonucleotide primers used for PCR were purchased from Integrated 
DNA Technologies, Inc. (IDT) (Coralville, IA).  The oligonucleotides were ordered 
at approximately 25 nmol concentration and purified using standard desalting 
techniques to remove contaminating organic salts.  Upon receipt in the 
laboratory, oligonucleotides were resuspended in DNAse-free H2O (HyClone, 
Logan, UT) to make a stock concentration of 100 pmol/µl. 
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All PCR reactions were performed using TaKaRa Taq Polymerase, along 
with the supplied 10X PCR buffer, dNTPs, and 25 mM MgCl2 (TAKARA BIO, Inc., 
Otsu, Shiga, Japan). 
Temperature cycling, which varied depending on the PCR protocol used, 
utilized the Applied Biosystems GeneAmp PCR 2700 (Foster City, CA) 
thermocycler.  
 
 
 Multiplex PCR   
 
The genotype of each isolate was determined by using a multiplex 
polymerase chain reaction described by Garmory et al. (2000), with minor 
changes (http://microvet.arizona.edu/research/ClostridiumWeb/methods.html, 
accessed September 8, 2003).  This multiplex PCR allowed us to determine the 
genotype of the strains of C. perfringens.  It enabled the identification of the four 
major toxin genes; cpa (alpha toxin), cpb (beta toxin), etx (epsilon toxin), and iA 
(iota toxin), if they were present in the genome of that strain.  This PCR method 
also detected the presence of cpe and/ or cpb2 if either was present in the 
genomic DNA of the organism.  Each of these six genes had a region that was 
amplified by a set of primers specific for that toxin gene (table 3).  The final 
genotype for each strain was based on results from three separate multiplex 
PCR reactions.  To assay for the six possible gene fragments, the following were 
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mixed together in one reaction tube: 2.6 µl of cpa-F-1438/cpa-R-1743 (10 
pmol/µl), 1.8 µl of cpb-F-871/cpb-R-1046 (10 pmol/µl), 2.6 µl of iA-F-275/iA-R-
701 (10 pmol/µl), 2.2 µl etx-F-227/etx-R-862 (10 pmol/µl), 1.8 µl of cpb2-F-
492/cpb2-R-1058 (10 pmol/µl), and 1.7 µl of cpe-F-439/cpe-R-650 (10 pmol/µl), 
5.0 µl 10X PCR buffer, 1.0 µl of 25 mM MgCl2 (for a final concentration of 2 mM), 
4.0 µl of dNTPs, 12.1 µl H20, 0.5 µl (2 units) of Taq, and 2.0 µl of C. perfringens 
genomic DNA (approximately 50 ng).  The gene fragments were amplified using 
the PCR with denaturing for 2 minutes at 95º C, followed by 35 cycles consisting 
of: 1 minute at 94º C, 1 minute at 55oC, 1 minute at 72º C, and an additional 
period of extension for 10 minutes at 72º C.  Eighteen microliters of each PCR 
product was mixed with 3.0 µl of loading dye (Promega, Madison, WI) and loaded 
onto a 1.5% agarose gel and electrophoresed for approximately 1 hour with 90 
volts.  The gel was stained using ethidium bromide and band patterns visualized 
with ultraviolet light.  A negative control using H2O in place of the sample DNA 
was processed along with the sample DNA for each PCR performed and run 
along with the sample DNA to ensure that reagents were free of any 
contaminating DNA.  Genomic DNA from the C. perfringens reference strains 
was also included with each PCR batch to ensure that the six genes being 
assayed for were indeed amplified with that mix of reagents, serving as positive 
controls.  
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Simplex PCR   
 
Simplex PCR reactions, using three separate sets of primers, were used 
to confirm the presence and further characterize cpb2 from isolates positive for 
cpb2 by the multiplex PCR.  Different primer sets, for different regions of cpb2, 
were used for each simplex PCR (table 4).  Three separate simplex PCR 
reactions were performed for each isolate because of reports that some strains 
were cpb2 positive using a set of PCR primers designed by Garmory et al. 
(2000), but that these same strains were not positive for cpb2 using primers 
designed by Herholz et al. (1999) (Marks and Kather, 2003).  We chose to 
perform a PCR reaction using the primer set for cpb2 described by Garmory et 
al. (2000) to verify the results from the multiplex PCR.  The simplex PCR using 
the primer set of Herholz et al. (1999) was used to determine if our strains 
remained cpb2 positive using this primer set.  The third set of PCR primers were 
designed in this laboratory in an attempt to amplify the entire cpb2 sequence 
according to the cpb2 nucleotide sequence described by Gibert et al. (1997).  
The protocol for each simplex PCR was essentially the same, differing only in the 
primer set used and the annealing temperature.  For each simplex PCR: 5.0 µl of 
each forward and reverse primer (10 pmol/µl) were mixed with 5.0 µl 10X PCR 
buffer, 1.0 µl of 25 mM MgCl2 (for a final concentration of 2 mM), 4.0 µl dNTPs, 
21.25 µl H20, 0.5 µl (2 units) of Taq, and 2.0 µl of C. perfringens genomic DNA 
(approximately 50 ng).  The gene fragment was amplified by denaturing for 2 
minutes at 95º C, followed by 35 cycles consisting of: 30 seconds at 94º C, 30 
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seconds at the annealing temperature required by the primers (table 4), 45 
seconds at 72º C, and finally an additional period of extension for 10 minutes at 
72º C.  A total of 18 µl of each PCR product was then mixed with 3.0 µl of 6X 
loading dye and was loaded onto a 1.5% agarose gel and run for approximately 1 
hour at 90 volts.  The gel was stained using ethidium bromide and visualized with 
ultraviolet light.  A negative control using H2O in place of the sample DNA was 
processed along with the sample DNA for each PCR performed and included 
with the sample DNA to ensure that reagents were free of any contaminating 
DNA.  Additionally, a reference strain of C. perfringens that was negative for 
cpb2 (ATCC 13124) was also run with each PCR batch of samples processed as 
a negative control.  A positive control using the cpb2 positive reference strain 
(NCTC 10719) was included with each PCR batch to ensure amplification of 
cpb2, if the gene was present in the genomic DNA being assayed.  
 
 
Triplex PCR 
 
Jost et al. (2005) described what they called a triplex PCR that was used 
in this study to supplement the DNA sequencing results (described in a 
subsequent section).  It was also used to determine whether the cpb2 gene was 
a “consensus” type (group-1 cpb2, the designation used by our laboratory) or an 
“atypical” type (group-2 cpb2, the designation used by our laboratory).  For the 
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triplex PCR, three individual primers were used, including two forward primers, 
one specific for the group-1 cpb2 and the other specific for the group-2 cpb2; and 
a reverse primer common to both sequences (table 5), which is the same reverse 
primer for cpb2 used in the multiplex PCR.  For each triplex PCR reaction, 2.5 µl 
of each primer (10 pmol/µl) were mixed with 5.0 µl of 10X PCR buffer, 1.0 µl of 
25 mM MgCl2 (for a final concentration of 2 mM), 4.0 µl dNTPs, 35.25 µl of H20, 
0.5 µl (2 units) of Taq, and 2.0 µl of C. perfringens genomic DNA (approximately 
50 ng).  The gene segments were amplified using the protocol described by Jost 
et al. (2005), with minor modifications.  Briefly, denaturation was performed for 2 
minutes at 95º C, followed by 35 cycles consisting of: 30 seconds at 94º C, 30 
seconds at 50º C, 30 seconds at 72º C, with an additional period of extension for 
10 minutes at 72º C.  A total of 18 µl of each PCR product was mixed with 3.0 µl 
of 6X loading dye, loaded onto a 1.5% agarose gel, and run for approximately 1 
hour at 90 volts.  The gel was stained using ethidium bromide and visualized with 
ultraviolet light.  Expected amplification products were a 304 base pair product 
for group-1 cpb2, and a 741 base pair product for group-2 cpb2.  A negative 
control using H2O in place of the sample DNA was processed along with the 
sample DNA for each PCR performed and run along with the sample DNA to 
ensure that reagents were free of any contaminating DNA.  As a positive control, 
DNA collected from C. perfringens ATCC 27324, which contains both the group-1 
cpb2 gene and the group-2 cpb2 gene, was processed with our unknown sample 
to ensure that each type of cpb2 gene would amplify if present in the genomic 
DNA sample.   
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Nucleotide Sequencing and Amino Acid Sequence Prediction   
 
Nucleotide sequences of the cpb2 gene from the genomic DNA of C. 
perfringens strains were produced using a D-rhodamine matrix on an ABI Prism 
310 Genetic Analyzer (Applied Biosystems, Foster City, CA) automated 
sequencer.  
At the commencement of this portion of this investigation, two cpb2 
sequences had been published by others (Gibert et al., 1997; Shimizu et al., 
2001).  The first published sequence, termed CWC245-cpb2 (our laboratory’s 
designation), came from a type C strain of C. perfringens, from a piglet with 
necrotic enteritis (Gibert et al., 1997).  The second sequence was CP13-cpb2 
(our laboratory’s designation), from a type A strain of C. perfringens, identified 
during a whole genome sequencing project (chromosomal and plasmid) of strain 
13 (Shimizu et al., 2001; Shimizu et al., 2002a).   
The primers we designed for sequencing cpb2 were primarily based on 
CP13-cpb2 because the strains we tested were all identified as type A C. 
perfringens originally isolated from humans.  We designed three sets of primers 
to amplify cpb2, or regions of cpb2.  The first set of primers, 13G-cpb2-492/1058, 
corresponded to the same primers used in the multiplex PCR (table 3), with a few 
base changes made when the CP13-cpb2 sequence was used for the primer 
design.  The PCR primers 13G-cpb2-492/1058 amplified a 567 base pair region 
of cpb2 (figure 5).  The second set of primers, 13H-cpb2-377/950, were the same 
primers as those used in cpb2PCR-2 (Herholz et al., 1999), with minor base 
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changes according to the CP13-cpb2 sequence.  This second set of PCR 
primers, 13H-cpb2-377/950 amplified a 574 base pair region of cpb2, which 
overlaps with the region amplified by the first set of primers by 459 base pair 
(figure 5).  The third primer set, 13M-cpb2(-)22/(+)33, was designed to amplify 
the entire open reading frame of cpb2, and was also based on the CP13-cpb2 
sequence (figure 5).  Sequences were obtained for all cpb2 positive strains, 
using a minimum of one of the primer sets described above.  Multiple primer sets 
were used as needed for a cpb2 positive C. perfringens strain in an effort to 
obtain the entire cpb2 nucleotide sequence for each strain.  
PCR was performed as described previously (see previous section on 
polymerase chain reaction, simplex PCR).  Four microliters of the PCR reaction 
was combined with 2.0 µl of H20 and 1.0 µl of 6X loading dye, and 
electrophoresed through a 1.5% agarose gel at 100 volts for 1 hour.  If only one 
band at the expected size was seen, the remaining PCR product was purified by 
spin dialysis through a Sepharose CL-6B (Sigma) column.  If multiple bands were 
observed in the PCR product, the remaining 46 µl of PCR product was combined 
with 7.0 µl of 6X loading dye and run in two adjacent wells of a 1.5% agarose gel 
at 100 V for 1 hour.  The band at the expected size was cut out of the gel and 
purified by electroelution using cellulose dialysis tubing with a MW cut-off of 
12,000-14,000 (Sigma).  The quantitation and qualification of DNA was 
performed as previously described under the section heading “Genomic DNA 
isolation from C. perfringens isolates” prepared for nucleotide sequencing 
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according to the protocol provided with the ABI Prism 310 Genetic Analyzer 
(Applied Biosystems) automated sequencer. 
The Basic Local Alignment Search Tool (BLAST) was used to search for 
similar or related sequences that were published in the NCBI database 
(http://www.ncbi. nlm.nih.gov/BLAST/) (Altschul et al., 1990).  
Alignment studies of DNA sequences and amino acid sequences were 
performed using ClustalW, through the European Bioinformatics Institute (EBI) 
website: http://www.ebi.ac.uk/clustalw/ (Higgins et al., 1994).  The ClustalW 
program calculates the best matches for submitted sequences to sequences 
within its database producing an alignment of sequences that aides investigators 
in the determination of identity, similarity, and possible homology between 
sequences.  The pairwise alignment scores produced by the ClustalW program 
correspond to the percent identity between sequences that are reported in the 
results section.  Similarity between sequences means that the sequences share 
a statistically significant number of bases or amino acids.  Homology indicates 
shared ancestry between two sequences, and can be inferred for sequences that 
have a high percentage of identity or similarity.  However, a high percentage of 
identity or similarity does not automatically imply homology.  Consensus 
sequences were determined using the nucleotide sequence alignment generated 
by the ClustalW program for the cpb2 sequences (and partial sequences) for our 
C. perfringens strains.  For differences in nucleotide bases between sequences, 
the base that was found in the majority of sequences was selected and used in 
the consensus sequence.   
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Nucleic acid sequences were then translated using an online translation 
tool to convert the nucleotide sequence (DNA or RNA) into a deduced protein 
sequence (http://au.expasy.org/tools/dna.html) available from the ExPASy 
(Expert Protein Analysis System) proteomics server of the Swiss Institute of 
Bioinformatics (SIB) (Gasteiger et al., 2003). 
 
 
Isolation of Culture Supernatant Proteins 
 
Proteins were isolated from the culture supernatant essentially as 
described by Waters et al. (2003).  Briefly, an isolated colony of C. perfringens 
from a CDC-AnBAP was used to inoculate two 10 ml tubes of Brain Heart 
Infusion Broth (BHIB) (Gibco) and grown overnight under anaerobic conditions at 
35º C.  The overnight culture was centrifuged to pellet the bacterial cells, and the 
culture supernatant was then transferred to a clean tube.  Proteins were 
precipitated overnight at 4º C, after the addition of 4.76 grams of ammonium 
sulfate ((NH4)2SO4) (Fisher Scientific) per 10 ml of culture supernatant.  
Precipitated proteins were collected by centrifugation at 27,000 x g in a Sorvall 
RC-5B plus centrifuge (Thermo Electron) using the SS-34 rotor at 4º C for 20 
minutes, followed by a wash with 2.0 ml of cold acetone, and another 
centrifugation at 27,000 x g in a Sorvall RC-5B plus centrifuge (Thermo Electron) 
using the SS-34 rotor at 4º C for 20 minutes.  The remaining acetone was 
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allowed to evaporate, and the proteins were then resuspended in 1.5 ml of H2O.  
The concentrated cell culture supernatant proteins were stored at -20º C. 
 
 
Western Blotting 
 
Western Blotting with Polyclonal Anti-Beta2 Antibody 
 
Western blotting was performed according to the basic protocol provided 
with the Invitrogen NuPAGE® Novex Bis-Tris gels using the XCell IITM Blot 
Module, with minor modifications.  Thirty microliters of the concentrated cell 
culture supernatant proteins were mixed with 30 µl of lithium dodecyl sulfate 
(LDS) sample buffer (Invitrogen, Carlsbad, CA), and this mixture was heated in 
boiling H2O for 5 minutes.  The samples were then immediately placed on ice, 
and 15 µl of each sample was loaded into a single well of a NuPAGE® Novex    
10% Bis-Tris 15 well (1.5mm) gel or 10 well (1.5 mm) gel (Invitrogen).  Proteins 
were separated by electrophoresis at 200 volts for 40 minutes, using MES SDS 
running buffer (Invitrogen).  The separated proteins were transferred to an 
ImmobilonTM-P Polyvinylidene Difluoride (PVDF) membrane (Millipore Co., 
Billerica, MA), using the XCell IITM Blot Module set at 35 volts for 2 hours.  The 
PVDF membrane was stained using a Ponceau S solution [0.1% (w/v) (Sigma) in 
5% (v/v) acetic acid (Sigma)] to verify separation of the proteins and then washed 
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with H2O to remove the Ponceau S solution.  The membrane was blocked 
overnight at 4º C with Tris buffered saline plus 0.1% (v/v) Tween-20 (Sigma) 
(TBST) and 5% Carnation® non-fat dried milk (Nestlé® USA, Glendale, CA).  
Next, the membrane was probed with a 1:5,000 dilution (in TBST + 5% 
Carnation® non-fat dried milk) of polyclonal rabbit anti-beta2 antibody and 
incubated at room temperature for 3 hours.  This antibody was kindly provided by 
Dr. Popoff (Gibert et al., 1997), and produced in rabbits using the CWC245 type 
C strain of C. perfringens.  This was followed by four, 15 minutes washes of 
TBST.  The membrane was then incubated with a 1:500,000 dilution (in TBST + 
5% Carnation® non-fat dried milk) of a donkey anti-rabbit horseradish peroxidase 
(HRP) labeled antibody (Amersham Biosciences, Piscataway, NJ) for 1 hour at 
room temperature, and followed again by four, 15 minutes washes in TBST.  
Finally, the membrane was incubated for 5 minutes with ECL AdvanceTM 
(Amersham Biosciences) which is a chemiluminescent substrate, and apposed to 
autoradiography film for 30 seconds to 15 minutes.  The film was developed 
using a Kodak Medical X-Ray processor (Rochester, NY).   
 
 
Western Blotting with Monoclonal Anti-Beta2 Antibody 
 
A second Western blotting procedure was performed using a monoclonal 
goat anti-beta2 antibody kindly provided by Dr. Songer (Bueschel et al., 2003), 
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according to the same procedure as described above with a few changes.  The 
monoclonal antibody was generated using the cpb2 sequence described by 
Gibert et al. (1997), minus the coding region for the signal sequence; 
characterization of the specific epitope was not described.  The blocking buffer 
used was TBST plus 3% bovine serum albumin (BSA) (Sigma), plus 0.1% 
sodium azide (NaN3) (Sigma); this solution was also used as the diluent for the 
primary and secondary antibodies.  The membrane was blocked for 3 hours at 
room temperature, followed by an overnight incubation at room temperature with 
the monoclonal goat anti-beta2 antibody diluted 1:25.  After washing with TBST, 
the membrane was incubated for 2 hours at room temperature with a 1:10,000 
dilution of donkey anti-goat IgG-HRP labeled antibody (Amersham Biosciences).  
The remaining steps were the same as in the protocol described above.     
 
 
Stripping Probed Membranes 
 
Membranes were stripped of primary and secondary antibodies using 
RestoreTM Western blot stripping buffer (Pierce, Rockford, IL).  Briefly, the 
membrane was rinsed in TBST and incubated in the RestoreTM Western blot 
stripping buffer for 15 minutes at room temperature, followed by a wash in TBST 
for 5 minutes at room temperature.  The membrane was stored wet, wrapped in 
plastic wrap at 4º C until it was re-probed.  
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Cloning cpb2 for Expression by Escherichia coli 
 
The functional region of cpb2 (the beta2 gene, minus the 90 base pair 
region that codes for the predicted signal sequence in C. perfringens), as 
described by Gibert et al. (1997), was cloned into a plasmid vector and 
expressed in E. coli.  Western blotting assays showed that most of the 
recombinant beta2 protein toxin was in the cell culture supernatant versus the 
pellet of E. coli.  Therefore, the cell culture supernatant of the recombinant E. 
coli, which included the recombinant beta2 protein toxin, was collected and 
concentrated for use in future experiments.   
 
 
Preparation of the cpb2 Insert 
 
A 707 base pair region of the cpb2 gene corresponding to the segment 
between base 124 and base 831 (figure 5) was amplified using PCR.  During the 
PCR reaction a BamH1 restriction enzyme site was added to the 5’ end, and an 
EcoR1 restriction enzyme site was added to the 3’ end to allow for directional 
insertion into the vector.  These restriction enzyme sites, at these specific 
locations, were chosen because the vector that we selected has a BamH1 and 
an EcoR1 site at a location that allowed for insertion of the gene segment of cpb2 
in the proper orientation within the vector (figure 6).  Also, the region of cpb2 that 
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was selected for insertion into the plasmid vector, did not contain either a BamH1 
or an EcoR1 site.  To amplify the desired 707 base pair region of cpb2 and to 
add the restriction enzyme sites, two sets of primers were used in the PCR 
reactions (table 6), one set designed by this laboratory and the other set 
designed by Bueschel et al. (2003) and Jost et al. (2005).  For each PCR 
reaction, 5.0 µl of both the forward and reverse primers (10 pmol/µl) were mixed 
with 5.0 µl of 10X PCR buffer, 1.0 µl of 25 mM MgCl2 (for a final concentration of 
2 mM), 4.0 µl of dNTPs, 21 µl of H20, 0.5 µl (2 units) of Taq, and 2.0 µl of C. 
perfringens genomic DNA (approximately 50 ng).  The gene fragment, along with 
the flanking restriction enzyme sites, was amplified by denaturing for 2 minutes at 
95º C, 10 cycles of: 30 seconds at 94º C, 30 seconds at 48º C, 1 minute at 72º C, 
10 cycles of: 30 seconds at 94º C, 30 seconds at 54º C, 1 minute at 72º C, 
followed by 15 cycles of: 30 seconds at 94º C, 30 seconds at 60º C, 1 minute at 
72º C and an additional period of extension for 10 minutes at 72º C.  Two 
microliters of the PCR product was mixed with 1.0 µl of 6X loading dye, and 4.0 
µl of H2O, loaded onto a 1.5% agarose gel, and electrophoresed for 1 hour at 90 
volts.  The gel was stained using ethidium bromide and visualized with ultraviolet 
light.  A negative control using H2O in place of the sample DNA was processed 
with each batch of samples prepared for PCR.  If only one band of the expected 
size was observed, the remaining PCR product was purified by spin dialysis 
through a Sepharose CL-6B (Sigma) column.  Spin dialysis is a gel filtration 
chromatography technique used to separate small molecules from high 
molecular weight DNA.  If multiple bands were observed in the PCR product, the 
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remaining 48 µl of PCR product was combined with 7.0 µl of 6X loading dye and 
electrophoresed in two adjacent wells of a 1.5% agarose gel at 100 volts for 1 
hour.  The band at the expected size was cut out of the gel and purified by 
electroelution using dialysis tubing with a MW cut-off of 12,000- 14,000.  
Quantitation and qualification of the PCR product DNA was performed as 
previously described under the section heading “Genomic DNA isolation from C. 
perfringens isolates” to determine the amount needed for use in the restriction 
enzyme digest. 
Digestion of the cpb2 amplicon with BamH1 (Invitrogen) and EcoR1 
(Invitrogen) was performed in one reaction mixture.  Briefly, 10 µg of cpb2 
amplicon was mixed with 2.0 µl of 10X React® 3 buffer (supplied with the 
enzymes (Invitrogen)), 1.0 µl of BamH1, 1.0 µl of EcoR1, and H2O to bring the 
total volume to 20 µl.  The reaction mixture was incubated at 35º C overnight.  To 
verify that the amplicon was not digested by the restriction enzymes within the 
cpb2 segment, and was of the appropriate size (716 base pair, including the 
added bases from the PCR), 2.0 µl of the reaction mixture was combined with 1.0 
µl of 6X loading dye, and 4.0 µl of H2O and electrophoresed through a 1.5% 
agarose gel for 1 hour at 90 volts.  The gel was stained using ethidium bromide 
and visualized with ultraviolet light.  The remaining reaction mixture was purified 
using spin dialysis through a Sepharose CL-6B column.  
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Ligation of the cpb2 Insert with the pRSET Vector 
 
We chose to use the pRSET A,B,C vector system (Invitrogen) because of 
the features of the vectors.  The pRSET vector system comes with three vectors, 
designated A, B, C, with differences in their reading frames, allowing for selection 
of the recombinant vector that places the insert in the correct reading frame for 
expression.  Each of the pRSET vectors has multiple restriction enzyme sites to 
allow for directional cloning, an ampicillin resistance gene (bla) for antibiotic 
selection of E. coli that contain the pRSET vector plasmid, and the T7 promoter 
which controls gene expression in an E. coli strain with lacI controlled expression 
of T7 RNA polymerase. 
Depending on the primer set used to amplify the cpb2 insert (table 6), 
either the pRSET A vector or the pRSET B vector was used.  Vectors were 
digested with the same restrictions enzymes used to digest the inserts, following 
the same procedure described above.  
Ligation of the vector with the insert used T4 DNA ligase (Promega).  
Briefly, a 1:3 ratio of vector to insert was mixed with 2.0 µl of 10X buffer (provided 
with the enzyme (Promega)), 1.0 µl of T4 DNA ligase, and H2O to bring the total 
volume to 20 µl.  This mixture was incubated at room temperature overnight.  To 
verify that ligation reactions occurred, 2.0 µl of the reaction mixture was 
combined with 1.0 µl of 6X loading dye, and 4.0 µl of H2O and electrophoresed 
through a 1.5% agarose gel for 1 hour at 90 volts.  The gel was stained using 
ethidium bromide and visualized with ultraviolet light.   
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Top 10F’ E. coli Transformation for Plasmid Maintenance  
 
After ligation of the vector and cpb2 insert, the ligation reaction mixture 
was used to transform Top10F’ E. coli (see table 7 for a description of the 
genotype), using the protocol provided with the pRSET vector system.  Briefly, 
100 ng of the ligation mixture was added to 100 µl of competent Top10F’ E. coli, 
and incubated on ice for 30 minutes.  The cells were heat shocked for 45 
seconds at 42º C and then incubated on ice for 2 minutes, followed by the 
addition of 500 µl of SOC broth [20 grams of tryptone (Bacto Laboratories Pty, 
Ltd., Liverpool, United Kingdom), 5.0 grams of yeast extract (Bacto), 2.0 ml of 5 
M NaCl (Sigma), 2.5 ml of 1 M KCl (Sigma), 10 ml of 1 M MgCl2 (Sigma), 10 ml 
of 1 M MgSO4 (Sigma), 20 ml of 1 M glucose (Bacto), bring the total volume to 
1.0 liter with distilled H2O and autoclave to sterilize].  The newly transformed 
Top10F’ E. coli were then incubated at 35º C for 1 hour with shaking, plated onto 
Luria-Bertani (LB) agar [10 grams of tryptone (Bacto), 5.0 grams of yeast extract 
(Bacto), 10 grams of NaCl (Sigma), adjust pH to 7.5 using NaOH, add 15 grams 
of agar (Bacto), adjust the volume to 1.0 liter with distilled H2O and heat to melt 
the agar into solution, autoclave to sterilize] containing 50 µg/ml of ampicillin 
(Sigma) and incubated at 35º C overnight.  Colonies that grew on the LB agar 
plates with ampicillin were presumed to contain the pRSET vector, which carries 
an ampicillin resistance gene (bla), and individual colonies were selected to test 
for the presence of the cpb2 insert in the pRSET plasmid vector.  
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Plasmid Isolation 
 
The plasmids from colonies that grew on the LB agar with ampicillin plates 
after overnight incubation were isolated using the protocol for small-scale 
plasmid DNA isolation by alkaline lysis.  A single colony was inoculated into 3.0 
ml of LB broth containing 50 µg/ml of ampicillin and grown at 35º C with shaking 
overnight.  The 3.0 ml overnight culture was centrifuged for 1 minute in a 
microcentrifuge at 14,000 x g to pellet the cells and the supernatant was 
discarded.  The cell pellet was resuspended in 100 µl of a solution of 50 mM 
glucose, 10 mM ethylenediaminetetraacetic acid (EDTA), 25 mM Tris-HCl (pH 
8.0), and 2 mg/ml of lysozyme (Sigma), and incubated for 5 minutes at room 
temperature.  Next, 200 µl of a solution consisting of equal volumes of 0.4 N 
NaOH and 2% sodium dodecyl sulfate (SDS) was added to the viscous cell 
solution.  The following step involved the addition of 150 µl of 3 M sodium acetate 
and incubation on ice for 5 minutes to allow formation of precipitate.  The mixture 
was centrifuged for 15 minutes in a microcentrifuge at 14,000 x g to pellet the 
debris.  The supernatant was transferred to a clean tube with 1.0 ml of cold 100% 
ethanol and incubated at -20º C for 1 hour.  Next, the tube containing the plasmid 
DNA in ethanol was centrifuged for 20 minutes in a microcentrifuge at 14,000 x g 
to pellet the plasmid DNA.  The ethanol was aspirated from the tube, 250 µl of 
70% ethanol was added to wash the pellet, and the tube was centrifuged for 5 
minutes in a microcentrifuge at 14,000 x g.  The ethanol was removed by 
aspiration, and the pellet of plasmid DNA was allowed to air dry completely 
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before being resuspended in 40 µl of H2O.  After dissolving the pellet, 1.0 µl of 
RNase A solution (10 mg/ml) (Sigma) was added, and the tube was incubated at 
35º C for 30 minutes.  After this incubation, 10 µl of 5X stop mix (2% SDS, 25% 
glycerol, 0.05% bromophenol blue, and 0.05% xylene cyanol) was added, and 
the tube was incubated at 70º C for 15 minutes to stop enzyme activity.  The 
plasmid DNA was then purified by spin dialysis using a Sepharose CL-6B 
column.  
The presence and orientation of the inserted cpb2 in the plasmid was 
determined using the following methods.  First, a cpb2PCR-1 simplex PCR 
reaction (described under the section heading “polymerase chain reaction: 
simplex PCR”) was used to determine if a 567 base pair region of cpb2 could be 
amplified from the plasmid, demonstrating the presence of cpb2 as a part of the 
plasmid.  Next, the plasmid was digested with HindIII restriction enzyme 
(Promega).  Briefly, 10 µg of plasmid DNA, 2.0 µl of 10X buffer (supplied with the 
enzyme (Promega), 1.0 µl of HindIII enzyme and H2O to a total volume of 20 µl, 
was incubated at 35º C for four hours.  The entire digest reaction was mixed with 
3.0 µl of 6X loading dye, and electrophoresed on a 1.5% agarose gel at 100 volts 
for 1 hour.  The gel was stained with ethidium bromide and viewed under 
ultraviolet light.  If the cpb2 gene was successfully inserted into the plasmid in the 
correct orientation, two bands were expected with different band sizes dependent 
on whether the cpb2 type was of the group-1 or group-2 type.  If the cpb2 gene 
inserted was of group-1, bands at 3415 base pair and 163 base pair were 
expected.  If the cpb2 gene inserted was of group-2, the bands expected were 
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2896 base pair and 673 base pair.  The third method used nucleotide sequencing 
to verify the presence of the cpb2 insert in the pRSET vector, as well as the 
orientation and reading frame of the cpb2 insert, using a primer corresponding to 
the T7 promoter.  These samples were sent for sequencing to the Indiana 
University School of Medicine’s Biochemistry Biotechnology Facility, which 
utilizes a Perkin Elmer/Applied Biosystems 3100 Genetic Analyzer and Big Dye 
Terminator chemistry v3.1 (http://www.bbf.iu.edu/Getting_Started/HOME.htm, 
accessed June 16, 2005).   
 
 
BL21(DE3)pLysS E. coli Transformation for Protein Expression 
 
After isolation of the plasmid and verification of the cpb2 insert in the 
pRSET vector, the plasmid was transformed into BL21(DE3)pLysS E. coli (see 
table 7 for a description of the genotype) for expression of the recombinant 
protein.  We followed the protocol recommended by the supplier of the pRSET 
vectors.  Briefly, 100 ng of the plasmid DNA was added to 100 µl of competent 
BL21(DE3)pLysS E. coli, and incubated on ice for 30 minutes.  The cells were 
heat shocked for 45 seconds at 42º C and then incubated on ice for 2 minutes, 
followed by the addition of 500 µl of SOC broth.  The newly transformed 
BL21(DE3)pLysS E. coli cells were incubated at 35º C for 1 hour with shaking.  
Our initial experiments transforming BL21(DE3)pLysS E. coli with cpb2 vectors 
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showed that cells plated onto LB agar plate containing chloramphenicol (34 
µg/ml) (Sigma) and ampicillin (100 µg/ml) (Sigma) either grew very slowly or not 
at all.  Because of this complication, we chose to follow an alternative protocol for 
toxic genes (genes of proteins that could potentially be toxic to the E. coli used to 
produce that protein) with minor modifications.  Instead of inoculating agar plates 
with the mixture from the transformation reaction, 250 µl of the transformation 
reaction mixture was added to 10 ml of SOC broth containing chloramphenicol 
(34 µg/ml) and ampicillin (100 µg/ml) and incubated at 35º C overnight with 
agitation.  BL21(DE3)pLysS E. coli cells that incorporated the plasmid vector will 
now carry the resistance genes for the antibiotics chloramphenicol and ampicillin.    
Next, 5 ml of the overnight growth was added to 50 ml of SOC broth containing 
chloramphenicol (34 µg/ml) and ampicillin (100 µg/ml).  This culture was 
incubated at 35º C with agitation until the cells reached mid-log phase, 
determined using an optical density at 600 nm (OD600) of 0.3.  Isopropyl-β-D-
thiogalactopyranosid (IPTG) at a final concentration of 1 mM was added to the 
mid-log phase culture to induce expression of the beta2 protein toxin via 
expression of the T7 RNA polymerase from the lacUV5 promoter.  After the 
addition of IPTG, the cells were incubated an additional 2 hours at 35º C with 
agitation.  Pilot experiments demonstrated that maximum secretion of the 
recombinant protein occurred after 2 hours of incubation at 35º C with agitation 
after addition of the IPTG and that the majority of the protein toxin was secreted 
in the cell culture supernatant.  Therefore, after the 2 hour induction, the cells 
were pelleted and the proteins concentrated from the supernatant as described 
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above (refer to section: “isolation of culture supernatant proteins”).  During the 
pilot experiments the cell culture supernatant was separated from the cell pellet 
and these were separately tested by Western blotting using the polyclonal anti-
beta2 antibody, as well as the monoclonal anti-beta2 antibody to determine 
where the majority of the recombinant beta2 protein was located The E. coli of 
the cell pellet were lysed by heating cells to 100º C for 5 minutes, prior to 
performing the western blotting experiment.  The Western blotting procedures 
were performed as previously described (refer to the section: “Western blotting”).  
These pilot experiments revealed that most of the recombinant beta2 protein was 
located in the cell culture supernatant of induced E. coli clones. 
 
 
Protein Concentration Determination 
 
The Coomassie PlusTM protein assay kit (Pierce, Rockford, IL) was used 
to determine the concentration of the total supernatant proteins collected after 
the E. coli was pelleted.  Briefly, a series of bovine serum albumin (BSA) 
standards were made and assayed along with our unknown concentrations of 
recombinant proteins.  Optical density (OD) values were obtained by measuring 
the BSA standards and recombinant proteins in a Molecular Devices (Sunnyvale, 
CA) Vmax Kinetic microplate reader, at 565 nm absorbance.  A standard curve 
was prepared by plotting the average OD value for each BSA standard versus its 
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concentration (in µg/ml), and the estimated concentration for each recombinant 
protein was determined from the standard curve.  
 
 
Cell Cytotoxicity Assays 
 
To assess the activity of the recombinant beta2 protein toxin on live cells, 
we used cell cytotoxicity assays with caco-2 cells (ATCC, number HTB-37).  
Caco-2 cells are a cell line derived from a colorectal adenocarcinoma.  They are 
epithelial by morphology, adhere to cell culture plates, and express 
characteristics of enterocyte differentiation.  The gastrointestinal diseases of C. 
perfringens type A strains have severe effects in the colon; therefore, caco-2 
cells were an appropriate cell line to use in our assays.   
The propagation and subculturing conditions for caco-2 cells were 
performed according to the guidelines suggested by the supplier.  The media 
used for growth of caco-2 cells was Dulbecco’s Modified Eagle media with 
nutrient mixture F-12 (DMEM/F-12) (Gibco-Invitrogen Cell Culture, Carlsbad, 
CA); this is a minimum essential medium (Eagle) containing 2.0 mM L-glutamine 
and Earle’s balanced salt solution with 1.5 grams/liter of sodium bicarbonate, 0.1 
mM non-essential amino acids, and 1.0 mM sodium pyruvate (80% of the total 
volume), plus 20% (of the total volume) fetal bovine serum.  Cells were incubated 
at 35º C in a 5% CO2 incubator, and the culture medium replaced every 2 to 3 
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days until cells were subcultured, which occurred once a week.  To subculture 
cells, the growth medium was removed, and a solution of 0.25% trypsin and 0.53 
mM EDTA (T-EDTA) added to the culture flask.  The culture flask was incubated 
at 35º C until the caco-2 cells detached from the surface.  The caco-2 cells in T-
EDTA were poured into a 12 ml cell culture tube and centrifuged in a tabletop 
centrifuge for 5 minutes to gently pellet the cells.  The T-EDTA was aspirated 
from the tube, and the cells resuspended in 1X phosphate buffered saline (PBS) 
(Gibco).  Four fields were counted on a hemocytometer and averaged to 
determine the cell density; counting of additional fields did not significantly affect 
the final averaged cell density.  The caco-2 cells in 1X PBS were diluted using 
the growth medium (pre-warmed to 35º C) to obtain a final concentration of 1.5 x 
104 cells/ well and plated onto 48 well or 96 well flat-bottomed polystyrene cell 
culture plates (Corning Inc., Corning, NY) depending on the assay.  One third of 
the cells were reserved for re-plating in a cell culture flask and grown as 
described above.   
Upon the initial receipt of the cells, the caco-2 cells were grown and 
subcultured as described above with cells at each passage reserved and frozen 
in 95% growth medium + 5% DMSO, and stored at -80º C.  It was noted that after 
five subculturings the caco-2 cells exhibited some morphological changes that 
suggested degeneration, including cell rounding and cell detachment.  Therefore, 
for our experiments cells from passage five were grown and used within five 
subculturings, after which fresh passage five cells were pulled from storage.    
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Trypan Blue Exclusion Assay 
 
Caco-2 cells were grown in 48-well flat bottomed plates until reaching 80% 
confluency (about 48 hrs of growth).  Cells were rinsed once with pre-warmed 
(35º C) 1X PBS before addition of 1X PBS (used as a control) or recombinant 
protein dilutions.  Each recombinant protein assayed was diluted in 1X PBS, in 
three dilutions of 100 µg/ml, 50 µg/ml, and 12.5 µg/ml.  Four experimental wells 
for each dilution were set up, to allow for assaying at three time points of 2 hours, 
5 hours, and 8 hours.  The dilutions of recombinant proteins were added to the 
appropriate well after the cell monolayers were rinsed, and incubated at 35º C in 
a humid, 5% CO2 incubator.  To determine the relative percent of viable versus 
non-viable cells, we used the method of trypan blue exclusion (Freshney, 1994).  
At each time point, the recombinant protein dilution was aspirated from the cells, 
and 200 µl of 0.4% trypan blue solution (Sigma) (diluted 1:1 with 1X PBS) was 
added to the well.  After incubation for 2 minutes, the trypan blue solution was 
aspirated from the well, and 100 µl of 1X PBS was added to the well to prevent 
the cells from drying.  The individual wells were imaged using a Nikon Eclipse 
TS100-F inverted microscope (Nikon, Melville, NY), at 20x magnification.  
Images of two separate fields at 20x magnification were taken for each individual 
well (representing a single dilution at a single time point).  The images were 
captured using a Nikon coolpix 4500 digital camera (Nikon) and converted to the 
tagged image file format (TIFF) using Adobe Photoshop® v. 7.0 (Adobe Systems 
Inc., San Jose, CA).  Using the digital image, the number of viable unstained 
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cells versus non-viable stained cells was counted manually.  The two images for 
each well (representing a single dilution at a single time point) were averaged 
together to obtain the final percentage of viable cells that was reported.  The low 
number of replicates for the trypan blue exclusion assay precluded meaningful 
statistical comparison.     
 
 
Lactate Dehydrogenase (LDH) Assay 
 
To determine if the recombinant beta2 toxin caused membrane damage 
and cytolysis of caco-2 cells, we used the Lactate Dehydrogenase (LDH) assay 
(Oxford Biomedical Research, Oxford, MI).  This method utilizes a colorimetric 
assay kit that measures the amount of LDH that is released by damaged or lysed 
cells (Korzeniewski and Callewaert, 1983).  Measuring the amount of LDH 
released by damaged or lysed cells provided a method for comparison of the 
effect of different recombinant protein toxins, at different concentrations, on the 
caco-2 cells over a set period of time (8 hours).  We followed the procedure for 
the chemotoxicity assay provided with the kit, with minor changes.  
Caco-2 cells were grown in 96-well flat bottomed plates until reaching 
approximately 80% confluency (about 48 hours).  Because the growth medium 
contained serum, cells were gently rinsed three times with serum free assay 
medium (1X PBS + 1% (w/v) BSA) before beginning the assay.  Each 
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recombinant protein that was assessed was diluted in the assay medium at 100 
µg/ml, 50 µg/ml, or 12.5 µg/ml.  Experimental wells for each dilution of each 
recombinant protein were set up in quadruplicate, and control wells were set up 
in triplicate.  Controls were used to measure the amount of LDH spontaneously 
released by the caco-2 cells (caco-2 cells exposed to assay medium only) and 
the maximum amount of LDH released by completely lysed caco-2 cells (using 
the lysing reagent provided with the kit).  The dilutions of recombinant proteins 
were added to the test wells after the cell monolayers were rinsed, and were 
incubated at 35º C in a humid 5% CO2 incubator for 8 hours.  To assay for the 
amount of LDH released, the 100 µl of supernatant from the wells (controls, 
enzyme dilutions, and experimental), was transferred to a clean optically clear 96 
well flat bottomed plate.  Dilutions of 1:50, 1:100, 1:500, 1:1000, 1:1500, 1:2000, 
1:2500, and 1:3000, were prepared with the LDH enzyme control provided with 
the kit and assayed along with the experimental wells.  This series of dilutions 
was performed for each individual assay, and was used to generate the standard 
curve used to estimate the amount LDH released by the experimental wells.  A 
total volume of 100 µl of fresh substrate mixture (consisting of buffer, substrate, 
color enhancer and color reagent; all provided with the kit) was added to each 
well for color development.  Color was allowed to develop for 30 seconds in 
darkness, at which point 50 µl of 1N HCl was added to each well to stop further 
development of the color reaction.  The absorbance for each well was measured 
at 490 nm in a Molecular Devices (Sunnyvale, CA) Vmax Kinetic microplate 
reader.  
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The amount of LDH released by the experimental caco-2 cells exposed to 
the varied dilutions of recombinant protein toxin was quantitated by plotting the 
average absorbance values for control dilutions against the concentration of LDH 
(in units/ml) at each dilution to produce a standard curve.  A best-fit line was 
calculated for each standard curve, and the amount of LDH released for the 
experimental wells determined from the standard curve.   
 
 
Statistical Analysis 
 
Statistical analyses were performed using StatView 5.0.1 (SAS Institute 
Inc., Cary, NC).  Chi square two-tailed analysis was used to determine the 
statistical difference between matched data sets which compared a diseased 
population set to the normal, or control group, population set.  An analysis of 
variance (ANOVA) followed by Fisher’s Post-hoc testing was used to determine 
the significant difference between the percentage cell damage (% CD) for the 
LDH assays.  P-values <0.05 were considered significant.  
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RESULTS 
 
 
Clostridium perfringens Isolates 
 
Because C. perfringens type A is usually present in the intestinal 
microbiota of healthy humans, 100 well-characterized isolates from two fecal 
flora studies of healthy human volunteers were included in the present 
investigation.  The majority were isolated from stool samples collected from 88 
healthy males, with an age range of 21 to 51 years.  The samples were collected 
between January 1985 and December 1985.  The remaining 12 isolates were 
from stool samples from 1 female and 11 males, all of whom were over 18 years 
of age (exact age range is unknown), and were collected between November 
1979 and September 1980.  For purposes of this study, these 100 strains were 
designated as the population of C. perfringens isolates from healthy volunteers, 
and provided a control group for comparison with the other two groups of C. 
perfringens strains that were originally isolated from specimens collected from 
human patients with C. perfringens related diseases.    
There are two gastrointestinal diseases associated with C. perfringens 
type A in humans, antibiotic associated diarrhea (AAD) and food-borne illness.  
Both diseases are associated with the presence of the enterotoxin.  In this study, 
there were 144 isolates of C. perfringens from stool samples of patients 
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suspected of having AAD and 17 isolates from the stool samples of patients from 
two outbreaks of C. perfringens food-borne illness.  Seventy-nine of the C. 
perfringens isolates were obtained from stool samples from patients who were 
suspected to have AAD between November 1994 and January 1995. The ages 
of these patients ranged from 17 months to 82 years of age, and 40 of the 
patients were male with the remaining 39 patients female. The remaining 65 C. 
perfringens isolates were collected from the stool samples of patients suspected 
of having AAD during January 1997 to December 1997.  The ages and genders 
of these patients were not available.  Finally, the remaining 17 isolates were from 
two separate outbreaks of C. perfringens food-borne illness that occurred in April 
and May of 1997 (10 isolates) and April of 1998 (7 isolates). The ages and 
genders of these patients were not available.  This gave a total of 161 isolates in 
the population of C. perfringens isolates that were from patients with either C. 
perfringens food-borne illness or AAD.  
Other diseases associated with C. perfringens can occur in almost any 
anatomic location of the human body.  In most instances, the C. perfringens 
involved in these extraintestinal diseases are acquired endogenously, from the 
patient’s own intestinal microbiota rather than from an exogenous source (Winn 
et al., 2006).  Although the primary focus of this study was on C. perfringens 
gastrointestinal diseases, 59 isolates were included from extraintestinal patient 
specimens from which C. perfringens had been isolated and identified, to allow 
for comparisons between the C. perfringens fecal isolates and extraintestinal 
isolates from other infected sites.  There was a wide range of sources for these 
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extraintestinal isolates including: blood from patients with bacteremia, infected 
soft-tissue wounds and abscesses, bile, peritoneal fluid, spleen, vaginal 
discharge material, and other wound sites and unknown sources.  These isolates 
were from specimens that had been collected between January 1997 and August 
2004, from 36 female and 23 male patients.  The ages of these patients ranged 
from 3 months to 91 years.  These 59 isolates are included together in the 
extraintestinal diseases group.  
 
 
Genotype Results Determined by PCR 
 
Multiplex PCR 
 
A multiplex PCR method was used to determine the genotype of all of the 
C. perfringens isolates from the three populations described above.  Six primer 
sets were used to produced amplicon bands corresponding to the size of the 
amplified a portion of a gene, if that gene was present in the genomic DNA 
purified from the C. perfringens isolate (table 3, figure 7).  The four major lethal 
toxin genes produced amplicon bands of the following sizes: the alpha toxin gene 
(cpa), 324 base pair; the beta toxin gene (cpb), 196 base pair; the epsilon toxin 
gene (etx), 655 base pair; and the iota toxin gene (iA), 446 base pair.  
Additionally, if present in the genome of the isolate being analyzed, the 
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enterotoxin gene (cpe) was indicated by an amplicon band at 233 base pair, and 
the beta2 toxin gene (cpb2) was indicated by an amplicon band at 567 base pair.   
ATCC and NCTC reference strains served as positive controls for the 
multiplex PCR procedure for each C. perfringens bio-type (figure 7).  Additional 
ATCC and NCTC strains were included based on previous reports identifying 
them as C. perfringens strains positive for cpb2 (i.e., C. perfringens ATCC8009, 
NCTC10719, and NCTC4964).  All reference strains were positive for cpa, and 
for the appropriate major lethal toxin gene(s).  Although other investigators 
reported ATCC8009 and NCTC4964 to carry cpb2 (Garmory et al., 2000), the 
strains that we received were cpb2 negative.  In addition to the major lethal toxin 
gene(s), ATCC12917 was positive for cpe, the enterotoxin gene.  ATCC27324, 
the type E strain, was positive for cpe and cpb2.  A type C strain, NCTC10719 
was also cpb2 positive.  
An H2O blank was used as a negative control in all PCRs.  Additionally, 
genomic DNA from a strain of C. sporogenes and a strain of C. difficile from the 
Anaerobe Laboratory stock culture collection, were tested to verify that other 
Clostridium spp. did not react with the primers used in the multiplex PCR, or any 
other PCRs that were performed.  An image of a representative gel of multiplex 
PCR results for the genomic DNA from C. perfringens isolates from patients with 
C. perfringens gastrointestinal diseases is shown in figure 8.  
All three populations of C. perfringens isolates tested were classified as 
type A, based on the presence of cpa only and the absence of the other three 
major lethal toxin genes.  The majority of isolates, 61% of the total number of 
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isolates from all three populations, were positive only for cpa and were negative 
for cpe and cpb2.  The percentage of isolates positive for only cpa varied 
between the three populations as follows: 88% of isolates from fecal samples 
from healthy human volunteers, 54% from fecal specimens from humans with 
gastrointestinal diseases, and 75% of the isolates from specimens received from 
humans with extraintestinal illnesses.   
Isolates that were positive for cpe and/or cpb2, in addition to cpa were 
identified in each of the three populations.  In the population of isolates from 
healthy human volunteers, 10% of isolates were positive for cpb2 and cpa, 1% 
were positive for cpe and cpa, and 1% were positive for cpb2, cpe, and cpa.  The 
results from the isolates from healthy volunteers were used as the control group 
in the statistical analysis of the results obtained from the other two populations of 
isolates.   
Of the isolates from patients with C. perfringens related gastrointestinal-
diseases, 24% were positive for cpb2 and cpa, and 6% were positive for cpb2, 
cpe, and cpa.  Therefore, 30% of these isolates were cpb2 positive, which was 
significantly greater than the number of isolates that were positive for cpb2 in the 
population of isolates from healthy volunteers (p<0.01).  Of note, the number of 
cpb2 positive gastrointestinal isolates was significantly higher (p<0.01) when 
compared to the population of extraintestinal disease isolates.  A total of 16% of 
isolates from patients with C. perfringens related gastrointestinal-diseases were 
positive for cpe and cpa, in addition to the 6% that were positive for cpb2, cpe, 
and cpa.  Compared to the 2% of isolates that were positive for cpe in the 
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population from healthy human volunteers, the 22% of cpe positive isolates was 
significantly higher (p<0.01).  The 22% of cpe positive isolates in the 
gastrointestinal-diseases was also significantly higher (p<0.05) then the 3% of 
cpe isolates in the extraintestinal population of isolates.  The difference in the 
percentages of isolates that were positive for cpb2, cpe, and cpa, between the 
patient population with C. perfringens related gastrointestinal-disease (6%) 
versus the population of isolates from healthy volunteers (1%) was also 
significant (p<0.01).   
In the population from patients with C. perfringens related extraintestinal 
diseases, 20% of isolates were positive for cpb2 and cpa.  Although this was a 
higher percentage than the 10% of cpb2 and cpa positive isolates in the 
population from healthy volunteers, it was not found to be a significant difference.  
Only 5% of the isolates from patients with C. perfringens related extraintestinal 
diseases were cpe and cpa positive, which was not significantly different from the 
1% of cpe and cpa positive isolates observed in the population of isolates from 
healthy volunteers.  No isolates in the population from C. perfringens related 
extraintestinal diseases were found to carry cpb2, cpe, and cpa.   
The various combinations of genes identified in the three populations of C. 
perfringens isolates and the percentage of each combination are shown in table 
8.  Shown in figure 9 is a comparison of the percentages of the cpa positive, cpa 
and cpb2 positive, and cpa, cpb2 and cpe positive isolates from each of the three 
populations of C. perfringens isolates.  
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Simplex PCR 
 
In approximately 50% of the multiplex PCR reactions performed on the 
DNA obtained from isolates positive for both cpe and cpb2, the band for cpb2 
was very faint when visualized using UV light.  To confirm the presence of cpb2 
and cpe in an individual isolate’s DNA, a simplex PCR, using a single set of 
primers for cpb2, was performed.  We used the cpb2 primer set from the 
multiplex PCR, without any of the other primer sets included in the reaction 
mixture; this simplex PCR is referred to as cpb2PCR-1 (figure 5 shows the 
location of the primers in the nucleotide sequence of cpb2).  All isolates that were 
determined to be cpb2 positive by multiplex PCR were confirmed as cpb2 
positive using cpb2PCR-1 (table 9).  Isolates that were positive for cpe, but not 
cpb2 by the multiplex PCR were also tested for the presence of cpb2 by 
cpb2PCR-1, but none were found to be cpb2 positive.   
Two other simplex PCR reactions with primer sets designed to amplify 
different regions of cpb2 were also performed.  The purpose of these simplex 
PCR reactions was to further characterize the cpb2 genes C. perfringens isolates 
from the three different populations that were positive for cpb2 in the multiplex 
PCR.  Herholz et al. (1999) described a set of primers for cpb2 that amplified a 
574 base pair region of cpb2, but which was 185 base pair further upstream of 
the region amplified by the primer set for cpb2 used in the multiplex PCR and 
cpb2PCR-1; these primers were used in the simplex PCR cpb2PCR-2 (figure 5).  
Some isolates that were cpb2 positive by cpb2PCR-1 did not produced a band to 
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indicate that the 574 base pair fragment of cpb2 was amplified in the cpb2PCR-2 
assay.  In all three populations of C. perfringens isolates, 71 of the 320 isolates 
were cpb2 positive by the multiplex PCR and confirmed using cpb2PCR-1.  
However, only 19 of the 71 cpb2 positive C. perfringens isolates were positive for 
cpb2PCR-2.  The highest percentage of positive cpb2PCR-2 isolates was in the 
population of isolates from healthy human volunteers, in which 9 of the 11 
isolates (82%) were positive by cpb2PCR-2 (table 9).  In the population of 
isolates from humans with C. perfringens gastrointestinal diseases, only 9 of the 
48 (19%) cpb2 positive isolates were positive by cpb2PCR-2; and only 1 of 12 
(8%) isolates in the population from patients with extraintestinal C. perfringens 
diseases was cpb2PCR-2 positive (table 9).  
A third simplex PCR used a set of primers designed by this laboratory to 
amplify the entire coding region of cpb2 based on the cpb2 sequence described 
by Shimizu et al. (2001; 2002a) from C. perfringens strain 13 (accession number 
AP003515), which is referred to here as CP13-cpb2 (figure 5).  This third simplex 
PCR is referred to as cpb2PCR-3.  Only 5 of the 11 (45%) cpb2 positive C. 
perfringens isolates from the population of healthy volunteers were positive using 
cpb2PCR-3 (table 9).  None of the 48 cpb2 positive C. perfringens isolates from 
patients with gastrointestinal diseases or the 12 cpb2 positive isolates from 
patients with extraintestinal illnesses were positive by cpb2PCR-3.  
Seventy-one C. perfringens isolates from all three populations of isolates 
were determined to be cpb2 positive using the multiplex PCR, and confirmed as 
cpb2 positive by cpb2PCR-1.  However, only 19 of those isolates were positive 
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using cpb2PCR-2, and only 5 of those isolates were positive using cpb2PCR-2.  
This strongly suggested to us that there was some genetic variability between the 
cpb2 genes carried by the C. perfringens isolates in our three populations.  
 
 
Triplex PCR 
 
Jost et al. (2005) designed a triplex PCR to separate cpb2 identified in 
different isolates of C. perfringens into two groups, which they termed 
“consensus” or “atypical”.  We also determined that there were different versions 
of cpb2 using DNA sequencing techniques. In the cpb2 positive isolates of C. 
perfringens from our three populations, we found the cpb2 version that Jost et al. 
(2005) termed atypical to be more common then their consensus cpb2.  
Therefore, our designation of group-2 cpb2 corresponds to the atypical cpb2 
version described by Jost et al., and the designation group-1 cpb2 corresponds 
to the consensus cpb2 version described by Jost et al. (2005). We chose to use 
the triplex PCR to provide information to supplement the DNA sequencing 
results, which are described in the following section. 
In the triplex PCR, a band of 304 base pair indicated that the cpb2 was 
part of the group-1 cpb2, and a band at 741 base pair identified a cpb2 gene as 
belonging to the group-2 cpb2.  Both group-1 and group-2 cpb2 were identified in 
all three of our study populations of C. perfringens isolates.  The highest 
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percentage of group-1 cpb2 was identified in the C. perfringens isolates from 
healthy human volunteers, with 5 of the 11 (46%) cpb2 positive isolates positive 
for only group-1 cpb2, and 2 of the 11 (18%) positive for group-1 and group-2 
cpb2 genes.  Four of the eleven (36%) cpb2 positive isolates from the healthy 
human volunteers were positive for only group-2 cpb2.  The majority of isolates 
from patients with C. perfringens related gastrointestinal disease carried only the 
group-2 cpb2 gene; a total of 35 of the 48 (73%) cpb2 positive isolates.  In the 
remaining cpb2 positive isolates from the population of patients with C. 
perfringens related gastrointestinal diseases, 5 of the 48 (10%) cpb2 positive 
isolates carried only group-1 cpb2, and 8 of the 48 (17%) cpb2 positive isolates 
carried both group-1 and group-2 cpb2.  In the population of isolates from C. 
perfringens related extraintestinal disease patients, the majority of isolates were 
group-2 cpb2, with 9 of the 12 (75%) cpb2 positive isolates positive for only 
group-2 cpb2.  In the remaining isolates from the population from C. perfringens 
related extraintestinal diseases, only 1 of the 12 (8%) cpb2 positive isolates was 
positive for only group-1 cpb2, and 2 of the 12 (17%) were positive for both 
group-1 and group-2 cpb2 genes.  
The percentages of cpb2 isolates that were positive for group-1 cpb2, or 
group-2 cpb2, or both group-1 and group-2 cpb2 as determined by the triplex 
PCR from all three populations of isolates are shown in table 10.  
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Nucleotide Sequences and Amino Acid Sequences Prediction  
 
The sequence of the cpb2 gene was published when the beta2 toxin was 
first described (accession number L77965, Gibert et al., 1997).  This sequence 
was determined from a single isolate of C. perfringens CWC245, which is a type 
C strain isolated from a piglet with necrotic enteritis.  This nucleotide sequence 
described by Gibert et al. (1997) will be referred to as CWC245-cpb2 from this 
point forward.  In 2001, Shimizu et al. published the entire genome of C. 
perfringens strain 13 (CP13), which was found to carry cpb2 (accession number 
AP003515) on the plasmid.  The cpb2 sequence described by Shimizu et al. 
(2002a) will be termed CP13-cpb2 from this point forward.  An alignment of the 
sequences with ClustalW (Chenna et al., 2003) comparing CP13-cpb2 to 
CWC245-cpb2 found 95% identity between the two nucleotide sequences (table 
11) within the open reading frame (ORF), and a 91% identity at the amino acid 
sequence level (table 12).    
We were able to sequence 80 fragments of cpb2 from 70 cpb2 positive 
isolates from all three populations of isolates, using PCR products obtained from 
reactions with different primer sets (figure 5).  Of all the cpb2 positive C. 
perfringens isolates, only one did not have any portion of its cpb2 sequenced.  
The complete 798 base pair cpb2 coding sequence was determined from 7 of the 
70 cpb2 positive isolates that were sequenced from our three populations.  The 
remaining cpb2 sequences ranged in completeness from 54% to 96% of the total 
798 base pair cpb2 coding sequence.  The number of bases or amino acids (for 
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the deduced protein sequences) for the cpb2 nucleotide sequences are shown in 
tables 13 - 20, which detail the nucleotide sequence alignment scores that 
indicate the percentage of identity for each sequence.  
Variations in the nucleotide sequence fragments of cpb2 were found in 
cpb2 positive C. perfringens isolates from the three populations of human 
sources, as well as in the cpb2 positive reference isolates.  The cpb2 sequences 
were assigned to one of three groups based on their similarity to the published 
sequences CWC245-cpb2 and CP13-cpb2 and to other cpb2 sequences within 
the group.  Similarity was determined based on the ClustalW pairwise alignment 
scores, which was used to determine the percentage of identity between 
sequences.  Based on nucleotide sequencing results, at least ten cpb2 positive 
isolates, in addition to the type E reference strain ATCC 27324, were found to 
carry two versions of cpb2.   
The complete cpb2 sequence from NCTC 10719 had 98% identity with 
CWC245-cpb2 and 95% identity with CP13-cpb2 at the nucleotide level, and 
96% identity with CWC245-cpb2 and 93% identity with CP13-cpb2 at the amino 
acid sequence level.  Two versions of cpb2 were identified for ATCC 27324, a 
type E reference strain.  The first cpb2 sequence of ATCC 27324 had 88% 
identity at the nucleotide level with CWC245-cpb2 and 85% identity to CP13-
cpb2, and at the amino acid sequence level had 86% identity with CWC245-cpb2 
and 81% identity with CP13-cpb2.  The second cpb2 sequence from ATCC 
27324 had 73% identity to both CWC245-cpb2 and CP13-cpb2 at the nucleotide 
level and 62% identity to CWC245-cpb2 and 63% identity with CP13-cpb2 at the 
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amino acid sequence level.  Alignment scores, representing the percentage of 
identity for the nucleotide sequences of cpb2 from both reference isolates are 
shown in table 13, and scores for the amino acid sequences are in table 14.   
Sixty of the eighty cpb2 sequences differed from CWC245-cpb2 by 24% to 
36% in the ClustalW pairwise alignment scores, and from CP13-cpb2 by 23% to 
34% at the nucleotide level.  However, these sequences aligned much more 
closely between each other, differing in their identity by 1% to 13% in the 
alignment scores at the nucleotide level.  These sequences were identified as 
belonging to the group-2 cpb2 sequences, and a consensus sequence based on 
the ClustalW alignment of the 58 cpb2 sequences was derived.  At the nucleotide 
level, the group-2 consensus sequence aligned with CWC245-cpb2 and CP13-
cpb2 by 71% identity (table 11), but at the protein level by 63% and 64% identity, 
respectively (table 12).  The complete nucleotide sequence of the group-2 cpb2 
consensus sequence is shown in alignment with CWC245-cpb2 and CP13-cpb2 
in figure 10.  The deduced protein sequence of the group-2 consensus sequence 
is shown in alignment with the protein sequences of CWC245-cpb2 and CP13-
cpb2 in figure 11.   
A subset of the group-2 cpb2 sequences was identified.  This subset 
consisted of four cpb2 positive C. perfringens isolates, two from the population of 
patients with C. perfringens related gastrointestinal diseases and two from the 
patients with extraintestinal C. perfringens related diseases.  These group-2 cpb2 
sequences, which we termed group-2T, were different from the group-2 
consensus sequence (and the other cpb2 sequences) in that there was a 
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deletion of 13 nucleotide base pair, from bases 106 to 119 (figure 10).  The 
deduced amino acid sequence derived from this group-2T cpb2 sequence with a 
13 base pair deletion results in a premature stop codon, producing a peptide of 
only 26 amino acids in length instead of the 265 amino acid peptide produced by 
the cpb2 sequences that do not have this 13 base pair deletion.   
Group-1 cpb2 sequences were identified in 13 C. perfringens isolates from 
the population of healthy human volunteers and humans with gastrointestinal 
disease.  The group-1 cpb2 sequences were similar at the nucleotide level to 
CWC245-cpb2 between 85% and 97% identity, and with CP13-cpb2 between 
91% and 99% identity (table 15).  At the protein level, group-1 cpb2 sequences 
were similar to CWC245-cpb2 between 78% and 91% identity, and with CP13-
cpb2 between 86% and 100% identity (table 16).  A total of 58 cpb2 sequences 
from C. perfringens isolates from all three populations of human sources belong 
to group-2, and had identity at the nucleotide level with CWC245-cpb2 between 
64% and 76%, and identity with CP13-cpb2 between 66% and 77% (table 17).  
The deduced protein sequence for group-2 cpb2 sequences were similar with 
CWC245-cpb2 between 56% and 70% identity, and with CP13-cpb2 between 
57% and 71% identity (table 18).   
The final grouping of cpb2 sequences, group-3, is composed of six 
sequences; one from a C. perfringens isolate from a healthy human volunteer 
and the remaining five from humans with gastrointestinal diseases.  Basic local 
alignment search tools (BLAST) analysis of the group-3 sequences determined 
that the closest genetic match was cpb2 from the published sequences 
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CWC245-cpb2 and CP13-cpb2, suggesting that these are variations of cpb2 and 
not random PCR amplification of another gene.  The six sequences in this group 
had less then 84% identity at the nucleotide level with the published sequences 
CWC245-cpb2 and CP13-cpb2, and less then 78% identity at the protein level.  
Identity with the consensus sequence derived from group-2 cpb2 sequences was 
lower, between 53% and 64% identity at the nucleotide level and between 47% 
and 61% identity at the protein level.  Among group-3 cpb2 sequences identity 
ranged from 62% to 96% at the nucleotide level, and from 53% to 96% identity at 
the protein level.  Results for group-3 cpb2 nucleotide sequences are shown in 
table 19, and protein sequences shown in table 20.  
Ten cpb2 positive isolates were found to carry two versions of cpb2 using 
nucleotide sequencing techniques.  These isolates were from the C. perfringens 
population from healthy volunteers and from the population with gastrointestinal 
diseases, in addition to the type E reference strain ATCC 27324.  ATCC 27324, 
the C. perfringens type E reference strain, was found to carry both a group-1 and 
a group-2 version of cpb2.  Of the ten C. perfringens isolates from our three 
populations that were found to carry two versions of cpb2, 6 carried group-1 and 
group-2 versions, 2 carried a group-1 and a group-2T version, and 2 carried a 
group-2 and a group-3 version (table 21).    
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Phenotype Results Determined by Western Blotting 
 
Previous studies by Bueschel et al. (2003) and Waters et al. (2003) found 
variability in the phenotypic expression of beta2 toxin by cpb2 positive isolates of 
C. perfringens from animal sources.  Some isolates produced detectable 
amounts of toxin, while others did not produce detectable toxin.  These 
investigations also found that the beta2 protein is secreted in the culture 
supernatant, and is not part of the cell content released upon cell lysis.  To detect 
the beta2 protein in the cell culture supernatant of cpb2 positive C. perfringens 
isolates from our three populations, we used Western blotting with a polyclonal 
anti-beta2 antibody that was kindly provided by Dr. M. R. Popoff.  Images of 
representative Western blots are shown in figure 12; an immunoreactive signal at 
28 kDa correlates to the expected size of the secreted form of the beta2 protein 
toxin.  Due to a limited supply, Western blotting using a monoclonal anti-beta2 
antibody was not performed on the culture supernatant fluid from cpb2 positive 
C. perfringens isolates.       
The percentage of cpb2 positive C. perfringens isolates that expressed a 
detectable level of the beta2 toxin varied among the three populations.  The 
highest percentage of isolates that expressed the beta2 protein toxin was from 
the population of humans with gastrointestinal disease, with 75% (36 of 48) of 
isolates producing a detectable level of beta2 protein toxin.  In the population of 
isolates from healthy human volunteers, 55% (6 of 11) expressed a detectable 
level of the beta2 protein.  Detectable levels of the beta2 protein toxin was 
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observed in only 42% (5 of 12) of the C. perfringens isolates from extraintestinal 
specimens.   
We also observed variation in the production of a detectable level of the 
beta2 toxin by C. perfringens isolates that carried group-1, group-2, or group-3 
versions of cpb2.  Of the six C. perfringens isolates with only group-1 cpb2, only 
one was positive for the beta2 protein toxin (reference strain NTC 10719).  In the 
group-2 cpb2 positive C. perfringens isolates, 80% (33 of 41) were identified as 
producing the beta2 protein toxin by Western blotting with the polyclonal anti-
beta2 antibody. A high percentage, 71% (10 of 14), of C. perfringens isolates 
carrying both group-1 and group-2 cpb2 also produced the beta2 protein toxin.  
None of the four isolates that carried a group-2T cpb2, or the two isolates that 
also carried a group-1 cpb2, were found to produce the beta2 protein toxin.  Of 
the group-3 cpb2 isolates, 50% (2 of 4) were found to produce the beta2 protein 
toxin.  One of the two cpb2 positive C. perfringens isolates with both group-2 and 
group-3 cpb2 was also found to produce a detectable level of the beta2 protein 
toxin.  Table 21 displays the Western blotting results using the polyclonal anti-
beta2 antibody, for isolates from each of the human populations of C. perfringens 
isolates divided into cpb2 groupings, as well as results for the cpb2 positive 
reference strains NCTC 10719 and ATCC 27324.  
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Recombinant E. coli cpb2 Clones 
 
We were able to successfully construct 18 recombinant cpb2-pRSET 
plasmids (table 22).  A map of the plasmid, with a pRSETB vector and a group-2 
cpb2 insert is shown in figure 6.  Each plasmid was initially selected by size, 
approximately 3.6 kilo base pair, which include the 2.9 kilo base pair size pRSET 
vector plus the 707 base pair cpb2 insert.  Subsequent testing was performed for 
each plasmid constructed to verify that a cpb2 gene was inserted into the pRSET 
vector, and that it was in the correct orientation and reading frame.  The simplex 
PCR, cpb2-PCR1, was performed for every plasmid constructed to verify the 
presence of a cpb2 gene insert for each plasmid selected.  Finally, nucleotide 
sequencing was performed for each plasmid by the Indiana University School of 
Medicine’s Biochemistry Biotechnology Facility.  This was to ensure that the cpb2 
insert was in the correct orientation and the correct reading frame.   
One plasmid was constructed from C. perfringens type C reference strain 
NCTC 10719, which carried a cpb2 gene that was similar by 99% to the 
CWC245-cpb2 published cpb2 sequence; this plasmid is designated as 
pHRD101.  Four plasmids were constructed using cpb2 from C. perfringens 
isolates from the population of healthy human volunteers, twelve plasmids were 
from isolates from the population with gastrointestinal disease, and one plasmid 
was constructed from an isolate of C. perfringens from a patient specimen from 
an extraintestinal disease source.  Seven plasmids were constructed with cpb2 
from C. perfringens isolates that also carried cpe.  Different versions of cpb2, 
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from each of the different groups were represented in the plasmids constructed.  
Three plasmids were constructed using group-1 cpb2; these are designated as 
plasmids pHRD102, pHRD103, and pHRD104.  Ten plasmids were constructed 
with group-2 cpb2; these are the plasmids designated as pHRD201 to pHRD210.  
Two plasmids contained group-3 cpb2 and were designated as pHRD301 and 
pHRD302.  The remaining two plasmids had group-2T cpb2 inserts, and were 
designated as pHRD401 and pHRD402. 
After the successful construction of the plasmids containing cpb2, these 
plasmids were used to transform BL21(DE3)pLysS E. coli for expression of the 
recombinant beta2 protein. Additionally, a negative control was constructed using 
an E. coli transformed with an empty plasmid that consisted of a pRSETA vector 
without a cpb2 insert.  The pRSET plus cpb2 plasmids also contained resistance 
genes to chloramphenicol and ampicillin, allowing for the selection of 
successfully transformed E. coli.  Transformation was achieved for all 18 
plasmids constructed.  
Two separate Western blotting assays using the monoclonal anti-beta2 
antibody and the polyclonal anti-beta2 antibody were performed on the culture 
supernatant fluid from each recombinant cpb2 E. coli clone (table 23).  To verify 
production of a detectable level of the beta2 protein toxin, the Western blotting 
assays using the polyclonal anti-beta2 antibody was performed.  This was the 
same Western blotting assay that was used to determine if the beta2 protein 
toxin was produced by cpb2 positive C. perfringens isolates.  We also chose to 
use our limited supply of the monoclonal anti-beta2 antibody for Western blotting 
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assays on cell culture supernatant on the recombinant cpb2 E. coli to help further 
characterize the recombinant beta2 protein toxins.  With the monoclonal anti-
beta2 antibody Western blotting assay, eleven of the eighteen recombinant cpb2 
E. coli clones were positive for beta2 expression.   
 
 
Activity of Recombinant Beta2 Protein 
 
After expression of the recombinant beta2 toxin was induced by treatment 
with isopropyl-β-D-thiogalactopyranosid (IPTG), the culture supernatant fluid was 
collected and the proteins concentrated.  The total amount of protein for the 
culture supernatant fluid from each clone was determined, and dilutions made to 
obtain final concentrations of 100 µg/µl, 50 µg/µl, and 12.5 µg/µl for use in both 
cell cytotoxicity assays.  For all cell cytotoxicity assays, there was a negative 
control used, which was the cell culture supernatant from the E. coli that was 
transformed with the empty plasmid that consisted of the pRSETA vector, without 
a cpb2 insert.  
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Trypan Blue Exclusion Assays 
 
Results from the trypan blue exclusion caco-2 cytotoxicity assays 
demonstrate that the number of cells damaged in each assay is dependent on 
the recombinant cpb2 protein used, the concentration of the recombinant cpb2 
protein, and the length of time the recombinant protein is exposed to the caco-2 
cells.  Representative images from clone pHRD203 of the trypan blue stained 
caco-2 cell images collected by digital photo microscopy and used to count cells 
to determine the percentage of non-viable caco-2 cells are shown in figure 13.  
The percentage of non-viable caco-2 cells counted in the digital images taken for 
each cell culture well, were plotted on a bar graph to determine if the 
recombinant beta2 protein caused an increase in the percentage of non-viable 
caco-2 cells, compared to the negative control.  The cell culture supernatant from 
an E. coli transformed with an empty plasmid (a pRSETA vector without a cpb2 
insert) and grown and treated the same as the experimental E. coli that were 
transformed with the recombinant cpb2 plasmids, served as the negative control 
in these experiments.  The highest percentage of caco-2 cell damage that was 
observed with exposure to the cell culture supernatant fluid from the negative 
control is indicated on the bar graphs as the control upper limit.  This control 
upper limit is included on all of the trypan blue exclusion assay bar graphs to 
allow for comparison to the negative control.  The complete results of the 
negative control, labeled as BL21, are shown in figure 14.   
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The culture supernatant fluid containing recombinant beta2 protein from 
the pHRD101 E. coli clone caused an increase in the percentage of non-viable of 
caco-2 cells when the time of exposure was extended to 22 hours for all 
concentrations assayed (figure 14), but most notably at the highest 
concentration, 100 µg/µl.  A slight increase in the percentage of non-viable caco-
2 cells was also observed after 8 hours of exposure, but more then 60% of the 
caco-2 cells remained viable (figure 14) for each concentration of culture 
supernatant fluid recombinant beta2 protein from the pHRD101 clone.  
The recombinant cpb2 clones pHRD102, pHRD103, and pHRD104 with 
group-1 cpb2 genes inserted into the plasmid, all caused an increase in the 
percentage of non-viable caco-2 cells.  Clone pHRD102 increased the number of 
non-viable caco-2 cells from 20% to 99% during the 2 to 8 hours of incubation 
with the culture supernatant fluid proteins at a 100 µg/µl concentration (figure 
15).  Concentrations of 50 µg/µl and 12.5 µg/µl also caused an increase in non-
viable cells after 5 to 8 hours of incubation (figure 15) though to a lesser degree 
than 100 µg/µl.  An effect similar to clone pHRD102 was observed with the 
culture supernatant fluid from clone pHRD103, though with a higher percentage 
of non-viable cells for each concentration and length of time (figure 15).  The 
remaining group-1 cpb2 clone, pHRD104, caused an increase in non-viable cells 
between 44% to 98% after 5 to 8 hours of incubation for concentrations of 100 
µg/µl and 50 µg/µl  (figure 15).  After 5 hours of incubation with culture 
supernatant fluid proteins from pHRD104, the highest percentage of non-viable 
cells was observed for the 12.5 µg/µl concentration of culture supernatant fluid 
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proteins, almost twice the number of non-viable cells observed with 
concentrations 50 µg/µl and 100 µg/µl (figure 15).  
Culture supernatant fluid proteins from the ten group-2 cpb2 clones were 
also tested using the trypan blue exclusion assay for their effect on caco-2 cells.  
Five of the ten group-2 clones: pHRD201, pHRD205, pHRD206, pHRD207, and 
pHRD208, had a negligible effect on the caco-2 cells (figure 16).  The only 
increase above the control maximum was for pHRD205; at a concentration of 
100 µg/µl, after 8 hours of incubation 29% of the caco-2 cells were non-viable 
(figure 16).  The remaining five group-2 cpb2 clones: pHRD202, pHRD203, 
pHRD204, pHRD209, and pHRD210, all had a more discernable effect on the 
caco-2 cells, though to varying degrees.  The highest and most rapid effect 
observed was from clone pHRD203; culture supernatant from this clone killed 
99% of caco-2 cells within 2 hours at both concentrations of 100 µg/µl and 50 
µg/µl (figure 17).  At a concentration of 12.5 µg/µl, culture supernatant fluid from 
clone pHRD203 had a minimal effect after 2 and 5 hours of incubation; but 99% 
of caco-2 cells were non-viable after 8 hours (figure 17).  The culture supernatant 
fluid from clone pHRD202 had no clear effect after 2 hours at any concentration, 
but at 5 hours between 46% to 60% of cells were non-viable for the three 
concentrations, and after 8 hours between 75% and 88% of caco-2 cells were 
non-viable for all concentrations (figure 17).  Although there was a minimal effect 
on the cells for culture supernatant fluid from pHRD205 at 2 and 5 hours, at 8 
hours 98% of the caco-2 cells were killed at the 100µg/µl concentration (figure 
17).  Results for pHRD205 at concentrations of 50 µg/µl and 12.5 µg/µl were 
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difficult to understand; at both concentrations greater than 94% of caco-2 cells 
were non-viable after 2 hours, but only a minimal effect was observed at 5 hours 
and 8 hours (figure 17).  Clone pHRD209 caused an increase in the percentage 
of non-viable caco-2 cells that increased with time and concentration; though the 
greatest effect was only 46% of non-viable cells after 8 hours for 100 µg/µl (figure 
17).  The remaining group-2 cpb2 clone, pHRD210 showed a correlation 
between time and concentration after 8 hours, with 62% of caco-2 cells non-
viable for 100 µg/µl (figure 17).  However, at 2 and 5 hours the percentage of 
non-viable caco-2 cells was highest for the 50 µg/µl concentration of pHRD210 
culture supernatant fluid, followed by the 12.5 µg/µl concentration, with the 
lowest effect observed for 100 µg/µl (figure 17).   
The group-3 cpb2, is the group to which six cpb2 sequences were 
assigned when they were found to have, at the nucleotide level, less then 84% 
identity to the published cpb2 sequences and less then 64% with the group-2 
cpb2 consensus sequences.  Identity within the group was also variable, 
between 62% to 96% identity at the nucleotide level, which did not allow for any 
reasonable consensus sequence to be derived.  Two of the cpb2 genes from this 
varied group of cpb2 were randomly selected, and recombinant plasmids were 
constructed.  The culture supernatant fluid from each of these group-3 clones 
was tested for an effect on caco-2 cells.  At a concentration of 100 µg/µl, 
pHRD301 caused a gradual increase in the percentage of non-viable caco-2 
cells, from 11% to 19% between 2 and 8 hours (figure 18).  The opposite effect 
was observed for pHRD301 culture supernatant fluid at a concentration of 50 
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µg/µl, in which the percentage of non-viable cells decreased from 34% at 2 
hours, to 6% at 8 hours (figure 18).  At the lowest concentration, 12.5 µg/µl, 
pHRD301 had a minimal effect until after 8 hours, at which point 30% of caco-2 
cells were non-viable (figure 18).  Essentially no effect was observed for 
pHRD302, though a slight increase in the percentage of non-viable caco-2 cells 
above the control maximum was observed at 5 hours only for concentrations of 
50 µg/µl (12%) and 12.5 µg/µl (14%) (figure 18).   
Two clones with group-2T cpb2 were tested for their effects on caco-2 
cells measured by trypan blue exclusion.  These clones were expected to have 
activity similar to that observed for the group-2 cpb2 clones, because the region 
of the cpb2 gene that was selected for insertion into the vector used for cloning 
was after the 13 base pair deletion observed in the group-2T cpb2 nucleotide 
sequences.  For clone pHRD401, only a slight increase in the percentage of non-
viable caco-2 cells was observed at a concentration of 100 µg/µl after 5 and 8 
hours incubation (figure 18).  Clone pHRD402 had no effect above the negative 
control at any concentration or any time point measured in this assay (figure 18).   
 
 
Lactate Dehydrogenase (LDH) Assay 
 
With a colorimetric chemotoxicity assay kit, the amount of LDH released 
by caco-2 cells as an indicator of membrane damage was measured after 
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exposure to culture supernatant fluid from the recombinant cpb2 clones.  
Because the assay kit only allowed for a limited number of assays, all assays 
were measured after an incubation time of 8 hours.  Each concentration of 
culture supernatant fluid was assayed in quadruplicate, and the optical density 
readings measured by the spectrophotometer averaged and compared to the 
maximum LDH released by the controls according to the specifications in the 
protocol provided to determine the percentage of cell damage (% CD) for each 
concentration of each recombinant culture supernatant fluid.  An analysis of 
variance (ANOVA) with Fisher’s protected least significant difference (PLSD) 
Post-hoc testing was used to verify statistical significance versus the 
BL21(DE3)pLysS culture supernatant fluid protein control for each concentration 
of recombinant beta2 protein, with a confidence level of 95%.  
Recombinant beta2 protein in the culture supernatant fluid from pHRD101 
increased the percentage of cell damage as compared to the BL21(DE3)pLysS 
culture supernatant fluid control.  At 100 µg/µl and 12.5 µg/µl, the p-value was 
less than 0.001, and less than 0.05 at the 50 µg/µl concentration (figure 19).  The 
E. coli BL21(DE3)pLysS used as a control had a 19% CD, 13% CD, and 12% CD 
(figure 19), respectively for concentrations of 100 µg/µl, 50 µg/µl, and 12.5 µg/µl 
of culture supernatant fluid.  
For the recombinant cpb2 clones with group-1 cpb2 genes: pHRD102, 
pHRD103, and pHRD104, only pHRD102 had a significant increase in the % CD 
at all three concentrations (figure 20).  Culture supernatant fluid from pHRD104 
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caused a small increase in the % CD (p<0.05) versus the concentration control at 
12.5 µg/µl (figure 20), but not at 100 µg/µl or 50 µg/µl.  
The culture supernatant fluid proteins from the ten group-2 cpb2 clones 
were also tested for an effect on caco-2 cells using the LDH assay.  The LDH 
assays of the group-2 clones differed from the results observed in the trypan blue 
exclusion assay; however, the presentation of data for the same clones is shown 
using the same clusters as from the trypan blue exclusion assay results (see 
figures 16 and 17).  Culture supernatant fluid from pHRD201 increased the % CD 
at 100 µg/µl and 50 µg/µl  (figure 21); though not a significant difference within 
results between the two concentrations, the % CD at 50 µg/µl was higher than at 
100 µg/µl.  The effect of pHRD205 culture supernatant fluid was observed as an 
increase in the % CD at 50 µg/µl and 12.5 µg/µl versus the concentration control; 
however, there was not a significant increase at 100 µg/µl (figure 21).  No effect 
on the % CD was seen for pHRD206 at 100 µg/µl and 50 µg/µl, though a small 
increase was noted at 12.5 µg/µl compared to the concentration control (figure 
21).  A more dramatic effect was caused by pHRD207 culture supernatant fluid, 
with significant rises in the % CD observed for all three concentrations (figure 
21).  The culture supernatant fluid from pHRD208 did not have any significant 
effect on the % CD, at any concentration measured (figure 21).  Both pHRD202 
and pHRD203 significant increased the % CD at all three concentrations, with a 
noticeable decrease from the highest concentration to the lowest concentration 
assayed (figure 22).  The effect on the % CD of pHRD204 culture supernatant 
fluid also decreased from the highest concentration to the lowest concentration, 
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though only the effect measured for 100 µg/µl was significant versus the 
concentration control (figure 22).  The remaining group-2 cpb2 clones, pHRD209 
and pHRD210, had no significant effect on the % CD, except for pHRD209, 
which was slightly higher than the concentration control at 12.5 µg/µl (figure 22).  
Two clones were constructed using group-3 cpb2, and culture supernatant 
fluid from each clone was tested for an effect on caco-2 cells using the LDH 
assay.  At concentrations of 100 µg/µl and 50 µg/µl, pHRD301 significantly 
increased the % CD versus the concentration controls (figure 23), with a 
downward trend noted from the highest to the lowest concentration assayed.  
The culture supernatant fluid from pHRD302 caused a rise in the % CD at 50 
µg/µl and 12.5 µg/µl versus the concentration controls (figure 23), though there 
was not a significant difference between the three concentrations assayed.  
Neither of the group-2T cpb2 clones, pHRD401 and pHRD402 had significant 
effect in the % CD at any of the three concentrations assayed (figure 23). 
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DISCUSSION 
 
 
The Beta2 Toxin Gene, cpb2, was Identified in the Genome of Type A,              
C. perfringens Isolates from Human Sources 
   
At the inception of this investigation there were studies that had identified 
cpb2 and the beta2 toxin in some C. perfringens isolates from animals with 
gastrointestinal diseases.  However, there were no published studies regarding 
the recently described beta2 protein toxin and its possible relevance to C. 
perfringens related diseases in humans.  We identified cpb2 in the genome of C. 
perfringens isolates from humans; this served as an initial step to studying a 
possible role for the beta2 toxin from C. perfringens in gastrointestinal diseases 
in humans as well as C. perfringens extraintestinal diseases.  
 
 
cpb2 was Found in a Significantly Higher Percentage of C. perfringens      
Isolated from Humans with Gastrointestinal Diseases  
 
The results of this investigation revealed that the percentage of C. 
perfringens isolates from the population of patients with gastrointestinal diseases, 
which included patients with antibiotic-associated diarrhea (AAD) or food-borne 
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illness, had a significantly greater number of isolates that were positive for cpb2 
versus the control group (chi square analysis, p<0.01).  The C. perfringens 
isolates from the population of patients with extraintestinal diseases (specimen 
sources included blood and other normally sterile body fluids, as well as 
aspirates from wounds and other soft tissue samples) carried cpb2 at a greater 
frequency than the control population.  However, this difference was not 
statistically significant.  Because C. perfringens is commonly encountered in the 
normal fecal microbiota of healthy humans (Hentges, 1983), it was important to 
include a population of C. perfringens isolates from fecal samples from healthy 
human volunteers.  This population served as a control group in our study to 
allow for comparison against C. perfringens isolates from humans with 
gastrointestinal diseases and from humans with extraintestinal diseases.  The 
results of this investigation are in agreement with recently published studies that 
have also identified cpb2 positive C. perfringens isolated from intestinal sources 
from humans with gastrointestinal diseases (Fisher et al., 2005; Miyamoto et al., 
2006).  However, our investigation is unique in that it also includes a comparably 
sized control population of isolates from healthy humans.       
Because isolates can be a distinct type (type A to E), we also analyzed 
our C. perfringens isolates for the four major toxin genes: cpa, cpb, etx, and iA, 
and the enterotoxin gene cpe, that are used to type C. perfringens.  This was in 
addition to our surveillance for the presence of cpb2.  All 320 C. perfringens 
isolates from the three populations studied were classified as type A, indicating 
that the alpha toxin gene cpa was the only one of the four major toxin genes 
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present.  These results are in agreement with previous studies that found type A 
to be the predominant type in the normal fecal microbiota of humans (Hatheway, 
1990) and the type most often isolated from patients with C. perfringens related 
gastrointestinal diseases, including AAD (Modi and Wilcox, 2001).  Type A 
strains are also associated with extraintestinal C. perfringens related diseases, 
including clostridial myonecrosis or gas-gangrene (Rood and Cole, 1991).  
 
 
The Enterotoxin Gene was also Identified in the C. perfringens Isolates          
from All Populations  
 
CPE, the C. perfringens enterotoxin, is a 35 kDa protein produced from 
the cpe gene, and it is strongly linked to food-borne C. perfringens disease in 
humans (McClane, 1992; Stark and Duncan, 1971).  Further, enterotoxin positive 
C. perfringens have also been linked to non-food-borne gastrointestinal diseases, 
including AAD (McClane, 1994).  There is good evidence that CPE plays a role in 
food-borne disease, sporadic diarrhea, and AAD; however, the enterotoxin is 
produced only during sporulation of C. perfringens and released upon lysis of the 
vegetative cell and release of the spore (Czeczulin et al., 1993).  Therefore, 
conditions that will induce sporulation and subsequent lysis of the vegetative 
cells to release the spore are needed to implicate the C. perfringens enterotoxin 
as a possible cause for associated diseases.   
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For human fecal isolates, we grouped samples from C. perfringens AAD 
together with the samples from humans with C. perfringens food-borne diseases 
into one population identified as isolates from humans with C. perfringens related 
gastrointestinal diseases.  This grouping allowed for more generalized 
comparisons to the C. perfringens isolates from healthy human volunteers and 
isolates from humans with extraintestinal C. perfringens diseases.  While the 
focus of this investigation was not on the enterotoxin per se, we note that cpe 
was identified in 47% of the isolates from humans with C. perfringens food-borne 
illness, which was significantly higher than the 19% of cpe positive isolates from 
humans with C. perfringens related AAD (p<0.01, chi square analysis).  
The total number of cpb2 positive C. perfringens isolates from humans 
with gastrointestinal diseases was significantly higher than cpb2 isolates from the 
control population from healthy volunteers.  This result was not definitive, 
however, because isolates from humans with gastrointestinal diseases also had 
a significantly higher frequency of the enterotoxin gene, cpe.  The occurrence of 
both cpb2 and cpe was significantly greater in the population of isolates from 
humans with gastrointestinal diseases than in isolates from the control 
population.  We did not identify cpb2 and cpe in a single isolate in the C. 
perfringens isolates from humans with extraintestinal diseases.    
Although cpe was identified in the genome of C. perfringens isolates from 
all three of our study populations, including isolates that were also cpb2 positive, 
further study of cpe or production of the enterotoxin was beyond the scope of this 
investigation.  A recent study by Fisher et al. (2005) suggested that the beta2 
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toxin could act as an accessory toxin in AAD caused by enterotoxin positive C. 
perfringens in humans.  Future investigations in this area should include both 
individual and paired studies of cpb2 and cpe.  This will be necessary to aid in 
determining whether these two toxins contribute to C. perfringens diseases 
synergistically or are associated with different disease presentations.  Such a 
study would also be useful for determining if the presence of both genes in a 
strain can impact the virulence potential of C. perfringens and its associated 
diseases. 
 
 
Other PCR Assays Produced Results that were used to Further Characterize 
cpb2 in the C. perfringens Isolates from All Populations  
 
Different PCR techniques, including the multiplex PCR (Garmory et al., 
2000) and simplex PCR (Herholz et al., 1999; the simplex cpb2PCR-2), as well 
as different primer sets were used in this study to amplify various regions of the 
cpb2 gene.  Of the 71 cpb2 positive isolates of C. perfringens, only 19 were 
positive when tested with the simplex cpb2PCR-2 assay.  Marks and Kather 
(2003) obtained similar results; they observed that the simplex cpb2PCR-2 assay 
produced fewer amplified cpb2 bands from isolates than the multiplex PCR.  This 
observation could be explained by differences in the primer sets used in the 
different PCR assays.  For the simplex cpb2PCR-2, the primer set is for a 574 
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base pair region (bases 143 to 716), while the multiplex PCR primer set is for a 
546 base pair region (bases 258 to 803, figure 5).  The primer sets from these 
two PCR assays differ from the original published sequences (CWC245-cpb2 
and CP13-cpb2) by just two bases.  For the multiplex PCR (which used the same 
cpb2 primers that were used in the simplex PCR, cpb2PCR-1), there was one 
base difference in each of the forward and reverse primers.  In contrast, for the 
simplex cpb2PCR-2, the sequences for the forward primer were identical, but two 
bases were different in the reverse primer (figure 5).  The observation of fewer 
isolates as cpb2 positive when the simplex PCR cpb2PCR-2 was used may be 
due to the base differences between the primer sequence and the cpb2 
sequences of the C. perfringens isolates.  This would make primer annealing 
(and subsequent amplification) less likely.   
An additional simplex PCR (cpb2PCR-3) was designed in an effort to 
amplify the entire coding region of cpb2.  This new PCR assay used primers 
based on the CP13-cpb2 sequence (Shimizu et al., 2001; 2002a).  With this 
primer set, only five cpb2 positive isolates (all from the population of healthy 
human volunteers) had cpb2 that produced a band indicating amplification of 
cpb2.  Results from these three PCR assays, the multiplex PCR (Garmory et al., 
2000), the simplex cpb2PCR-2 (Herholz et al., 1999), and the simplex cpb2PCR-
3, serve to emphasize that cpb2 is a variable gene that is not highly conserved.  
The genetic variability of cpb2 is important because this characteristic makes it 
unusual if not unique among the toxin genes of C. perfringens. 
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In addition to the multiplex PCR and the simplex PCR assays described 
above, a triplex PCR (Jost et al., 2005) has been used to differentiate cpb2 into 
two types, group-1 or group-2 (table 24).  Jost et al. (2005) designated the two 
types of cpb2 as either “atypical” or “consensus”.  We chose to place our isolates 
in three groups based on the cpb2 type that was found in an isolate.  Our group-2 
cpb2 correlates with the “atypical” sequence described by Jost et al. (2005); 
however, the group-2 cpb2 was more common in our work and therefore was not 
“atypical” (table 10).  The “consensus” sequence referred to by Jost et al. (2005) 
correlates with our group-1 cpb2.  There were no sequences described by Jost et 
al. (2005) that correlated with our group-3 cpb2.  Group-2 cpb2 was the version 
identified in the majority of cpb2 positive C. perfringens isolates and was the 
most common version in the C. perfringens isolates from patients with 
gastrointestinal diseases (in 73% of isolates).  Group-1 cpb2 was identified in 
46% of C. perfringens isolates from healthy human volunteers, although it was 
also observed in the other two populations of C. perfringens isolates.  
Additionally, we identified 12 C. perfringens isolates that were positive for both 
group-1 and group-2 cpb2, a phenomenon that was not described by Jost et al. 
(2005) and has not been described by others.  This suggests that some strains of 
C. perfringens carry multiple versions of cpb2.  
When we progressed to the next phase of our research involving the 
nucleotide sequencing of the cpb2 genes in our C. perfringens isolates 
(described in the subsequent section), a number of flaws were noted with the 
triplex PCR as it applies to differentiation of cpb2 into two groups.  The 
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nucleotide sequencing results revealed multiple variations of cpb2 and not simply 
two versions.  The triplex PCR incorrectly identified four sequences as group-1 
cpb2 that had at most 79% identity to the CP13-cpb2.  The nucleotide 
sequencing results indicated that these belonged to different groupings.  
Additionally, it was found that there was a subset of the group-2 cpb2 that the 
triplex PCR cannot distinguish.   
 
 
A Range of Genetic Variation was Identified in the cpb2 Genes from the            
C. perfringens Isolates at the Nucleotide Level and in the Predicted              
Amino Acid Sequences 
 
Variation in the cpb2 genes and in the predicted protein sequence of the 
beta2 toxin could explain differences in virulence between isolates as well as 
differences in diseases and disease severity between different isolates of C. 
perfringens.  Other investigators have demonstrated that sequences of most C. 
perfringens toxin genes tend to be highly conserved, with variants having 
different amino acids at only two or three positions (Hunter et al., 1992; Hunter et 
al., 1993; Sheedy et al., 2004).  Given the expected conservative nature of C. 
perfringens toxin gene sequences, it was surprising to us that the two published 
cpb2 sequences (Gibert et al., 1997; Shimizu et al., 2002a) aligned with only 
95% identity at the nucleotide sequence level and with 91% identity at the amino 
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acid level (with 21 different amino acids out of the 265 amino acid sequence).  
Additional information was found in GenBank (http://www.ncbi.nlm. 
nih.gov/Genbank/index.html); there were cpb2 sequences that were identified by 
the submitters as pseudogenes (accession numbers AJ537533-AJ537551), but 
these sequences were not described in the published literature.  In order to 
develop a better understanding of the apparent variability in cpb2 sequences, we 
performed nucleotide sequencing of portions of cpb2 from C. perfringens isolates 
from all three populations.  
Using PCR techniques with multiple primer sets, Jost et al. (2005) and 
Fisher et al. (2005) determined that there were genetic variants of cpb2 and 
subdivided cpb2 positive C. perfringens isolates into two groups.  However, the 
nucleotide sequencing results from a total of 80 cpb2 sequences in our study 
populations revealed a much wider range of variation in the nucleotide 
sequences of cpb2.  All cpb2 positive C. perfringens had at least a portion of 
cpb2 sequenced (with one exception due to technical difficulties), and ten 
isolates had portions of two distinct versions of cpb2 sequenced.  In the C. 
perfringens cpb2 positive isolates from all three study populations, we identified 
two distinct groups (group-1 and group-2) and one subgroup (group-2T) of cpb2 
sequences.  A third group (group-3) was designated to identify cpb2 sequences 
that were distinct from the other groups, but these sequences were also distinct 
from other sequences within the group.  The cpb2 sequences were assigned to 
different groupings to allow for comparison of the different versions of cpb2 and 
their association with isolates from the different C. perfringens populations.   
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Many of the C. perfringens Isolates from Humans with Gastrointestinal Diseases 
Carried the Group-2 cpb2 
 
Group-2 cpb2 was the genetic variant most commonly found in C. 
perfringens isolates from humans with gastrointestinal diseases (including those 
associated with AAD and food-borne diseases), as well as in the control 
population and the population of C. perfringens isolates from humans with 
extraintestinal diseases.  It is interesting to note that group-2 cpb2 is more than 
25% different in sequence identity compared to the original published sequences: 
CP13-cpb2 and CWC245-cpb2.  Also of note was a subset of sequences that 
had very high identity to the other group-2 sequences, but the sequences in this 
group-2T subset of group-2 had a 13 base pair deletion in the first 120 base pair 
of the ORF.  This deletion results in a premature stop codon and, if expressed, a 
truncated form of the beta2 protein.  
The cpb2 positive C. perfringens isolates also contained a number of other 
variants of cpb2.  Genes classified as group-1 cpb2 were most similar to the 
published sequence CP13-cpb2.  The group-1 cpb2 includes 13 sequences that 
were similar by an average of 97% identity to the published sequence CP13-
cpb2 from a human type A strain (Shimizu et al., 2002a).  The group-1 cpb2 
sequences were identified in C. perfringens isolates from all three populations.  
However, 17 of the 22 total group-1 cpb2 were identified in C. perfringens 
isolates that also carried a group-2 or group2T cpb2.  
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The six cpb2 group-3 sequences had similarity of less then 70% identity 
with the published sequences (CP13-cpb2 and CWC245-cpb2) and the group-2 
consensus sequence (that was derived from the 58 group-2 cpb2 and the 4 
group-2T cpb2).  Five of these sequences were from C. perfringens isolates from 
patients with gastrointestinal diseases, and the remaining sequence was from an 
isolate from a healthy human volunteer.  This grouping was based more on the 
observed differences from the published sequences and the group-2 consensus 
than on identity with other cpb2 sequences within the grouping.  Two of these six 
sequences were found in C. perfringens isolates that also carried a group-2 
cpb2.   
 
 
Many of the C. perfringens Isolates from Humans Carried Two                       
Distinct Variants of cpb2  
 
Nucleotide sequencing results, combined with results from the triplex 
PCR, provided evidence that 27% (19 of 71) of the cpb2 positive C. perfringens 
isolates carried two distinct versions of cpb2.  Six isolates that were shown to 
carry either a single group-1 or group-2 cpb2 by triplex PCR were shown by 
nucleotide sequencing to carry multiple versions of cpb2.  Two of these six 
isolates carried a group-2 cpb2 and a group-3 cpb2; the remaining four carried a 
group-1 and group-2 cpb2.  As shown by other researchers (Jost et al., 2005; 
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Fisher et al., 2005) and our results, there are multiple genetic variations of cpb2.  
However, our results also provide evidence that an isolate of C. perfringens can 
carry multiple versions of cpb2; other investigators have not described this 
phenomenon.  Studies of the plasmid-borne toxin genes of C. perfringens, 
including cpb2, have shown that the toxin genes can be on multiple different 
plasmids and that a single isolate can carry multiple plasmids (Li et al., 2007; 
Sayeed et al., 2007).  There is also evidence that the plasmids that carry many of 
the toxin genes of C. perfringens are able to undergo conjugative transfer 
(Brynestad et al., 2001; Fisher et al., 2005; Miyamoto et al., 2002), which would 
allow for the exchange of genetic material carried by C. perfringens strains on 
distinct plasmids.  It appears reasonable that a C. perfringens strain could carry 
multiple different versions of cpb2.  It is possible that the different versions of 
cpb2 are associated with different plasmids, although additional work is needed 
to provide evidence to support this idea.  
 
 
The Beta2 Protein was not Expressed by Every cpb2 Positive C. perfringens 
Isolate from the Different Populations of Isolates 
 
Variation in the expression or level of expression of the beta2 protein toxin 
is another factor that could explain differences in disease presentation, severity, 
and virulence of C. perfringens strains that cause diseases in humans.  While 
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some investigators found a correlation between the presence of cpb2 and 
production of the beta2 toxin by C. perfringens isolates from piglets (Waters et 
al., 2003), our analysis of beta2 toxin expression by cpb2 positive C. perfringens 
isolates demonstrated that the mere presence of cpb2 does not necessarily 
correlate with beta2 toxin production.  Isolates positive for beta2 toxin expression 
were identified in all three populations, and the percentage of cpb2 positive 
isolates that expressed beta2 toxin ranged from 42% to 79% for our different 
study populations (table 21).  Isolates that carried only a group-1 cpb2, a group-
2T cpb2, or both a group-1 and a group-2T cpb2 were all negative for beta2 
protein expression. Only three of the six isolates with a group-3 cpb2 or a group-
2 and group-3 cpb2 produced the beta-2 protein.  Other investigators have also 
described discrepancies in the presence of cpb2 and production of the beta2 
toxin.  One such study found that 97% of cpb2 positive isolates from pigs were 
positive for beta2 toxin production, while only 50% of isolates from other animal 
species (e.g. avian, bovine, canine, etc.) produced beta2 toxin (Bueschel et al., 
2003).  Results from this study demonstrate that the presence of group-2 cpb2 is 
more likely to correlate with beta2 protein expression than merely the presence 
of any cpb2.  This indicates that simply carrying a cpb2 gene does not equate 
with the production of the beta2 toxin by a C. perfringens isolate.  When 
considering only group-2 cpb2 isolates, 79% were positive for beta2 toxin 
expression, and most of these isolates were from the C. perfringens collected 
from the fecal samples of humans with gastrointestinal diseases (including AAD 
and food-borne illness isolates). 
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The Group-2 cpb2 Found in the Majority of cpb2 Positive C. perfringens Isolates 
from Humans with Gastrointestinal Diseases were Most Likely to Produce the 
Beta2 Protein  
 
The group-2 cpb2 sequence was the most common sequence found in all 
populations in this study, including the control population of healthy human 
volunteers.  The group-2 cpb2 sequence was also the most common link 
between C. perfringens isolates that produced the beta2 toxin.  In isolates that 
contained group-2 cpb2 (either alone or in conjunction with a group-1 or group-3 
cpb2), more than 78% (77 of 98) produced the beta2 toxin.  In contrast, none of 
the isolates containing group-2T were found to produce the beta2 toxin.  Of 
isolates that did not carry either group-2 or group-2T cpb2, only 30% (3 of 10) 
produced the beta2 toxin.  These results are consistent with the results of Fisher 
et al. (2005) in which there was also a strong link between production of the 
beta2 toxin and the cpb2/cpe sequence in type A strains of C. perfringens.  While 
the findings in the present study as well as those reported by Fisher et al. (2005) 
provide evidence that the beta2 toxin is a factor in AAD and other gastrointestinal 
diseases associated with C. perfringens, this deduction is not unequivocal 
because not all cpb2 isolates in these studies produced the beta2 toxin.  
A possible explanation as to why the beta2 toxin was not produced by all 
group-2 cpb2 isolates may be related to the cpb2 nucleotide sequence.  It is 
possible that there were undetected mutations that could result in deletions or 
frame shift errors; this is a very real possibility for the cpb2 sequences in the 
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present study for which the entire nucleotide coding sequence could not be 
determined.  It is possible that some C. perfringens isolates that were negative 
for beta2 toxin production carried a group-2T cpb2 instead of a complete group-2 
cpb2, which we were only able to detect using nucleotide sequencing techniques.  
Other explanations are possible, however, because five isolates with group-2 
cpb2 that were negative for production of the beta2 toxin were definitely not 
group-2T cpb2; these were sequenced from the start codon of cpb2 and did not 
have the 13-base pair deletion.  Additional genetic factors that influence 
production of a protein include the presence of promoters within the nucleotide 
sequence, as well as other non-nucleotide signaling elements that trigger the cell 
to begin production of a protein.  Because our results indicate that simply 
carrying a viable cpb2 sequence does not equate with production of beta2 toxin 
by a C. perfringens isolate, further research that focuses on these other factors is 
needed.  
Of the 22 isolates that carried a group-1 cpb2 sequence, 11 were found by 
the Western blotting assay to produce the beta2 protein toxin.  However, all of 
these 11 isolates also carried a group-2 cpb2.  The assay we used did not 
distinguish between beta2 toxin from group-1 cpb2 versus beta2 toxin from 
group-2 cpb2.  None of the C. perfringens isolates from our three populations 
that carried only a group-1 cpb2, only a group-2T cpb2, or both group-1 and 
group-2T cpb2 were found to produce the beta2 toxin.  
The low number C. perfringens isolates in each of the groups of cpb2 
(further confounded by the various combinations when two versions of cpb2 were 
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present) precluded meaningful statistical comparison of results from Western 
blotting.  However, the results described here suggest that group-2 or possibly 
group-3 cpb2 versions are more likely to play a role in C. perfringens diseases in 
humans because isolates with a cpb2 from either of those groups had a higher 
percentage of beta2 toxin positive isolates than those isolates with a group-1 
cpb2.  Further study is needed to provide more information on the variations of 
the cpb2 gene, as well as which versions are capable of producing a viable beta2 
toxin. 
There are many possible explanations for why cpb2 positive isolates did 
not produce the beta2 protein.  Reportedly most toxins of C. perfringens are 
expressed if the gene is present (Meer and Songer, 1997).  However, silent 
genes (or cryptic genes) have been described in C. perfringens.  Probably the 
most well-known examples are the type E strains of C. perfringens that are cpe 
positive but do not produce the enterotoxin, even under conditions that induce 
sporulation (Billington et al., 1998).  It is also possible that a toxin was produced 
but not detected using our assay.  This possibility seems unlikely, however, 
because culture supernatant fluid from only C. perfringens cpb2 positive isolates 
was tested for the presence of the beta2 protein.  This procedure was used 
following preliminary results that showed that the beta2 protein is secreted and 
does not remain associated with the vegetative cell.  Results of Western blotting 
analysis by Fisher et al. (2005) and Waters et al. (2003) also support the beta2 
toxin as secreted by vegetative C. perfringens.  Furthermore, all cultures of C. 
perfringens in this study were grown to the log phase to ensure that there was 
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sufficient time to allow for expression and subsequent secretion of the beta2 
toxin.   
An additional possibility to explain why the beta2 toxin is not produced at a 
detectable level by some C. perfringens cpb2 positive isolates could be in the 
regulation of expression, which can occur at multiple levels including during 
transcription and translation.  In another investigation on cpb2/cpe positive C. 
perfringens isolates from humans, a quantitative Western blotting assay revealed 
that there was a ten-fold range of variation in the level of beta2 toxin produced 
(Fisher et al., 2005).  It has also been shown using techniques to analyze mRNA 
that levels of the cpb2 transcript could vary by as much as a 35-fold difference 
between C. perfringens isolates from pigs and horses (Water et al., 2005) and 
that the level of transcription had a positive correlation with the level of beta2 
toxin production (Harrison et al., 2005).  This is important because others have 
described a correlation between the level of toxin produced and the severity of 
the symptoms of C. perfringens diseases (Dupuy and Matamouros, 2006).  It is 
interesting to note that a study describing group-1 and group-2 (table 24) cpb2 in 
veterinary and human C. perfringens isolates found that only isolates with a 
group-1 cpb2 produced a corresponding mRNA transcript and beta2 toxin while 
isolates with a group-2 cpb2 did not produce cpb2 mRNA or beta2 toxin (Jost et 
al., 2005).  
Expression of the beta2 toxin appears to be positively regulated indirectly 
by VR-RNA (of the VirR/VirS two component regulatory system), with maximal 
production reached by the late log phase of growth (Ohtani et al., 2003).  Current 
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evidence supports VirR/VirS elements as the primary mode of regulation for 
many of the virulence genes of C. perfringens (Lyristis et al., 1994; Shimizu et al., 
1994).  At present, the external stimuli that trigger activation of this system (and 
whether these are environmental or growth phase related) have not been 
identified for C. perfringens.  The actual mechanism of gene regulation by VR-
RNA has not yet been described, although it does not appear to regulate gene 
transcription by binding to complementary DNA or RNA of a promoter region 
(Shimizu et al., 2002b).  Additional studies of the VirR protein have shown that it 
binds independently to two imperfect direct repeats (CCCAGTTNTNCAC) 
located upstream of the gene promoter (Cheung and Rood, 2000).  Additional 
work has shown that the spatial organization of these repeats is important for 
transcription of the gene (Cheung et al., 2004).  Future studies of the upstream 
region of cpb2 in C. perfringens isolates are needed to determine if these 
imperfect direct repeats are at the proper upstream location.  If the proper spatial 
organization is not shown, this could potentially explain the differences observed 
in production of the beta2 toxin by cpb2 positive C. perfringens isolates.  More 
studies on the mechanism of VR-RNA and the components involved in its 
mechanism of regulation are also needed.  These could help identify additional 
areas of difference in the upstream and downstream regions of cpb2 and 
determine whether these factors could subsequently affect regulation and 
expression of the beta2 toxin.  
The anti-beta2 antibodies that were used in this study are an additional 
factor that may complicate the understanding of regulation and expression of the 
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beta2 toxin.  The antibodies used were polyclonal anti-beta2 raised in rabbits but 
against the porcine cpb2 sequence (Gibert et al., 1997), which was determined to 
be only 71% similar to the group-2 cpb2.  Therefore, these antibodies might not 
have recognized epitopes of the beta2 protein toxin of some of our isolates (even 
if it was produced).  Future studies using antibodies developed specifically 
against the beta2 toxins produced by the different cpb2 groups will provide 
valuable information regarding which version of the beta2 toxin is produced by 
isolates that carry multiple version of cpb2.  Such studies would also decrease 
the probability that epitopes of the beta2 protein toxin of some isolates would fail 
to be recognized. 
 
 
E. coli Clones that Expressed Recombinant Beta2 Protein were Constructed and 
used to Study Potential Differences in the Activity Level of the Beta2 Protein from 
the Different Variants of cpb2 on Cultured Caco-2 Cells 
 
To study the different versions of cpb2 that were discovered, we 
constructed 18 recombinant cpb2 plasmids of representatives from each cpb2 
group.  These plasmids were used to transform E. coli, which then expressed the 
recombinant beta2 protein.  For all clones, including those with group-2T cpb2, 
the region of cpb2 inserted into the vector began after the signal sequence.  The 
signal sequence is the region of the 13 base pair deletion of group-2T; this 
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means that the group-2T clones should essentially be the same as the group-2 
cpb2 clones.  Other investigators have cloned cpb2 into cpb2/cpe negative type 
A C. perfringens strains for over-expression of the beta2 protein toxin (Fisher et 
al., 2005; Harrison et al., 2005).  However, we chose to use an E. coli strain 
(BL21(DE3)pLysS) that was developed for expression of recombinant proteins to 
minimize the possibility that other C. perfringens toxins (such as the alpha toxin) 
or enzymes might affect the results of the cell cytotoxicity assays.   
Expression of the beta2 toxin by each cpb2 E. coli clone was verified with 
the polyclonal anti-beta2 antibody (Gibert et al., 1997) and Western blotting 
techniques.  This was the same anti-beta2 antibody that was used to determine 
production of the beta2 toxin by the C. perfringens isolates from the three 
different populations.  However, when a monoclonal anti-beta2 antibody 
(Bueschel et al., 2003) was used, only 11 of the 18 recombinant cpb2 E. coli 
clones were positive (table 23).  This monoclonal antibody was created against 
the original beta2 toxin (Gibert et al., 1997) that had the signal sequence 
removed (Bueschel et al., 2003).  There was a limited supply of this monoclonal 
antibody, so we were unable to use it to assess all of the C. perfringens isolates 
from the three different populations.  These results are difficult to interpret 
because the recombinant clones that were negative in this assay carried cpb2 
from all groups; as a result, we could not determine if the monoclonal anti-beta2 
antibody reacted only with beta2 toxin from a specific cpb2 group.  There was no 
correlation between recombinant cpb2 E. coli clones that were negative in the 
monoclonal anti-beta2 assay and whether the corresponding C. perfringens 
  115 
isolates were positive or negative in the assay that used the polyclonal anti-beta2 
antibody.  Four clones that were from C. perfringens isolates that were negative 
with the polyclonal anti-beta2 assay had the corresponding cpb2 clones positive 
using the monoclonal anti-beta2 antibody.  Conversely, three clones that were 
from C. perfringens isolates that were positive in the polyclonal anti-beta2 assay 
had a corresponding clone that was negative with the monoclonal anti-beta2 
assay.  A possible explanation for these contradictory results could be 
immunogenic differences between various beta2 toxins from the different groups 
of cpb2.  Possible differences in immunogenicity could also potentially explain 
differences in the disease types and disease presentations for C. perfringens 
diseases in humans.  Future studies with antibodies developed against beta2 
proteins from the different groups of cpb2 could provide valuable information 
regarding the immunogenic difference and potential cross-reactivity between the 
different beta2 proteins from the different groups of cpb2.  
 
 
Beta2 Toxin from Clones with Either a Group-1 or a Group-2 cpb2 (Found in the 
Majority of C. perfringens Isolates from Humans with Gastrointestinal Diseases) 
were Most Likely to be Cytotoxic to Caco-2 Enterocytes  
 
The cpb2 gene was cloned into E. coli to produce recombinant beta2 
toxin.  The results showed variability in the level of activity of the recombinant 
  116 
beta2 toxin on caco-2 cells between clones from the different groups of cpb2.  
These assays using caco-2 cells were performed because expression of beta2 
toxin by C. perfringens isolates is not sufficient evidence to link the beta2 toxin to 
diseases in humans.  It must also be demonstrated that the protein can function 
as an active toxin capable of producing damage to enterocytes or other cell types 
(i.e., cytotoxicity).  Two separate cell cytotoxicity assays, both of which used 
caco-2 enterocytes, were used to test cell culture supernatant fluid containing the 
recombinant beta2 protein from the E. coli clones.  When cpb2 was first 
described, purified beta2 protein was shown to be cytotoxic to CHO (Chinese 
hamster ovary) cells and intestinal I407 cells as well as lethal to mice (Jolivet-
Reynaud et al., 1986; Gibert et al. 1997).  These findings established the beta2 
protein as a putative toxin.  We chose the caco-2 cultured cell line because the 
gastrointestinal diseases of type A strains of C. perfringens can potentially have 
severe effects in the human colon, making caco-2 cells (which are derived from a 
colorectal adenocarcinoma and express features of polarized enterocyte 
differentiation) appropriate cells to use.   
Our cell cytotoxicity assays showed a wide range in the level of activity on 
caco-2 cells of the cell culture supernatant fluid that contained the recombinant 
beta2 toxin.  The recombinant beta2 toxin was shown to have the ability to 
damage and kill enterocytes using the trypan blue exclusion assay.  The second 
cell cytotoxicity assay showed that the recombinant beta2 cell culture 
supernatant proteins were damaging the caco-2 cells, as determined by 
measuring the amount of lactate dehydrogenase (LDH) in the extracellular assay 
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buffer.  LDH is a cytosolic component released upon cell lysis and considered to 
be an indicator of membrane integrity.  It is often used as an indicator of cytolysis 
for caco-2 cells as well as other cell culture lines (Araki et al., 2001).  The 
advantage of the LDH assay versus the trypan blue exclusion assay is that it 
identifies when a substances is damaging to the cell membrane instead of simply 
indicating that a cell is damaged or dead.  
Both cytotoxicity assays showed that the recombinant beta2 protein from 
clones with group-1, group-2, or group-3 cpb2 all have the potential to cause cell 
death of enterocytes.  Clones expressing group-2T beta2 recombinant proteins 
did not cause a significant increase in the percent of dead caco-2 cells in either 
assay (Figures 11 and 16).  Results of the trypan blue exclusion assay did not 
always correlate with results for the LDH assay for clones with group-1, group-2, 
or group-3 cpb2.  However, the LDH assay measures a specific cytosolic 
component that is released upon cell lysis while the trypan blue exclusion assay 
reflects changes in the permeability of the cell membrane that allows the trypan 
blue dye to enter the damaged cell.  Additionally, we chose the 8 hour end point 
for the LDH measurement in order to keep exposure times similar to the trypan 
blue exclusion assay.  Therefore, although the caco-2 cells may have been 
damaged, cell lysis might not have occurred at the time (8 hours) the assay 
buffer was removed and assayed.  Degradation of the recombinant beta2 protein 
over time may have affected the assay; this would suggest that the stability of the 
beta2 protein might vary between the different groups of cpb2, as has been 
described by others (Gibert et al., 1997; Vilei et al., 2005).  There are other 
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additional technical factors that could have impacted our results.  Because it can 
be technically challenging and time consuming, we chose not to purify the 
recombinant beta2 toxin; therefore, other proteins produced by the E. coli could 
have affected the stability of the recombinant beta2 toxin.  Additionally, the 6x-
HIS tag that precedes the recombinant beta2 toxin was also not removed, and 
this could have influenced the protein structure of the recombinant beta2 toxin, 
thereby affecting its activity level with regards to the caco-2 cells.  
Despite the lack of a clear correlation between results from the trypan blue 
exclusion assay and the LDH assay, we were able to make a number of 
important observations regarding the activity of recombinant beta2 proteins.  
First, recombinant beta2 proteins have the ability to damage enterocytes and 
cause cell death (with the exception of group-2T beta2 proteins).  Second, an 
increase in concentration of the recombinant beta2 proteins often resulted in a 
corresponding increase in the percent of dead cells or damaged cells.  Third, an 
increase in the length of time the recombinant beta2 protein was exposed to 
caco-2 cells typically produced an increase in the percent of cell damage.  This 
observation was noted for increases in the length of beta2 exposure to caco-2 
cells at different concentrations of the recombinant beta2 proteins. 
The authors who originally described cpb2 also noted that beta2 protein 
was cytotoxic for CHO (Chinese hamster ovary) cells and intestinal I407 cells 
(which ATCC now considers to be HeLa cells; Jolivet-Reynaud et al., 1986; 
Gibert et al. 1997).  To date, there has been only one publication by others 
addressing the effect of the beta2 toxin on caco-2 cells (Fisher et al., 2005).  
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Fisher and colleagues (2005) described cell damage (as measured by an 
assessment of cell morphologic changes) after 5 hours of exposure to cell culture 
supernatant fluid from a type A cpb2+/cpe+ strain (vegetative, not sporulating 
cells).  These same investigators also cloned a group-1 cpb2 (which they termed 
CPB2h2, table 24) and a group-2 cpb2 (which they termed CPB2h1, table 24) 
into cpb2/cpe negative type A strains of C. perfringens.  The beta2 toxin was 
purified from the cell culture supernatant fluid from each of these clones.  It was 
discovered that a 13-fold higher concentration of the purified beta2 from the 
group-1 cpb2 was required to damage 50% of the caco-2 cells in the assay 
versus the group-2 cpb2 after 2 hours of exposure to the caco-2 cells (Fisher et 
al., 2005).  These investigators used a modified version of the purification 
technique of Gibert et al. (1997) but did not note if there was any degradation or 
instability of their purified beta2 toxin.  The results described by Fisher et al. 
(2005) as well as the results we described here indicate that variable 
concentrations of the beta2 toxin in vivo could explain differences in disease 
severity and presentation by different C. perfringens in human gastrointestinal 
diseases.   
Determining the actual role of cpb2 and the beta2 toxin in diseases 
caused by C. perfringens in humans, especially gastrointestinal diseases such as 
AAD and food-borne illnesses, awaits further study.  In particular, these studies 
will need to define the mechanism of regulation of beta2 toxin, determine the 
specific activity of the beta2 toxin, and identify the location of that activity in 
human tissue.  Questions on the stability of beta2 toxin both in host tissue and in 
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different culture media also need to be addressed.  It is hoped that the results of 
the experiments described in this investigation will contribute to understanding 
the potential contribution of the beta2 toxin to the virulence of C. perfringens and 
the many different types diseases this organism can cause in humans.  
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SUMMARY OF CONCLUSIONS 
 
 
The Beta2 Protein Toxin Gene, cpb2, was Identified in the Genome of Type A    
C. perfringens Isolates from Human Sources   
 
Although cpb2 was identified in all three of our study populations, chi-
square statistical analysis showed that cpb2 is found in a significantly higher 
percentage of isolates from humans with C. perfringens related gastrointestinal 
diseases than in C. perfringens isolates from healthy human volunteers.  Though 
a higher percentage of isolates from humans with extraintestinal C. perfringens 
diseases carried cpb2 compared to the healthy human volunteer isolates, this 
difference was not statistically significant.  Other PCR assays produced results 
that were used to further characterize cpb2 and provided information regarding 
the possible genetic differences of cpb2 in the C. perfringens isolates from all the 
populations that were studied in this investigation.  
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A Range of Genetic Variation was Identified in the cpb2 Genes from the            
C. perfringens Isolates at the Nucleotide Level as well as in the Predicted Amino 
Acid Sequences 
 
Genetic variation in the cpb2 genes and the predicted protein sequence of 
the beta2 protein toxin in isolates of C. perfringens could explain differences in 
virulence between isolates, presentation, disease, and disease severity.  In the 
C. perfringens isolates from humans with gastrointestinal diseases, including 
those with an AAD association and those from food borne disease isolates, 
group-2 cpb2 (which varied by more then 30% identity to the currently published 
cpb2 sequences, CP13-cpb2 and CWC245-cpb2) was the genetic variant most 
commonly found.  A number of other variants of cpb2 were also identified in the 
cpb2 positive isolates, although how these differences might affect disease 
presentation, disease severity, and virulence remains unclear.  Finally, a number 
of isolates were found to carry two distinct versions of cpb2, each from a different 
group.  
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The Beta2 Protein was not Expressed by Every cpb2 Positive C. perfringens 
Isolate from the Different Populations of Isolates 
 
Difference in the expression or level of expression of the beta2 protein 
toxin is another factor that could explain differences in disease presentation, 
disease severity, and virulence of C. perfringens strains that cause diseases in 
humans.  Seventy-nine percent of group-2 cpb2 C. perfringens isolates (including 
isolates that carried both a group-1 and group-2 cpb2) were positive for beta2 
protein expression; most of these isolates were from the C. perfringens collected 
from the fecal samples of humans with gastrointestinal diseases, including 
patients with AAD or food-borne outbreak isolates.  Isolates that carried only a 
group-1 cpb2, a group-2T cpb2, or both a group-1 and a group-2T cpb2 were all 
negative for beta2 protein expression.  Only 50% of isolates with a group-3 cpb2 
or a group-2 and group-3 cpb2 produced the beta-2 protein.  There are many 
different possible reasons for why some cpb2 positive C. perfringens isolates 
failed to express the beta2 toxin.    
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E. coli Clones that Expressed Recombinant Beta2 Protein were Constructed and 
used to Study Potential Differences in the Activity Level of the Beta2 Protein from 
the Different Variants of cpb2 on Cultured Caco-2 Cells  
 
The recombinant beta2 proteins were able to cause a range of cellular 
damage to the caco-2 cultured cells at different concentrations of the protein.  It 
was also noted that the two group-2T clones, despite having the entire coding 
region, had no effect on caco-2 cells as measured by either assay.  It appeared 
that recombinant beta2 toxin from clones with either a group-1 or a group-2 cpb2 
(found in the majority of C. perfringens isolates from humans with gastrointestinal 
diseases) were most likely to be cytotoxic to caco-2 enterocytes.  However, there 
were no obvious differences in the level of activity between the recombinant 
beta2 protein from these different cpb2 group clones using either the trypan blue 
exclusion assay or the lactate dehydrogenase (LDH) assay. 
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Table 1.  Traditional biochemical test results and short-chain fatty acids detected by GLC for C. perfringens and selected 
other clinically significant clostridia.  
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Carbohydrate fermentation reactions: +: positive; -: negative; +(-): most strains positive, some negative; -(+): most 
strains negative, some positive;+/-: some strains positive, some strains negative; w: weakly positive; v: variable results.  
Milk reactions: d: digest; c= clot (or curd); d&c: digest & clot; d/c: some strains digest, some strains clot; c(d): most 
strains clot, some strains digest;  -: negative. 
Short-chain fatty acids (GLC): Capital letters indicate major products, lower case letters indicate minor products, 
parentheses indicate variable reactions.
A= acetic; P= propionic; IB= isobutyric; B= butyric; IV= isovaleric; V= valeric; IC= isocaproic, C= caproic, L= lactic, S= 
succinic.
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Type Alpha Beta Epsilon Iota
A X
B X X X
C X X
D X X
E X X
Toxin(s) Produced
Table 2. The five types of C. perfringens and the major 
toxins produced by each type. 
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Gene Primer     Primer Sequence (5’ to 3’)
Amplicon size (bp)
Reference
cpa-Fa-1438 GCTAATGTTACTGCCGTTGA
cpa-Rb-1743 CCTCTGATACATCGTGTAAA 
cpb-F-871 GCGAATATGCTGAATCATCTA  
cpb-R-1046 GCAGGAACATTAGTATATCTTC 
iA-F-275 ACTACTCTCAGACAAGACAG 
iA-R-701 CTTTCCTTCTATTACTATACG 
etx-F-227 GCGGTGATATCCATCTATTC  
etx-R-862 CCACTTACTTGTCCTACTAAC  
cpb2-F-492 AGATTTTAAATATGATCCTAACC  
cpb2-R-1058 CAATACCCTTCACCAAATACTC  
cpe-F-439 GGAGATGGTTGGATATTAGG  
cpe-R-650 GGACCAGCAGTTGTAGATAC  
Alpha toxin gene 
(cpa)
Beta toxin gene 
(cpb)
Iota toxin gene      
(iA)
Epsilon toxin gene 
(etx)
Gibert et al. 
1997
Czeczulin et al. 
1993
Beta2 toxin gene 
(cpb2)
Enterotoxin gene 
(cpe)
567
233
Titball et al. 
1989  
Hunter et al. 
1993
Perelle et al. 
1993
Hunter et al. 
1993
Table 3.  Multiplex PCR primer sets.
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bR=reverse primer.
655
aF=forward primer.
324
446127
Simplex 
PCR Primer name
Amplicon 
size     
(bp)
Annealing 
temperature 
(oC)
Reference
cpb2-Fa-492
cpb2-Rb-1058 
hb2F-377 GA A AGGT A A TGGAGA A T T A T C T T A A TGC
hb2R-950 GCAGA A T CAGGA T T T TGACCA T A T ACC
myb2F-33 GA A T TGT A A A A A A A A T T T CAGGG
myb2R+22 CAC T T CA T A T T T T T T C T A TGC
cpb2PCR-1
cpb2PCR-2
cpb2PCR-3
567
574
847
Refer to Table 3.
Table 4.  Three simplex PCR reactions used to confirm and characterize cpb2 from C. perfringens isolates.  
aF=forward primer.
bR=reverse primer.
Garmory et al. 
2000
Herholz et al. 
1999
This research 
Primer 5' to 3'
55
48
50
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Primer Sequence (5' - 3')
Grp1cpb2Fa ATTATGTTTAGGAATACAGTTA
Grp2cpb2F  CAATTGGGGGAGTTTATCCACAA
cpb2R-1058b CAATACCCTTCACCAAATACTC
aF=forward primer
bR=reverse primer
Table 5. The two forward primers, and single reverse primer used in 
the triplex PCR.
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Compatable 
pRSET vector Reference
A TGCGGA T CCA A TGA AGTGA A T A A A T AC C This research
A A A TGGA T CCA AGGA A A T CGACGC T T A T This research
A TGCGA A T T CC T A TGCACA A T A T CC T T C This research
CC T A A T ACAGTGGA T CCA A A TGA AGTG Jost et al. 2005
T A T A A A T A A A T AGA A T T C T C T A A A ACC Jost et al. 2005
GT CAC T T CAGA A T T C T T T C T A TGCAC Bueshel et al. 2003
a
b
Designates location of restriction enzyme cut site.
Restriction enzyme recognition sequence is highlighted in yellow.  
Restriction enzyme recognition sequence is highlighted in green.
Table 6.  Primers used to amplify cpb2 and add restriction enzyme cut sites, to allow for insertion of the cpb2 
sequence into the pRSET A or B vector.
BamH1
b2clnBamH1-Fa
13b2clnBamH1-F
b2clnEcoR1-Rb
AtypBamH1B2-F
AtypEcoR1B2-R
ConEcoR1B2-R
EcoR1
R=reverse primer
F=forward primer
Primer sequence (5' - 3')Primer Name
B
A
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E. coli strain Genotype description Purpose
TOP 10F'
F' {lacIq, Tn10(TetR)} mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 deoR araD139 Δ(ara-leu)7697 
galU galK rpsL (StrR) endA1 nupG
Propagation and 
maintenance
BL21(DE3)pLysS F-, ompT hsdSB (rB-mB-) gal dcm (DE3) pLysS (CamR) Expression of protein
Table 7.  The E. coli strains used in cloning cpb2,and a description of their genotypes as listed by the 
supplier (Invitrogen). 
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Isolate Population
Healthy
Gastrointestinal  
Diseases
Extraintestinal  
Disease
(n=100) (n=161) (n=59)
cpa 88 (88%) 88 (54%)  44 (75%)
cpa, cpb2 10 (10%) 38 (24%) 12 (20%)
cpa, cpe 1 (1%) 25 (16%)   3 (5%)
cpa, cpb2, cpe 1 (1%) 10 (6%) 0
Positive gene(s)
Table 8.  Multiplex PCR genotype results for the C. perfringens isolates that 
have been divided into three populations, isolates from a group of healthy 
human volunteers, isolates from patients with C. perfringens related 
gastrointestinal diseases, and isolates from patients with C. perfringens related 
extraintestinal diseases.
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Isolate Population
Healthy Gastrointestinal Disease
Extraintestinal 
Disease
(n= 11) (n= 48) (n= 12)
cpb2PCR-1 11 (100%) 48 (100%) 12 (100%)
cpb2PCR-2 9 (82%) 9 (19%) 1 (8%)
cpb2PCR-3 5 (45%) 0 0
Simplex PCR
Table 9.  Results from the three separate simplex PCRs that were perfomed to 
further characterize and classify the cpb2 genotypes identified in the three 
different populations of C. perfringens isolates.  
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Isolate Population
Healthy Gastrointestinal Disease
Extraintestinal 
Disease
(n= 11) (n= 48) (n= 12)
Group 1 
(consensusl) 5 (46%) 5 (10%) 1 (8%)
Group 2 
(atypical) 4 (36%) 35 (73%) 9 (75%)
Group 1 and 
Group 2 2 (18%) 8 (17%) 2 (17%)
Triplex  PCR
Table 10.  Results of the triplex PCR that was used to determine the cpb2 
group for a C. perfringens isolate, with the isolates divided into the three 
different populations.  Most C. perfringens isolates carried cpb2 from one 
group, however, isolates were identified from all three populations of C. 
perfringens isolates that carried at least two versions of cpb2, one from each 
group. 
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C CWC245 -- 95 71
A CP13 95 -- 71
A Grp 2 71 71 --
cpb2 Sequence
Table 11.  ClustalW pairwise alignment scores (indicating percent 
similarity) of the published sequences of cpb2, CWC245 and CP13, 
and the Group-2 (Grp2) cpb2 consensus sequence determined in 
this study. 
CWC245 CP13 Grp 2Bio Type cpb2 Sequence
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C CWC245 -- 91 63
A CP13 91 -- 64
A Grp 2 63 64 --
cpb2 Sequence
Table 12.  ClustalW pairwise alignment scores (indicating percent 
similarity) of the deduced protein sequences of the beta2 toxin from 
the published sequences of cpb2 from CWC245 and CP13, and the 
deduced protein sequence from the Group-2 (Grp2) cpb2 consensus 
sequence determined in this study. 
CWC245 CP13 Grp 2Bio Type cpb2 Sequence
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Reference 
Strain
Number of 
Base Pairs CWC 245 CP13 Grp 2
 10719 816 98 95 72
27324(1)a 618 88 85 69
27324(2) 560 73 73 92
a
Table 13.  ClustalW pairwise alignment scores (indicating percent 
identity) of the cpb2 sequences from cpb2 positive reference strains 
versus the published sequences of cpb2, CWC245 and CP13, and the 
Group-2 (Grp2) cpb2 consensus sequence. 
Parantheses next to the strain number indicates that more then one 
version of cpb2 was identified for that isolate. Alignment scores 
shown in that row, are only for that version of cpb2. 
Clustal W Pairwise Alignment score 
versus cpb2 Sequence:
Bio Type
C
E
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Reference 
Strain
Number of 
Amino 
Acids
CWC 245 CP13 Grp 2
 10719 265 96 93 63
27324(1)a 215 86 81 70
27324(2) 186 62 63 86
a
Table 14.  ClustalW pairwise alignment scores (indicating percent 
identity) of the deduced protein sequences of the beta2 toxin from cpb2 
positive reference strains versus the published sequences CWC245 and 
CP13, and the deduced protein sequence from the Group-2 (Grp2) cpb2 
consensus sequence. 
Parantheses next to the strain number indicates that more then one 
version of cpb2 was identified for that isolate. Alignment scores shown 
in that row, are only for that version of cpb2. 
Clustal W Pairwise Alignment score 
versus cpb2 Sequence:
E
C
Bio Type
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Research 
Isolate Number
Number of 
Base Pairs CWC245 CP13 Grp 2
1009 843 93 98 67
1010 675 92 98 73
1014 897 94 99 71
1017 822 94 99 72
1066(1)b 543 85 93 67
1067(1) 570 92 99 72
1068(1) 584 91 97 70
1069(1) 567 92 97 71
2109(1) 574 92 98 72
2116(1) 584 97 93 72
2120 846 94 99 71
2121(1) 908 90 95 67
2122(1) 599 92 91 69
b Parantheses next to the research isolate number indicates that more then 
one version of cpb2 was identified for that isolate.  Alignment scores shown in 
that row, are only for that version of cpb2. 
GI
GI
GI
a Population source indicates which population of human sources the isolate 
is from. HV: Healthy volunteers, GI: Gastrointestinal diseases.
GI
GI
HV
HV
Table 15.  ClustalW pairwise alignment scores (indicating percent identity) of 
Group-1 cpb2 sequences versus the published cpb2 sequences, CWC245 
and CP13, and the Group-2 (Grp2) consensus cpb2 sequence.      
Clustal W Pairwise Alignment score 
versus cpb2 Sequence:
HV
HV
Population 
Sourcea
HV
HV
HV
HV
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Research 
Isolate Number
Number of 
Amino Acids CWC245 CP13 Grp 2
1009 265 89 98 62
1010 225 88 96 66
1014 265 90 98 64
1017 265 90 99 63
1066(1)b 182 78 87 60
1067(1) 189 84 94 65
1068(1) 194 87 95 64
1069(1) 188 86 96 67
2109(1) 190 88 97 66
2116(1) 194 93 86 65
2120 265 91 100 64
2121(1) 265 90 98 62
2122(1) 199 89 86 65
a Population source indicates which population of human sources the isolate is 
from. HV: Healthy volunteers, GI: Gastrointestinal diseases.
b Parantheses next to the research isolate number indicates that more then 
one version of cpb2 was identified for that isolate.  Alignment scores shown in 
that row, are only for that version of cpb2. 
HV
HV
GI
HV
GI
GI
Table 16.  ClustalW pairwise alignment scores (indicating percent identity) of 
the deduced protein sequences of the beta2 toxin from Group-1 cpb2 
sequences versus the deduced beta2 toxin sequence from published cpb2 
sequences, CWC245 and CP13, and the Group-2 (Grp2) consensus cpb2 
sequence.      
Clustal W Pairwise Alignment score 
versus cpb2 Sequence:
GI
GI
HV
HV
Population 
Sourcea
HV
HV
HV
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Research 
Isolate Number
Number of 
Base Pairs
CWC245 CP13 Grp 2
HV 1008 810 71 71 97
HV 1066(2)b 819 72 73 98
HV 1067(2) 793 69 70 97
HV 1068(2) 781 70 70 96
HV 1069(2) 824 71 72 98
HV 1093 867 66 68 93
GI 2010 543 74 74 97
GI 2012 784 69 71 96
GI 2016 564 74 74 91
GI 2023 807 70 70 96
GI 2048 558 75 75 95
GI 2049 786 69 69 95
GI 2050(2) 801 71 71 96
GI 2051 785 72 72 98
GI 2052 811 73 73 98
GI 2061 813 70 70 96
GI 2062 538 73 73 99
GI 2063 818 71 71 99
GI 2064 826 72 72 98
GI 2065 560 75 75 98
GI 2066 813 72 73 98
GI 2067 809 72 72 98
Clustal W Pairwise Alignment score 
versus cpb2 Sequence:
Table 17.  ClustalW pairwise alignment scores (indicating percent identity) of 
Group-2 cpb2 sequences versus the published cpb2 sequences, CWC245 
and CP13, and the Group-2 (Grp2) consensus cpb2 sequence.  Isolates 
shadowed in gray, belong to Grp2T, and carry a 13 base pair deletion in the 
open reading frame of cpb2.     
Population 
Sourcea
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GI 2068 485 75 74 98
GI 2069 774 70 71 96
GI 2070 777 68 68 95
GI 2071 775 69 69 96
GI 2073 792 69 69 97
GI 2074 806 70 70 97
GI 2076 823 74 74 94
GI 2077 545 69 70 95
GI 2082 538 71 71 97
GI 2093 484 64 67 87
GI 2107 541 72 72 97
GI 2108(2) 783 69 69 96
GI 2109(2) 488 66 66 87
GI 2110 561 70 70 88
GI 2115 798 70 70 98
GI 2116(2) 775 68 68 97
GI 2121(2) 815 72 72 98
GI 2122(2) 699 67 67 95
GI 2124 522 69 69 92
GI 2125 523 74 74 90
GI 2128 771 67 68 95
GI 2132 782 68 68 96
GI 2133 542 73 73 96
GI 2134 780 68 68 96
GI 2137 778 68 68 95
GI 2139 548 74 74 95
GI 2140 513 68 68 89
EI 3002 805 72 72 98
EI 3008 454 74 73 99
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EI 3017 558 75 75 98
EI 3023 545 73 71 94
EI 3032 557 75 75 98
EI 3033 563 76 77 97
EI 3037 789 71 71 99
EI 3040 790 71 72 99
EI 3042 777 72 72 98
EI 3044 786 70 71 98
EI 3052 794 71 71 98
b Parantheses next to the research isolate number indicates that more then 
one version of cpb2 was identified for that isolate.  Alignment scores shown in 
that row, are only for that version of cpb2. 
a Population source indicates which population of human sources the isolate is 
from. HV: Healthy volunteers, GI: Gastrointestinal diseases, EI: Extra-intestinal 
diseases. 
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Research 
Isolate number
Number of 
Amino Acids
CWC245 CP13 Grp 2
HV 1008 261 62 62 96
HV 1066(2)b 262 62 63 97
HV 1067(2) 261 59 60 93
HV 1068(2) 252 59 60 96
HV 1069(2) 264 62 63 98
HV 1093 255 61 62 98
GI 2010 181 67 67 96
GI 2012
GI 2016 185 66 67 85
GI 2023 256 60 61 95
GI 2048 285 69 69 92
GI 2049 256 58 59 94
GI 2050(2) 256 60 60 92
GI 2051 261 63 63 98
GI 2052
GI 2061 263 58 60 92
GI 2062 179 67 67 97
GI 2063 261 62 62 97
GI 2064 265 62 63 97
Clustal W Pairwise Alignment score 
versus cpb2 Sequence:
Table 18.  ClustalW pairwise alignment scores (indicating percent identity) of 
the deduced protein sequences of the beta2 toxin from Group-1 cpb2 
sequences versus the deduced beta2 toxin sequence from published cpb2 
sequences, CWC245 and CP13, and the Group-2 (Grp2) consensus deduced 
beta2 toxin sequence.  Isolates shadowed in gray belong to Grp2T, and carry a 
13bp deletion in the open reading from of cpb2 resulting in a premature stop 
codon, which does not allow for a complete amino acid sequence to be 
deduced.     
Population 
Sourcea
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GI 2065 186 69 69 97
GI 2066 262 62 62 98
GI 2067 261 62 63 98
GI 2068 181 66 66 96
GI 2069 255 59 60 96
GI 2070 256 59 60 96
GI 2071 256 60 61 97
GI 2073 262 61 61 97
GI 2074 262 59 59 95
GI 2076 263 65 66 92
GI 2077 181 64 64 93
GI 2082 178 67 67 97
GI 2093 161 59 58 81
GI 2107 180 65 65 93
GI 2108(2) 260 57 57 91
GI 2109(2) 162 58 58 82
GI 2110 187 60 60 83
GI 2115 262 61 62 98
GI 2116(2) 256 60 61 97
GI 2121(2) 261 62 63 96
GI 2122(2) 229 61 62 96
GI 2124 173 64 64 90
GI 2125 154 65 65 92
GI 2128 256 56 57 92
GI 2132 260 57 58 93
GI 2133 180 66 66 93
GI 2134 259 56 57 93
GI 2137 258 56 57 92
GI 2139 182 67 67 91
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GI 2140 170 56 57 78
EI 3002
EI 3008 151 66 65 98
EI 3017 185 69 69 95
EI 3023 181 66 67 91
EI 3032 185 67 67 96
EI 3033 187 70 71 93
EI 3037 256 61 62 98
EI 3040 256 62 62 98
EI 3042
EI 3044 255 60 61 97
EI 3052 256 61 62 98
b Parentheses next to the research isolate number indicates that more then 
one version of cpb2 was identified for that isolate.  Alignment scores shown in 
that row, are only for that version of cpb2. 
a Population source indicates which population of human sources the isolate is 
from. HV: Healthy volunteers, GI: Gastrointestinal diseases, EI: Extra-intestinal 
diseases. 
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CWC 245 CP13 Grp 2
HV 1028 554 70 71 53
GI 2152 598 78 79 67
GI 2153 579 71 77 67
GI 2096 574 72 74 63
GI 2108(3)b 530 81 84 62
GI 2050(3) 553 80 83 64
a
b Parentheses next to the research isolate number indicates that more then 
one version of cpb2 was identified for that isolate.  Alignment scores shown 
in that row, are only for that version of cpb2. 
Clustal W Pairwise Alignment score 
versus cpb2 Sequence:
Table 19.  ClustalW pairwise alignment scores (indicating percent identity) of 
Group-3 cpb2 sequences versus the published cpb2 sequences, CWC245 
and CP13, the Group-2 (Grp2) consensus cpb2 sequence.  
Population source indicates which population of human sources the isolate is 
from. HV: Healthy volunteers, GI: Gastrointestinal diseases.
Population 
Sourcea
Research 
Isolate number
Number of 
Base Pairs
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CWC 245 CP13 Grp 2
HV 1028 184 56 58 47
GI 2152 200 69 72 61
GI 2153 192 67 70 61
GI 2096 191 66 67 56
GI 2108(3)b 176 69 72 53
GI 2050(3) 183 72 78 57
a
b Parentheses next to the research isolate number indicates that more then 
one version of cpb2 was identified for that isolate.  Alignment scores shown 
in that row, are only for that version of cpb2. 
Table 20.  ClustalW pairwise alignment scores (indicating percent identity) of 
the deduced protein sequences of the beta2 toxin from Group-3 cpb2 
sequences versus the deduced beta2 toxin sequence from published cpb2 
sequences, CWC245 and CP13, and the Group-2 (Grp2) consensus dedueced 
beta2 toxin sequence.  
Population source indicates which population of human sources the isolate is 
from. HV: Healthy volunteers, GI: Gastrointestinal diseases.
Clustal W Pairwise Alignment score 
versus cpb2 Sequence:Population 
Sourcea
Research 
Isolate Number
Number of 
Amino Acids
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Positive Negative
1 -
1 & 2 - 1
Positive Negative
1 (n=1) - 1
2 (n=31) 27 4
2T (n=1) - 1
3 (n=3) 2 1
1 & 2 (n=9) 6 3
1 & 2T (n=1) - 1
2 & 3 (n=2) 1 1
1 (n=4) - 4
2 (n=2) 2 -
3 (n=1) - 1
1 & 2 (n=4) 4 -
2 (n=8) 4 4
2T (n=1) - 1
1 & 2 (n=2) 1 1
1 & 2T (n=1) - 1
a GI: Isolates from humans with C. perfringens related 
gastrointestinal diseases, HV:  Isolates from healthy human 
volunteers, EI: Isolates from humans with extra-intestinal C. 
perfringens related diseases. 
CWC245
cpb2 Group(s) ResultReference Strain
10719 (n=1)
27324 (n=1)
Isolate Populationa cpb2 Group(s)
Result
GI                          
(n=48)
HV                            
(n=11)
EI                             
(n=12)
Table 21.  Western blotting results of cell culture supernatant from 
cpb2 positive  C. perfringens reference strains and from C. 
perfringens isolates from human sources using a polyclonal anti-
beta2 antibody.  The cpb2 group(s) are based on sequencing and 
triplex PCR results. 
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Research Number 
of C. perfringens 
Isolate
Toxin Genes of the 
C. perfringens 
Isolate
cpb2 
genesb
Recombinant 
Plasmid 
Designation
NCTC 10719 cpa, cpb, cpb2 CWC245 pHRD101
1009 cpa, cpb2 1 pHRD102
    1 & pHRD103
2 pHRD203
2121 cpa, cpb2 1 & (2) pHRD104
1008 cpa, cpb2 2 pHRD201
2109 cpa, cpb2 (1) & 2 pHRD202
2140 cpa, cpb2 2 pHRD204
3037 cpa, cpb2 2 pHRD205
2074 cpa, cpb2, cpe 2 pHRD206
2076 cpa, cpb2, cpe 2 pHRD207
1093 cpa, cpb2 2 pHRD208
2066 cpa, cpb2, cpe 2 pHRD209
2049 cpa, cpb2 2 pHRD210
2152 cpa, cpb2, cpe 3 pHRD301
1028 cpa, cpb2, cpe 3 pHRD302
2052 cpa, cpb2 2T pHRD401
2012 cpa, cpb2, cpe (1) & 2T pHRD402
Population 
of Isolatea
Table 22.  Recombinant cpb2 plasmids constructed for cloning into E. coli 
BL21(DE3)pLysS for expression.  
Reference 
strain
EI
HV
GI 2120 cpa, cpb2, cpe
GI
GI
GI
HV
HV
GI
GI
GI
a GI: Isolates from humans with C. perfringens related gastrointestinal diseases, 
HV:  Isolates from healthy human volunteers, EI: Isolates from humans with 
extra-intestinal C. perfringens related diseases. 
b  The number indicates the group to which the version of cpb2 carried by a C. 
perfringens isolate belongs.  Isolates with two versions of cpb2 have both 
versions listed.  The group number not in parentheses was the cpb2 gene used 
to construct the plasmid. 
GI
GI
GI
GI
HV
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mAb pAb
CWC245 Pa P
1 P P
1 N P
1 P P
2 P P
2 P P
2 P P
2 P P
2 N P
2 P P
2 N P
2 N P
2 N P
2 P P
3 N P
3 P P
2T P P
2T N P
a P: Positive result.  N: Negative result. 
Table 23.  Results from two separate Western blotting 
assays using either monoclonal (mAb) or polyclonal (pAb) 
anti-beta2 antibody, on the cell culture supernatant fluid 
(CSF) from the recombinant E. coli cpb2 clones.
Recombinant                       
E. coli - CSF
Recombinant 
Plasmid number cpb2 group
pHRD302
pHRD401
pHRD402
pHRD208
pHRD210
pHRD301
pHRD204
pHRD205
pHRD206
pHRD207
pHRD201
pHRD202
pHRD203
pHRD209
pHRD101
pHRD102
pHRD103
pHRD104
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 in this 
investigation
 in the 
original 
publication
the original 
cpb2 sequence 
(CWC245-
cpb2)a
 the group-2 
cpb2 
consensus 
sequence 
Group-1 92% 70% - -
Group-2 71% 96% - -
Group-3 75% 63% - -
Gibert et 
al. (1997)
CWC245-
cpb2 cpb2 - 71%
92% identity to 
group-1 L77965
C. perfringens 
type C strain 
CWC245,  piglet 
with necrotizing 
enterocolitis
Shimizu et 
al. (2001, 
2002) 
CP13-cpb2 cpb2 95% 71% 97% identity to group-1 AP003515
Strain 13, a C. 
Perfringens type 
A, human isolate
GenBank 
accession 
number
Source of C. 
perfringens 
isolate(s)
Table 24. Comparison of sequence variants of cpb2 described in this investigation, in the current literature, and 
GenBank.
Similarity(% identity) of the 
sequence compared to:
Name of the cpb2 
sequence:
Reference
Comparison to 
other cpb2 
groups described 
in this study
Human fecal 
samples, and 
other 
extraintestinal 
human 
specimens
This study -
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Same as the 
CWC245-
cpb2
Consensus 
cpb2 - 71%
92% identity to 
group-1 -
Reference:       
Gibert et al., 
1997
Similar to 
group-2 
consensus 
sequence
Atypical 
cpb2 71% 98%
98% identity to 
the  group-2 
consensus 
sequence
AY609161 - 
AY609183b
C. perfringens 
stains, types A -E 
from animal 
sources from the 
CEDUc 
97% identity 
to CP13-
cpb2
CPB2h2 94% 72% 97% identity to group-1
AY730632 - 
AY730634, 
AY730636
Similar to 
group-2 
consensus 
sequence
CPB2h1 71% 99%
99% identity to 
the  group-2 
consensus 
sequence
AY730630 - 
AY730631, 
AY730635
c CEDU: Clostridial Enteric Disease Unit, at the University of Arizona
b Accession numbers AY609164 and AY609183 have the same 13 base-pair deletion seen in the 
group-2T cpb2. Accession numbers AY6097178 - AY609182 have a single deletion of a thymine base 
220 base-pairs after the start codon that would result in a truncated protein of only 73 amino acids. 
d AAD: antibiotic associated diarrhea, SD: sporadic diarrhea. 
a Similarity is based on the average of the ClustalW alignment scores for the group being compared.
Jost et al. 
(2005, 
2006)
Fisher et 
al. (2005)
AAD or SDd  C. 
perfringens 
isolates from 
humans
153
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Figure 1.  Traditional methods for identification of C. perfringens isolates in the 
clinical microbiology laboratory.  
 Image a: Gram’s stain of C. perfringens showing the typical appearance of 
       large, boxcar-shaped Gram-positive rods.  
 Image b: Colonies of C. perfringens on an anaerobe blood agar (prepared  
       with sheep blood).  The arrow indicates the inner zone of   
       hemolysis.  The arrow-head indicates the outer zone of   
       hemolysis.  
 Image c: Growth of C. perfringens on egg yolk agar.  The creamy white  
      precipitate within the agar (arrow) indicates a positive lecithinase  
      reaction.  
 Image d: Milk proteolysis test with abundant gas production, curdle and  
      digestion typical of C.perfringens.   
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Figure 2.  Typical results for C. perfringens short-chain fatty acid analysis using 
gas-liquid chromatography.   
 Image a:  Volatile short-chain fatty acid profile.  
 Image b: Non-volatile short-chain fatty acid profile.   
A: acetic acid, P: propionic acid, B: butyric acid, L: lactic acid, S: succinic acid.  
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Figure 3.  The VirS/VirR- VR-RNA regulatory cascade, which controls many of 
the virulence genes of C. perfringens.  In response to some unknown stimuli, 
VirS undergoes autophosphorylation, and subsequently phosphorylates VirR, 
located in the cell cytoplasm.  After phosphorylation VirR can either directly 
regulate transcription by binding to specific promoters in the DNA, or VirR can 
bind to the promoter region for VR-RNA (VirR- regulated RNA).  The increase in 
VR-RNA in the cell cytoplasm, results in both positive and negative regulation of 
a number of toxin genes in C. perfringens (Image from Shimizu et al., 2002). 
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Anaerobe Laboratory stock organism culture in CM broth  
(room temperature) 
Inoculate a CDC-AnBAP with ~200 µl of broth 
(overnight incubation at 35o C, Anaerobic conditions) 
Inoculate a new CDC-AnBAP with one well isolated colony  
(overnight incubation at 35o C, anaerobic conditions) 
(Repeat three times to ensure a pure culture and organism viability)  
PRAS-CMC broth tube 
Using well isolated 
 colonies from the  
CDC-AnBAP inoculate  
2-CMC broth tubes 
(overnight incubation at 35o C) 
PRAS-CMC broth tube 
Acidified with 400 µl of a 50% 
(w/v) H2SO4 solution  
Use an equal volume of ether to 
perform an extraction on the 
acidified culture 
Remove the organic layer for 
GLC analysis to obtain a profile 
of the volatile fatty acids 
continued on 
next page 
Colony morphology 
analysis and Gram’s 
stain reaction 
 158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Flow chart used for culture and identification of C. perfringens isolates.   
PRAS-CMC broth tube 
Used to inoculate:  
(by injection of 3 - 5 
drops through the 
rubber stopper of 
each tube) 
CM broth to make a new stock 
culture for storage 
(48 hour incubation at 35o C, 
storage at room temperature) 
PRAS media for biochemical 
phenotyping 
(overnight incubation at 35o C) 
• Carbohydrate fermentation 
(directly measure pH of the 
biochemical tube) 
• Other biochemical tests 
(read directly or after addition 
of indicator chemical) 
PY Base 
Glucose 
Lactose 
Maltose 
Mannitol 
Mannose 
Salicin 
Sucrose 
Trehalose 
Esculin Hydrolysis 
Gelatin Liquefaction 
Milk digestion 
Indole Production 
Nitrate Reduction 
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CWC245 GAAT TGTAAAAAAAAT T TCAGGGGGGAATATAAATGAAAA 40
CP13 GAAT TGTAAAAAAAAT T TCAGGGGGGAATATAAATGAAAA
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 AAAT TAT T TCAAAGT T TACTGTAAT T T T TATGT T T TCATG
CP13 AAAT TAT T TCAAAGT T TACTGTAAT T T T TATGT T T TCATA 80
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T T T TCT TAT TGT TGGAGCAATAAGTCCAATGAAAGCAAGT
CP13 T T T TCT TAT TGT TGGAGCAATAAGTCCAATGAAAGCAAGT 120
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 GCAAAAGAAATCGACGCT TATAGAAAGGTAATGGAGAAT T
CP13 GCAAAGGAAATCGACGCT TATAGAAAGGTAATGGAGAAT T 160
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 ATCT TAATGCT T TAAAAAACTACGATAT TAATACAGT TGT
CP13 ATCT TAATGCT T T TAAAAACTACGATAT TAATACGAT TGT 200
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 AAACAT T TCAGAAGATGAAAGAGTAAATAATGT TGAACAG
CP13 AAACGTATCAGAAGATGAAAGAGTGAATAGTGATGAAAAG 240
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 TATAGAGAAATGT TAGAAGAT T T TAAATATGATCCTAACC
CP13 TATAAAGAGATGT TAGAAGAGT T TAAATATGATCCTAACC 280
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 AACAACTGAAATCT T T TGAAATACT TAAT TCACAAAAGAG
CP13 AACAACTAAAATCT T T TGAAATACT TAAT TCACAAAAGAT 320
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 CGATAATAAAGAAATAT T TAATGTAAAAACTGAAT T T T TA
CP13 TGATAATAAAGAAATAT T TAATGTAAAAACTGAAT T TATG 360
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 AATGGTGCAAT T TATGATATCGAAT T TACTGTATCATCTA
CP13 AATGGTGCAAT T TATGATATGAAAT T TACTGTATCATCTA 400
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 AAGATGGAAAAT TAATAGTATCTGATATGGAAAGAACAAA
CP13 AAGATGGGGAAT TAATAGTATCTGACATGGAAAGAACAAA 440
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 AGT TGAGAATGAAGGAAAATATAT T T TAACACCATCAT T T
CP13 AAT TGAGAATGAGGGAAAATATAT T T TAACACCATCAT T T 480
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 AGAACTCAAGT T TGTACATGGGATGATGAACTAGCACAAG
CP13 AGAACTCAAGT T TGTACATGGGATGATGAAT TATCACAAT 520
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 CAAT TGGGGGAGT T TATCCACAAACATAT TCTGATAGAT T
CP13 CAAT TGGGGGAGT TGATCCAAAAACATAT TCTACTAGAT T 560
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 TACATAT TATGCAGATAATATAT TAT TAAACT TCAGACAA
CP13 TACATAT TATGCAGACAATATAT TAT TAAACT T TAGACAA 600
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 TATGCAACT TCAGGT TCAAGAGAT T TAAAAGTAGAATATA
CP13 TATGCAACT TCAGGT TCAAGAGAT T TAAAAGTAGAATATA 640
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 GTGT TGTAGATCAT TGGATGTGGAAAGATGATGT TAAAGC
CP13 GTGT TGTAGATCAT TGGT TATGGGGAGATGATGT TAAAGC 680
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T TCTCAAATGGTATATGGTCAAAATCCTGAT TCTGCTAGA
CP13 T TCTCAAATGGTGTATGGTCAAAACCCTGAT TCTGCTAGA 720
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 CAAATAAGAT TATATATAGAAAAAGGACAATCT T TCTATA
CP13 CAAATAAGAT TATATATAGAAAAAGGACAATCT T TCTATA 760
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 AATATAGAATAAGAAT TAAAAACT T TACACCTGCATCAAT
CP13 AATATAGAATAAGAATACAAAACT T TACACCTGCATCAAT 800
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 TAGAGTAT T TGGTGAAGGGTAT TGTGCATAGAAAAAAATA
CP13 TAGAGTAT T TGGTGAAGGATAT TGTGCATAGAAAAAAATA 840
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 TGAAGTGACT TAGTCACT TCATAT T T T T T T TACTAT TAAT
CP13 TCAAGTGACTAAGTCACT TCATAT T T T T TCTATGCT TAAT 880
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T T TAT TATATAAAAACCTAACATACATGAAAGTAT TCT TA
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CWC245 GTGT TGT AGA T CA T TGGA TGTGGA A AGA TGA TGT T A A AGC
CP13 GTGT TGT AGA T CA T TGGT T A TGGGGAGA TGA TGT T A A AGC 680
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T T C T CA A A TGGT A T A TGGT CA A A A T CC TGA T T C TGC T AGA
CP13 T T C T CA A A TGGTGT A TGGT CA A A ACCC TGA T T C TGC T AGA 720
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 CA A A T A AGA T T A T A T A T AGA A A A AGGACA A T C T T T C T A T A
CP13 CA A A T A AGA T T A T A T A T AGA A A A AGGACA A T C T T T C T A T A 760
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A A T A T AGA A T A AGA A T T A A A A AC T T T ACACC TGCA T CA A T
CP13 A A T A T AGA A T A AGA A T ACA A A AC T T T ACACC TGCA T CA A T 800
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T AGAGT A T T TGGTGA AGGGT A T TGTGCA T AGA A A A A A A T A
CP13 T AGAGT A T T TGGTGA AGGA T A T TGTGCA T AGA A A A A A A T A 840
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 TGA AGTGAC T T AGT CAC T T CA T A T T T T T T T T AC T A T T A A T
CP13 T CA AGTGAC T A AGT CAC T T CA T A T T T T T T C T A TGC T T A A T 880
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T T T A T T A T A T A A A A ACC T A ACA T ACA TGA A AGT A T T C T T A
CP13 T T T A T T A T A T A A A A ACC T A ACA T ACA TGA A AGT A T T C 920
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
sequences.  The bases highlighted in   indicate the location of the primers 
used in the multiplex PCR and cpb2PCR-1. The bases that are highlighted in  
green indicate the location of the  primers designed by Herholz  et al. (1999)
 that were used in cpb2PCR-2.  The bases that are highlighted in orange
indicate the location of the primers that were designed by this laboratory and used 
for cpb2PCR-3. 
 
Figure 5.  Locations of the three sets of primers that were used in our attempts to 
sequence cpb2 from our cpb2 positive C. perfringens isolates, as well as for the 
three simplex PCRs.  CWC245 is a C. perfringens type C strain (Gibert et al., 
1997), and CP13 is a type A C. perfringens strain (Shimizu et al., 2002).  The start 
and stop codons of the ORF are indicated by a box around the bases.  The black 
bar represents the signal sequences that is removed when the protein is secreted.           
* Below the sequences, indicates a match in the base pairs between the                                         
yellow
 
 
 
 
Figure 5.  Locations of the thr e sets of p imers that w re used in our at empts 
to sequence cpb2 from our cpb2 positive C. perfringens isolat s, as well as for 
the three simplex PCRs.  CWC245 is a C. perfringens type C strain (Gibert et al., 
1997), and CP13 is a type A C. perfringens strain (Shimizu et al., 2002).  The 
start and stop codons of the ORF are indicated by a box around the bases.  The 
black bar represents the signal sequences that are removed when the protein is 
secreted.  * Below the sequences indicates a match in the base-pairs between 
the sequences.  The bases highlighted in yellow indicate the location of the 
primers used in the multiplex PCR and cpb2PCR-1.  The bases that are 
highlighted in green indicate the location of the primers designated by Herholz et 
al. (1999) that were used in cpb2PCR-2.  The bases that are highlighted in 
orange indicate the location of the primers that were designed by this laboratory 
and used for cpb2PCR-2.  
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Figure 6.  Plasmid map of a group-2 cpb2 inserted into the plasmid pRSETB.  f1 
ori: bacteriophage f1 origin of replication.  pUC ori: bacterial pUC origin of 
replication.  Ampicillin (bla) resistance gene, a beta-lactamase to confer 
ampicillin resistance.  BamH1: BamH1 restriction enzyme site.  HindIII: HindIII 
restriction enzyme site.  EcoR1: EcoR1 restriction enzyme site.  Generated using 
PlasMapper (Dong et al., 2004). 
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CWC245 G A A T T G T A A A A A A A A T T T C A GGGGGG A A T A T A A A T G A A A A
CP13 G A A T T G T A A A A A A A A T T T C A GGGGGG A A T A T A A A T G A A A A
Grp 2 G A A A A T T A A A A A A A A T T T A A GGGGGG A A A C C A A A T G A A A A
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A A A T T A T T T C A A A G T T T A C T G T A A T T T T T A T G T T T T C A T G
CP13 A A A T T A T T T C A A A G T T T A C T G T A A T T T T T A T G T T T T C A T A
Grp 2 A A A T A A T A G T A A A A A G T A C A A T G A T G C T T T T A T T T T C T T G
* * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T T T T C T T A T T G T T GG A G C A A T A A G T C C A A T G A A A G C A A G T
CP13 T T T T C T T A T T G T T GG A G C A A T A A G T C C A A T G A A A G C A A G T
Grp 2 C T T A T T A T G T T T A GG A A T A C A G T T A C C T A A T A C A G T T A A A
* * * * * * * * * * * * * * * *
CWC245 G C A A A A G A A A T C G A C G C T T A T A G A A A GG T A A T GG A G A A T T
CP13 G C A A A GG A A A T C G A C G C T T A T A G A A A GG T A A T GG A G A A T T
Grp 2 G C A A A T G A A G T G A A T A A A T A C C A A T C T G T A A T GG T A C A G T
* * * * * * * * * * * * * * * * * * * * * *
CWC245 A T C T T A A T G C T T T A A A A A A C T A C G A T A T T A A T A C A G T T G T
CP13 A T C T T A A T G C T T T T A A A A A C T A C G A T A T T A A T A C G A T T G T
Grp 2 A T T T A G A A G C T T T T A A A A A T T A T G A T A T T G A T A C G A T A G T
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A A A C A T T T C A G A A G A T G A A A G A G T A A A T A A T G T T G A A C A G
CP13 A A A C G T A T C A G A A G A T G A A A G A G T G A A T A G T G A T G A A A A G
Grp 2 A G A T A T T T C T A A A G A T A G T A G A G C T G T T A C T A A A G A A G A A
* * * * * * * * * * * * * * * * * * * * *
CWC245 T A T A G A G A A A T G T T A G A A G A T T T T A A A T A T G A T C C T A A C C
CP13 T A T A A A G A G A T G T T A G A A G A G T T T A A A T A T G A T C C T A A C C
Grp 2 T A T A A A A A C A T G T T A A T GG A A T T T A A A T A T G A T C C T A A C C
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A A C A A C T G A A A T C T T T T G A A A T A C T T A A T T C A C A A A A G A G
CP13 A A C A A C T A A A A T C T T T T G A A A T A C T T A A T T C A C A A A A G A T
Grp 2 A A A A A C T T A A A T C A T A T G A A A T A A C A GG T T C A A G A A A A A T
* * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 C G A T A A T A A A G A A A T A T T T A A T G T A A A A A C T G A A T T T T T A
CP13 T G A T A A T A A A G A A A T A T T T A A T G T A A A A A C T G A A T T T A T G
Grp 2 T G A T A A T GG C G A A A T T T T T T C T G T G A A A A C A G A G T T T T T A
* * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A A T GG T G C A A T T T A T G A T A T C G A A T T T A C T G T A T C A T C T A
CP13 A A T GG T G C A A T T T A T G A T A T G A A A T T T A C T G T A T C A T C T A
Grp 2 A A T GG T G C T A T A T A C A A T A T GG A A T T T A C A G T A T C A T C T A
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A A G A T GG A A A A T T A A T A G T A T C T G A T A T GG A A A G A A C A A A
CP13 A A G A T GGGG A A T T A A T A G T A T C T G A C A T GG A A A G A A C A A A
Grp 2 T T G A T A A T A A A T T A A T GG T A A G T A A T A T G A A T A G A A T A T C
* * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A G T T G A G A A T G A A GG A A A A T A T A T T T T A A C A C C A T C A T T T
CP13 A A T T G A G A A T G A GGG A A A A T A T A T T T T A A C A C C A T C A T T T
Grp 2 A A T A G T A A A T G A A GG T A A A T A T A T T C C T A C A C C A A G T T T C
* * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A G A A C T C A A G T T T G T A C A T GGG A T G A T G A A C T A G C A C A A G
CP13 A G A A C T C A A G T T T G T A C A T GGG A T G A T G A A T T A T C A C A A T
Grp 2 A G A A C T C A A G T T T G T A C A T GGG A T G A C G A A T T A A G T C A A T
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 C A A T T GGGGG A G T T T A T C C A C A A A C A T A T T C T G A T A G A T T
CP13 C A A T T GGGGG A G T T G A T C C A A A A A C A T A T T C T A C T A G A T T
Grp 2 A T A T T GG A G A C G C T G T T A G T T T T A C A C G T T C T A G T A A A T T
* * * * * * * * * * * * * * * * * * * * *
CWC245 T A C A T A T T A T G C A G A T A A T A T A T T A T T A A A C T T C A G A C A A
CP13 T A C A T A T T A T G C A G A C A A T A T A T T A T T A A A C T T T A G A C A A
Grp 2 T C A A T A T A G T T C T A A T A C G A T T A C A T T A A A C T T T A G A C A A
* * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T A T G C A A C T T C A GG T T C A A G A G A T T T A A A A G T A G A A T A T A
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CWC245 A A G A T GG A A A A T T A A T A G T A T C T G A T A T GG A A A G A A C A A A
CP13 A A G A T GGGG A A T T A A T A G T A T C T G A C A T GG A A A G A A C A A A
Grp 2 T T G A T A A T A A A T T A A T GG T A A G T A A T A T G A A T A G A A T A T C
* * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A G T T G A G A A T G A A GG A A A A T A T A T T T T A A C A C C A T C A T T T
CP13 A A T T G A G A A T G A GGG A A A A T A T A T T T T A A C A C C A T C A T T T
Grp 2 A A T A G T A A A T G A A GG T A A A T A T A T T C C T A C A C C A A G T T T C
* * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A G A A C T C A A G T T T G T A C A T GGG A T G A T G A A C T A G C A C A A G
CP13 A G A A C T C A A G T T T G T A C A T GGG A T G A T G A A T T A T C A C A A T
Grp 2 A G A A C T C A A G T T T G T A C A T GGG A T G A C G A A T T A A G T C A A T
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 C A A T T GGGGG A G T T T A T C C A C A A A C A T A T T C T G A T A G A T T
CP13 C A A T T GGGGG A G T T G A T C C A A A A A C A T A T T C T A C T A G A T T
Grp 2 A T A T T GG A G A C G C T G T T A G T T T T A C A C G T T C T A G T A A A T T
* * * * * * * * * * * * * * * * * * * * *
CWC245 T A C A T A T T A T G C A G A T A A T A T A T T A T T A A A C T T C A G A C A A
CP13 T A C A T A T T A T G C A G A C A A T A T A T T A T T A A A C T T T A G A C A A
Grp 2 T C A A T A T A G T T C T A A T A C G A T T A C A T T A A A C T T T A G A C A A
* * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T A T G C A A C T T C A GG T T C A A G A G A T T T A A A A G T A G A A T A T A
CP13 T A T G C A A C T T C A GG T T C A A G A G A T T T A A A A G T A G A A T A T A
Grp 2 T A T G C A A C T T C T GG A T C A A G A T C C T T A A A GG T A A A A T A C A
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 G T G T T G T A G A T C A T T GG A T G T GG A A A G A T G A T G T T A A A G C
CP13 G T G T T G T A G A T C A T T GG T T A T GGGG A G A T G A T G T T A A A G C
Grp 2 G T G T A G T A G A C C A T T GG A T G T GGGGGG A T G A C A T T A G A G C
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T T C T C A A A T GG T A T A T GG T C A A A A T C C T G A T T C T G C T A G A
CP13 T T C T C A A A T GG T G T A T GG T C A A A A C C C T G A T T C T G C T A G A
Grp 2 T T C T C A A T GGG T A T A T GG T G A A A A T C C GG A T T A T G C T A G A
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 C A A A T A A G A T T A T A T A T A G A A A A A GG A C A A T C T T T C T A T A
CP13 C A A A T A A G A T T A T A T A T A G A A A A A GG A C A A T C T T T C T A T A
Grp 2 C A G A T A A A A T T A T A T C T A GG T T C A GG A G A A A C T T T C A A A A
* * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 A A T A T A G A A T A A G A A T T A A A A A C T T T A C A C C T G C A T C A A T
CP13 A A T A T A G A A T A A G A A T A C A A A A C T T T A C A C C T G C A T C A A T
Grp 2 A T T A T A G A A T T A A A G T A G A A A A T T A T A C T C C A G C A T C G A T
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
680
720
760
800
640
440
480
520
560
600
 167 
 
 
 
 
 
 
 
 
 
Figure 10.  Nucleotide alignment of three versions of cpb2.  CWC245, a C. 
perfringens type C isolate, and CP13, a type A C. perfringens strain, are 
published sequences.  The Grp2 cpb2 sequence is a consensus sequence 
derived from 58 nucleotide sequences that were homologous to each other by 
87% to 99%, that were determined in the course of this research study.  The start 
and stop codons of the open reading frame are shown by a box around the 
bases.  * Below the nucleotide sequences indicates a match between the base 
pairs.  The black bar above represents the signal sequences that is removed 
when the protein is secreted.  The double underline indicates the deletion seen in 
Group-2T, which results in a premature stop codon. 
 
CWC245 T A G A G T A T T T GG T G A A GGG T A T T G T G C A T A G A A A A A A A T A
CP13 T A G A G T A T T T GG T G A A GG A T A T T G T G C A T A G A A A A A A A T A
Grp 2 T A A A G T A T T T GG T G A GGG T T A T T G T T A T T A A A A A A A T G A G
* * * * * * * * * * * * * * * * * * * * * * * * * * * *
CWC245 T G A A G T G A C T T A G T C A C T T C A T A T T T T T T T T A C T A T T A A T
CP13 T C A A G T G A C T A A G T C A C T T C A T A T T T T T T C T A T G C T T A A T
Grp 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
CWC245 T T T A T T A T A T A A A A A C C T A A C A T A C A T G A A A G T A T T C T T A 920
CP13 T T T A T T A T A T A A A A A C C T A A C A T A C A T G A A A G T A T T C - - - 917
Grp 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
880
Figure 10.  Nucleotide alignment of three versions of cpb2.  CWC245, a C. 
perfringens type C isolate, and CP13, a type A C. perfringens strain, are published 
sequences.  The Grp2 cpb2 sequence is a consensus sequence derived from 58 
nucleotide sequences that were homologous to each other by 87% to 99%, that 
were determined in the course of this research study.  The start and stop codons of 
the open reading frame are shown by a box around the bases.  * Below the 
nucleotide sequences indicates a match between the base pairs.  The black bar 
above repr sents the signal s quences that is removed when the protein is 
secreted.  The double und rline indicates the deletion s en in Group-2T, which 
results in a pr matur  stop codon.  
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Figure 11.  Alignment of the protein sequences of the three versions of the beta2 
toxin, deduced from the gene sequences that were done as part of this 
investigation.  The black bar represents the signal sequences that is removed 
when the protein is secreted.  *Below the amino acid sequence indicates a match 
between amino acids.  : Conserved amino acid substitution.   . Semi-conserved 
amino acid substitution. 
CWC245 M K K I I S K F T V I F M F S C F L I V G A I S P M K A S A
CP13 M K K I I S K F T V I F M F S Y F L I V G A I S P M K A S A
Grp 2 M K K I I V K S T M M L L F S C L L C L G I Q L P N T V K A
* * * * * * * : : : : * * : * : * * . . . *
CWC245 K E I D A Y R K V M E N Y L N A L K N Y D I N T V V N I S E
CP13 K E I D A Y R K V M E N Y L N A F K N Y D I N T I V N V S E
Grp 2 N E V N K Y Q S V M V Q Y L E A F K N Y D I D T I V D I S K
: * : : * . * * : * * : * : * * * * * : * * * : : * :
CWC245 D E R V N N V E Q Y R E M L E D F K Y D P N Q Q L K S F E I
CP13 D E R V N S D E K Y K E M L E E F K Y D P N Q Q L K S F E I
Grp 2 D S R A V T K E E Y K N M L M E F K Y D P N Q K L K S Y E I
* . * . . * : * : : * * : * * * * * * * : * * * : * *
CWC245 L N S Q K S D N K E I F N V K T E F L N G A I Y D M E F T V
CP13 L N S Q K I D N K E I F N V K T E F M N G A I Y D M K F T V
Grp 2 T G S R K I D N G E I F S V K T E F L N G A I Y N M E F T V
. * : * * * * * * . * * * * * : * * * * * : * : * * *
CWC245 S S K D G K L I V S D M E R T K V E N E G K Y I L T P S F R
CP13 S S K D G E L I V S D M E R T K I E N E G K Y I L T P S F R
Grp 2 S S I D N K L M V S N M N R I S I V N E G K Y I P T P S F R
* * * . * : * * : * : * . : * * * * * * * * * * * *
CWC245 T Q V C T W D D E L A Q A I G G V D P Q T Y S D R F T Y Y A
CP13 T Q V C T W D D E L S Q S I G G V D P K T Y S T R F T Y Y A
Grp 2 T Q V C T W D D E L S Q Y I G D A V S F T R S S K F Q Y S S
* * * * * * * * * * : * * * . . . * * : * * :
CWC245 D N I L L N F R Q Y A T S G S R D L K V E Y S V V D H W M W
CP13 D N I L L N F R Q Y A T S G S R D L K V E Y S V V D H W L W
Grp 2 N T I T L N F R Q Y A T S G S R S L K V K Y S V V D H W M W
: . * * * * * * * * * * * * * . * * * : * * * * * * * : *
CWC245 K D D V K A S Q M V Y G Q N P D S A R Q I R L Y I E K G Q S
CP13 G D D V K A S Q M V Y G Q N P D S A R Q I R L Y I E K G Q S
Grp 2 G D D I R A S Q W V Y G E N P D Y A R Q I K L Y L G S G E T
* * : : * * * * * * : * * * * * * * : * * : . * : :
CWC245 F Y K Y R I R I K N F T P A S I R V F G E G Y C A -
CP13 F Y K Y R I R I Q N F T P A S I R V F G E G Y C A -
Grp 2 F K N Y R I K V E N Y T P A S I K V F G E G Y C Y -
* : * * * : : : * : * * * * * : * * * * * * *
Figure 11.  Alignment of the protein sequences of the three versions f t  
beta2 toxin, deduced from the gene s quences that were done as part of this 
investigation.  The black bar represents the signal sequences that is re ov  
when the protein is secreted.  *Below the amino acid sequence indicates a 
match between amino acids.  : Conserved amino acid substitution.   . Semi-
conserved amino acid substitution.
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Figure 12.  Western blotting analysis of beta2 protein toxin production by 
selected cpb2 positive C. perfringens isolates.  Cell culture supernatant protein 
from C. perfringens isolates was collected and subjected to SDS-polyacrylamide 
gel electrophoresis followed by western blotting using a poly-clonal anti-beta2 
antibody.  
 Image a: Clostridium perfringens isolates from patients with    
      gastrointestinal diseases.  Lanes 1, 2, 4, 5, 13, and 14 are  
      negative for production of the beta2 protein toxin.  Lanes 3  
      and 6-12 are positive for production of the beta2 protein toxin.   
      The arrow to the left indicates the migration size of the beta2  
      protein toxin immunoreactive band at 28 kDa.  
 Image b: Clostridium perfringens isolates from healthy human volunteers  
      and from patients with non-gastrointestinal C. perfringens related 
      diseases.  Lanes 1-3, 5, and 10-14 are negative for production of 
      the beta2 protein toxin.  Lanes 4, 6, 8 and 9 are positive for  
      production of the beta2 protein toxin.  The arrow to the left  
      indicates the migration size of the beta2 protein toxin   
      immunoreactive band at 28 kDa. 
a 
b 
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Figure 13.  The effects of recombinant beta2 protein from clone pHRD103 on 
caco-2 cells, measured using the trypan blue exclusion assay.  Caco-2 cells 
grown to 80% confluence were exposed to cell culture supernatant fluid from the 
E. coli clone with pHRD103, a recombinant group-1 cpb2 plasmid, at three 
different concentrations: 100 µg/ml, 50 µg/ml, and 12.5 µg/ml.  Trypan blue stain, 
which is taken up by cells that are dead or have damaged membranes, was 
added at three time points: 2 hours, 5 hours, and 8 hours to assess the effects of 
the three separate concentrations of the recombinant beta2 protein toxin over 
time.  The percentage of cell death determined from these images and plotted in 
bar graph form is shown in figure 15.   
Figure 14.  Trypan blue exclusion assay results for clone pHRD101 and the negative control clone BL21(DE3)pLysS.  
The highest percentage of caco-2 cell damage that was observed with exposure to the cell culture supernatant fluid 
from the BL21 control is indicated by the bold horizontal line that is labeled on the left side as the control upper limit.  
This control upper limit is also included on figures 15 - 18, the trypan blue exclusion assay bar graphs of the results of 
the remaining recombinant beta2 protein toxin samples. 
0
20
40
60
80
100
101 (100ug) 101 (50ug) 101 (25ug) 101 (12.5 ug) BL21 (100ug) BL21 (50ug) BL21 (25ug) BL21
(12.5ug) 
% Non-viable 
Caco-2 cells
Control 
upper limit
Recombinant Protein Concentration (µg/µl)
101
100 µg/µl
101
50 µg/µl
101
12.5 µg/µl
101
25 µg/µl
BL21
100 µg/µl
BL21
50 µg/µl
BL21
25 µg/µl
BL21
12.5 µg/µl
2 hr
5 hr
8 hr
22 hr
171
Figure 15.  Trypan blue exclusion assay results for clones pHRD102, pHRD103, and pHRD104.  The highest 
percentage of caco-2 cell damage that was observed with exposure to the cell culture supernatant fluid from the BL21 
control is indicated by the bold horizontal line that is labeled on the left side as the control upper limit. 
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Figure 16.  Trypan blue exclusion assay results for clones pHRD201, pHRD205, pHRD206, pHRD207, and pHRD208.  
The highest percentage of caco-2 cell damage that was observed with exposure to the cell culture supernatant fluid 
from the BL21 control is indicated by the bold horizontal line that is labeled on the left side as the control upper limit. 
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Figure 17.  Trypan blue exclusion assay results for clones pHRD202, pHRD203, pHRD204, pHRD209, and pHRD210.   
The highest percentage of caco-2 cell damage that was observed with exposure to the cell culture supernatant fluid 
from the BL21 control is indicated by the bold horizontal line that is labeled on the left side as the control upper limit. 
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Figure 18.  Trypan blue exclusion assay results for clones pHRD301, pHRD302, pHRD401, and pHRD402.   The 
highest percentage of caco-2 cell damage that was observed with exposure to the cell culture supernatant fluid from the 
BL21 control is indicated by the bold horizontal line that is labeled on the left side as the control upper limit. 
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Figure 19.  LDH release assay results comparing the effects of the recombinant beta2 protein from pHRD101 a group-1 
cpb2 clone, and the negative control BL21(DE3)pLysS (BL21).  The percentage of cell damage that was observed at 
each of the three concentrations, 100 µg/ml, 50 µg/ml, and 12.5 µg/ml for the negative control BL21 is the concentration 
control that was used for comparison to the percentage of cell damage that was observed after exposure to the cell 
culture supernatant for each of the experimental cpb2 clones, p<0.05 was considered significant. 
0
10
20
30
40
50
60
70
80
101(100ug) 101(50ug) 101(12.5ug) BL21(100ug) BL21(50ug) BL21(12.5ug)
% Cell 
Damage
Recombinant Protein Concentration (µg/µl)
101
100 µg/µl
01
50 µg/µl
101
12.5 µg/µl
BL21
50 µg/µl
BL 1
12.5 µg/µl
BL21
100 µg/µl
* P<0.05 vs. Concentration Control
** P<0.001 vs. Concentration Control
Incubation Time: 8 hr
Error bars: SEM
**
**
*
176
Figure 20.  LDH release assay results comparing the effects of the recombinant beta2 protein from pHRD102, 
pHRD103, and pHRD104, group-1 cpb2 clones after 8 hours of exposure to the cell culture supernatant with the 
recombinant beta2 protein toxin.  The percentage of cell damage that was observed at each of the three concentrations, 
100 µg/ml, 50 µg/ml, and 12.5 µg/ml for the negative control BL21 (shown in figure 19) is the concentration control that 
was used for comparison to the percentage of cell damage that was observed after exposure to the cell culture 
supernatant for each of the experimental cpb2 clones, p<0.05 was considered significant. 
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Figure 21.  LDH release assay results comparing the effects of the recombinant beta2 protein from pHRD201, 
pHRD205, pHRD206, pHRD207, and pHRD208, group-2 cpb2 clones after 8 hours of exposure to the cell culture 
supernatant with the recombinant beta2 protein toxin.  The percentage of cell damage that was observed at each of the 
three concentrations, 100 µg/ml, 50 µg/ml, and 12.5 µg/ml for the negative control BL21 (shown in figure 19) is the 
concentration control that was used for comparison to the percentage of cell damage that was observed after exposure 
to the cell culture supernatant for each of the experimental cpb2 clones, p<0.05 was considered significant. 
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Figure 22.  LDH release assay results comparing the effects of the recombinant beta2 protein from pHRD202, 
pHRD203, pHRD204, pHRD209, and pHRD210, group-2 cpb2 clones after 8 hours of exposure to the cell culture 
supernatant with the recombinant beta2 protein toxin.  The percentage of cell damage that was observed at each of the 
three concentrations, 100 µg/ml, 50 µg/ml, and 12.5 µg/ml for the negative control BL21 (shown in figure 19) is the 
concentration control that was used for comparison to the percentage of cell damage that was observed after exposure 
to the cell culture supernatant for each of the experimental cpb2 clones, p<0.05 was considered significant.  
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Figure 23.  LDH release assay results comparing the effects of the recombinant beta2 protein from pHRD301, 
pHRD302, group-3 cpb2 clones and pHRD401, and pHRD402, group-2 T cpb2 clones after 8 hours of exposure to the 
cell culture supernatant with the recombinant beta2 toxin.  The percentage of cell damage that was observed at each of 
the three concentrations, 100 µg/ml, 50 µg/ml, and 12.5 µg/ml for the negative control BL21 (shown in figure 19) is the 
concentration control that was used for comparison to the percentage of cell damage that was observed after exposure 
to the cell culture supernatant for each of the experimental cpb2 clones, p<0.05 was considered significant.   
0
10
20
30
40
50
60
70
80
301(100ug) 301(50ug) 301(12.5ug) 302(100ug) 302(50ug) 302(12.5ug) 401(100ug) 401(50ug) 401(12.5ug) 402(100ug) 402(50ug) 402(12.5ug)
% Cell 
Damage
Recombinant Protein Concentration (µg/µl)
3 1
100 
µg/µl
3 1
50 
µg/µl
302
50 
µg/µl
301
12.5 
µg/µl
4 2
100 
µg/µl
402
50 
µg/µl
402
12.5 
µg/µl
3 2
100 
µg/µl
302
12.5 
µg/µl
* P<0.05 vs. Concentration Control
** P<0.001 vs. Concentration Control
Incubation Time: 8 hr
Error bars: SEM
***
*
4 1
100 
µg/µl
401
50 
µg/µl
401
12.5 
µg/µl
**
*180
APPENDIX
           181
Research 
Number Specimen Source Genotype
a
cpb2 
group(s)b
Western 
Immunoblottingc
3017 Abdominal abscess cpa, cpb2 2 Nd
3033 Abdominal abscess cpa, cpb2 2 N
3029 Abdominal fluid cpa
3039 Abdominal fluid cpa
3052 Abdominal fluid cpa, cpb2 2 P
3018 Abdominal foreign body cpa
3014 Abdominal wound cpa
3041 Abdominal wound cpa
3044 Abdominal wound cpa, cpb2 2 P
3045 Abdominal wound cpa
3059 Abdominal wound cpa
3049 Abdominal wound cpa
3043 Abdominal wound cpa
3001 Abscess cpa
3002 Abscess cpa, cpb2 1 & 2T N
3058 Abscess cpa
3005 Bile cpa
3009 Bile cpa
3010 Bile cpa
3013 Bile cpa
3015 Bile cpa
3024 Bile cpa
3025 Bile cpa
3026 Bile cpa
3027 Bile cpa
3030 Bile cpa
3038 Bile cpa, cpe
3012 Bile-autopsy cpa
3057 Bile-autopsy cpa
3008 Biliary aspirate cpa, cpb2 1 & 2 N
3006 Blood cpa
3007 Blood cpa
Table A.  Specimen sources of the extra-intestinal C. perfringens isolates from 
humans.
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3023 Blood cpa, cpb2 2 P
3034 Blood cpa, cpe
3040 Blood cpa, cpb2 2 P
3046 Blood cpa
3047 Blood cpa
3050 Blood cpa
3011 Blood-autopsy cpa
3032 Blood-autopsy cpa, cpb2 2 P
3048 Blood-autopsy cpa
3053 Blood-autopsy cpa
3055 Buttock, wound cpa
3056 Duodenal fluid cpa
3031 Foot wound cpa
3035 Hematoma/ wound cpa
3036 Left leg wound cpa
3042 Perineal fluid cpa, cpb2 2T N
3028 Peritoneal cpa
3019 Peritoneal abscess cpa
3016 Peritoneal fluid cpa
3020 Peritoneal fluid cpa
3051 Peritoneal fluid cpa, cpb2 2 N
3054 Peritoneal/abdominal wound cpa
3021 Skin wound cpa, cpe
3003 Spleen-autopsy cpa
3004 Uvula wound cpa
3037 Vaginal discharge cpa, cpb2 2 N
3022 Wound, right 3rd toe cpa
d  N: negative result.  P: positive result.
c  Indicates the group(s) of the cpb2 for that isolate.
a Genotype of each C. perfringens isolate was determined using the multiplex 
PCR (Garmory et al., 2000). 
b Western immunoblotting assay for production of the beta2 protein toxin, using 
the polyclonal anti-beta2 antibody (Gibert et al., 1997).
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Research 
Number Genotype
a
cpb2 
group(s)b
Western 
Immunoblottingc
1066 cpa, cpb2 1 & 2 Pd
1067 cpa, cpb2 1 & 2 P
1068 cpa, cpb2 1 & 2 P
1069 cpa, cpb2 1 & 2 P
1009 cpa, cpb2 1 N
1010 cpa, cpb2 1 N
1014 cpa, cpb2 1 N
1017 cpa, cpb2 1 N
1008 cpa, cpb2 2 P
1093 cpa, cpb2 2 P
1028 cpa, cpe, cpb2 3 N
1084 cpa, cpe
1001 cpa
1002 cpa
1003 cpa
1004 cpa
1005 cpa
1006 cpa
1007 cpa
1011 cpa
1012 cpa
1013 cpa
1015 cpa
1016 cpa
1018 cpa
1019 cpa
1020 cpa
1021 cpa
1022 cpa
1023 cpa
1024 cpa
1025 cpa
1026 cpa
1027 cpa
1029 cpa
Table B.  C. perfringens isolates from fecal specimens 
from Healthy Human volunteers.
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1030 cpa
1031 cpa
1032 cpa
1033 cpa
1034 cpa
1035 cpa
1036 cpa
1037 cpa
1038 cpa
1039 cpa
1040 cpa
1041 cpa
1042 cpa
1043 cpa
1044 cpa
1045 cpa
1046 cpa
1047 cpa
1048 cpa
1049 cpa
1050 cpa
1051 cpa
1052 cpa
1053 cpa
1054 cpa
1055 cpa
1056 cpa
1057 cpa
1058 cpa
1059 cpa
1060 cpa
1061 cpa
1062 cpa
1063 cpa
1064 cpa
1065 cpa
1070 cpa
1071 cpa
1072 cpa
1073 cpa
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1074 cpa
1075 cpa
1076 cpa
1077 cpa
1078 cpa
1079 cpa
1080 cpa
1081 cpa
1082 cpa
1083 cpa
1085 cpa
1086 cpa
1087 cpa
1088 cpa
1089 cpa
1090 cpa
1091 cpa
1092 cpa
1094 cpa
1095 cpa
1096 cpa
1097 cpa
1098 cpa
1099 cpa
1100 cpa
d N: negative result.  P: positive result. 
a Genotype of each C. perfringens isolate was determined 
using the multiplex PCR (Garmory et al., 2000). 
c Western immunoblotting assay for production of the 
beta2 protein toxin, using the polyclonal anti-beta2 
antibody (Gibert et al., 1997).
b  Indicates the group(s) of the cpb2 for that isolate.
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Research 
Number Genotype
a cpb2 group(s)b
Western 
Immunoblottingc
2054 cpa, cpb2 1 Nd
2010 cpa, cpb2 2 P
2048 cpa, cpb2 2 P
2049 cpa, cpb2 2 P
2051 cpa, cpb2 2 N
2061 cpa, cpb2 2 P
2062 cpa, cpb2 2 P
2063 cpa, cpb2 2 P
2064 cpa, cpb2 2 P
2065 cpa, cpb2 2 P
2067 cpa, cpb2 2 P
2068 cpa, cpb2 2 P
2069 cpa, cpb2 2 P
2070 cpa, cpb2 2 P
2071 cpa, cpb2 2 P
2073 cpa, cpb2 2 P
2082 cpa, cpb2 2 N
2093 cpa, cpb2 2 P
2107 cpa, cpb2 2 P
2110 cpa, cpb2 2 P
2115 cpa, cpb2 2 P
2125 cpa, cpb2 2 P
2128 cpa, cpb2 2 P
2132 cpa, cpb2 2 P
2133 cpa, cpb2 2 P
2134 cpa, cpb2 2 P
2137 cpa, cpb2 2 P
2139 cpa, cpb2 2 P
2140 cpa, cpb2 2 N
2052 cpa, cpb2 2T N
2023 cpa, cpb2 1 & 2 P
2109 cpa, cpb2 1 & 2 P
2116 cpa, cpb2 1 & 2 P
2121 cpa, cpb2 1 & 2 P
2122 cpa, cpb2 1 & 2 P
Table C.  C. perfringens isolates from fecal specimens from 
patients with  suspected antibiotic associated diarrhea (AAD).
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2124 cpa, cpb2 1 & 2 P
2108 cpa, cpb2 2 & 3 N
2066 cpa, cpe, cpb2 2 P
2074 cpa, cpe, cpb2 2 P
2076 cpa, cpe, cpb2 2 N
2016 cpa, cpe, cpb2 1 & 2 N
2077 cpa, cpe, cpb2 1 & 2 N
2120 cpa, cpe, cpb2 1 & 2 N
2012 cpa, cpe, cpb2 1 & 2T N
2096 cpa, cpe, cpb2 3 N
2006 cpa, cpe
2007 cpa, cpe
2008 cpa, cpe
2009 cpa, cpe
2015 cpa, cpe
2017 cpa, cpe
2018 cpa, cpe
2047 cpa, cpe
2078 cpa, cpe
2079 cpa, cpe
2086 cpa, cpe
2087 cpa, cpe
2097 cpa, cpe
2098 cpa, cpe
2099 cpa, cpe
2100 cpa, cpe
2102 cpa, cpe
2104 cpa, cpe
2118 cpa, cpe
2001 cpa
2002 cpa
2003 cpa
2004 cpa
2005 cpa
2011 cpa
2013 cpa
2014 cpa
2019 cpa
2020 cpa
2021 cpa
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2022 cpa
2024 cpa
2025 cpa
2026 cpa
2027 cpa
2028 cpa
2029 cpa
2030 cpa
2031 cpa
2032 cpa
2033 cpa
2034 cpa
2035 cpa
2036 cpa
2037 cpa
2038 cpa
2039 cpa
2040 cpa
2042 cpa
2043 cpa
2044 cpa
2045 cpa
2046 cpa
2050 cpa
2053 cpa
2055 cpa
2056 cpa
2057 cpa
2058 cpa
2059 cpa
2060 cpa
2072 cpa
2075 cpa
2080 cpa
2081 cpa
2083 cpa
2084 cpa
2085 cpa
2088 cpa
2089 cpa
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2090 cpa
2091 cpa
2092 cpa
2094 cpa
2095 cpa
2101 cpa
2103 cpa
2105 cpa
2106 cpa
2111 cpa
2112 cpa
2113 cpa
2114 cpa
2117 cpa
2119 cpa
2123 cpa
2126 cpa
2127 cpa
2129 cpa
2130 cpa
2131 cpa
2135 cpa
2136 cpa
2140 cpa
2141 cpa
2142 cpa
2143 cpa
2144 cpa
d N: negative result.  P: positive result.
a Genotype of each C. perfringens isolate was determined using 
the multiplex PCR (Garmory et al., 2000). 
c Western immunoblotting assay for production of the beta2 protein 
toxin, using the polyclonal anti-beta2 antibody (Gibert et al., 1997).
b  Indicates the group(s) of the cpb2 for that isolate
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Research 
Number Genotype
a cpb2 group(s)b
Western 
Immunoblottingc
2152 cpa, cpe, cpb2 3 Pd
2153 cpa, cpe, cpb2 3 P
2145 cpa, cpe
2155 cpa, cpe
2157 cpa, cpe
2158 cpa, cpe
2160 cpa, cpe
2161 cpa, cpe
2146 cpa
2147 cpa
2148 cpa
2149 cpa
2150 cpa
2151 cpa
2154 cpa
2156 cpa
2159 cpa
d P: positive result.
Table D.  C. perfringens isolates from fecal specimens from 
patients with food-borne illness
a Genotype of each C. perfringens isolate was determined using 
the multiplex PCR (Garmory et al., 2000). 
c Western immunoblotting assay for production of the beta2 
protein toxin, using the polyclonal anti-beta2 antibody (Gibert et 
al., 1997).
b Indicates the group(s) of the cpb2 for that isolate.
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